



WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 211/36, 217/26, A61K 31/445		(11) International Publication Number: WO 96/29309
		(43) International Publication Date: 26 September 1996 (26.09.96)
(21) International Application Number: PCT/JP96/00643	(81) Designated States: AU, CA, CN, HU, JP, KR, MX, NZ, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 14 March 1996 (14.03.96)		
(30) Priority Data: 9505437.5 9524266.5	17 March 1995 (17.03.95) 28 November 1995 (28.11.95)	GB GB
(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).		
(72) Inventor; and (75) Inventors/Applicants (for US only): OHKUBO, Mitsuru [JP/JP]; 5-1-65, Fushimidai, Inagawa-cho, Kawabe-gun, Hyogo 666-02 (JP), TAKAHASHI, Fumie [JP/JP]; 3-4-29, Hishiyonishi, Higashiosaka-shi, Osaka 577 (JP), YAMAOKA, Toshio [JP/JP]; 1-4-5, Atagawa, Asahi-ku, Osaka-shi, Osaka 535 (JP), KATO, Masayuki [JP/JP]; 6-16-12, Goryo-oeyamacho, Nishikyo-ku, Kyoto-shi, Kyoto 610-11 (JP).		
(74) Agent: SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).		

(54) Title: N-ACYLP/EPIDITYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS



(57) Abstract

This invention relates to  $\beta$ -alanine derivatives represented by formula (1a) wherein each symbol is as defined in the specification and pharmaceutically acceptable salt thereof which is glycoprotein IIB/IIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NZ	Norway
BF	Burkina Faso	IE	Ireland	NO	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KZ	Kazakhstan	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KR	Democratic People's Republic of Korea	SD	Sudan
CF	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SG	Singapore
CI	Cote d'Ivoire	LJ	Liechtenstein	SI	Slovenia
CM	Cameroon	LK	Sri Lanka	SK	Slovakia
CN	China	LB	Liberia	SN	Senegal
CS	Czechoslovakia	LT	Lithuania	SZ	Swaziland
CZ	Czech Republic	LU	Luxembourg	TD	Chad
DE	Germany	LV	Latvia	TG	Togo
DK	Denmark	MC	Monaco	TJ	Tajikistan
EE	Estonia	MD	Republic of Moldova	TT	Trinidad and Tobago
ES	Spain	MG	Madagascar	UA	Ukraine
FI	Finland	ML	Mali	UG	Uganda
FR	France	MN	Mongolia	US	United States of America
GA	Gabon	MR	Mauritania	UZ	Uzbekistan
				VN	Viet Nam

BEST AVAILABLE COPY

## DESCRIPTION

N-Acyl[peptide]<sub>n</sub>[carboxylamino-carboxyl]<sub>m</sub> acids and their use as glycoprotein IIb/IIIa antagonists and fibrinogen - blood platelets binding inhibitors

## 5 TECHNICAL FIELD

The present invention relates to β-alanine derivative and a pharmaceutically acceptable salt thereof. More particularly, it relates to β-alanine derivative and a salt thereof which is glycoprotein IIb/IIIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets.

10

## BACKGROUND ART

In European Patent Application No. 512,831 A1, there are disclosed fibrinogen receptor antagonists.

15 In European Patent Application No. 445,796 A2, there are disclosed inhibitor of blood platelets aggregation.

## DISCLOSURE OF INVENTION

20 The present invention relates to β-alanine derivative and a salt thereof. More particularly, it relates to β-alanine derivative and a salt thereof which is glycoprotein IIb/IIIa antagonist and inhibitor of platelet aggregation, and useful as :

25 a drug for the prevention and/or the treatment of diseases caused by thrombus formation such as arterial thrombosis; arterial sclerosis; ischemic heart diseases [e.g. angina pectoris (e.g. stable angina pectoris, unstable angina pectoris including imminent infarction,

30 etc.), myocardial infarction (e.g. acute myocardial infarction, etc.), coronary thrombosis, etc.]; ischemic brain diseases [e.g. cerebral infarction (e.g. cerebral thrombosis (e.g. acute cerebral thrombosis, etc.), cerebral embolism, etc.), transient cerebral ischemia

35 (e.g. transient ischemic attack, etc.), cerebrovascular

spasm after cerebral hemorrhage (e.g. cerebrovascular spasm after subarachnoid hemorrhage, etc.), etc.); pulmonary vascular diseases (e.g. pulmonary thrombosis, pulmonary embolism etc.); peripheral circulatory disorder

5 [e.g. arteriosclerosis obliterans, thromboangiitis obliterans (i.e. Buerger's disease), Raynaud's disease, complication of diabetes mellitus (e.g. diabetic angiopathy, diabetic neuropathy, etc.), phlebothrombosis (e.g. deep vein thrombosis, etc.), etc.] or the like;

10 a drug for the prevention and/or the treatment of restenosis and/or reocclusion such as restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty (PTCA), restenosis and/or reocclusion after the administration of thrombolytic drug (e.g. tissue plasminogen activator (TPA), etc.) or the like;

15 a drug for the adjuvant therapy with thrombolytic drug (e.g. TPA, etc.) or anticoagulant (e.g. heparin, etc.);

20 a drug for the prevention and/or the treatment of the thrombus formation in case of vascular surgery, valve replacement, extracorporeal circulation [e.g. surgery (e.g. open heart surgery, pump-oxygenator, etc.)

25 hemodialysis, etc.], transplantation, or the like; a drug for the prevention and/or the treatment of disseminated intravascular coagulation (DIC), thrombotic thrombocytopenia, essential thrombocytosis, inflammation (e.g. nephritis, etc.), immune diseases, or the like; a drug for inhibiting of metastasis; or the like.


30 The β-alanine derivative of the present invention is expected to be useful as an inhibitor of cell adhesion and so is expected to be useful as

35 a drug for the prevention and/or the treatment of disseminated intravascular coagulation (DIC), thrombotic thrombocytopenia, essential thrombocytosis, inflammation

to 3 nitrogen atom(s), which may have one or more lower alkyl; ar(lower)alkoxy(lower)alkyl; hydroxy(lower)alkyl; lower alkoxy(lower)alkyl; cyclo(lower)alkyl; aroylamino(lower)alkyl; lower alkanoylamino(lower)alkyl which may have halogen; lower alkanoylamino having halogen; and aroylamino having halo(lower)alkyl; then R<sup>2</sup> is pentyloxycarbonyl, isopentyloxycarbonyl, isohexyloxycarbonyl, phenethyloxycarbonyl, aryloxycarbonyl or indanyloxycarbonyl, or a salt thereof.


The object compound (I) or a salt thereof can be prepared by the following processes.

Process 1



(e.g. nephritis, etc.), immune diseases, or the like; a drug for inhibiting of metastasis; or the like.

The object β-alanine derivative of the present invention can be shown by the following formula (I) :



wherein R<sup>1</sup> is piperidyl, piperidyl having amino protective group, tetrahydropyridyl, tetrahydropyridyl having amino protective group, azetidiny, azetidiny having amino protective group, tetrahydroisquinolyl or tetrahydroisquinolyl having amino protective group,

R<sup>2</sup> is carboxy or protected carboxy,

A<sup>1</sup> is lower alkylene, lower alkanyl-ylidene, lower alkenylene, cyclo(lower)alkylene or arylene,

A<sup>2</sup> is lower alkylene which may have one or more suitable substituent(s) or arylene,

$\text{---} \text{N} \text{---}$  is piperidinediyl or

tetrahydroisquinolinediyl, and

m is an integer of 0 or 1,


with proviso that

when R<sup>1</sup> is piperidyl,


A<sup>1</sup> is lower alkylene, and

A<sup>2</sup> is lower alkylene which may have one or more suitable substituent(s) except 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1

Process 3




(Ia)  
or a salt thereof




(Ib)  
or a salt thereof

Process 4




(Ic)  
or a salt thereof




(I)  
or a salt thereof

Process 2




(IV)  
or its reactive derivative at the carboxy group or a salt thereof

(V)  
or its reactive derivative at the amino group or a salt thereof



(I)  
or a salt thereof




(Id)  
or a salt thereof

### Process 5



### protecting reaction of carboxy

(Ie)  
or its reactive derivative  
at the carboxy group  
or a salt thereof



(If)  
or a salt thereof

wherein  $R^1, R^2, A^1, A^2, \bigcirc_{-N}$  and  $m$  are each as defined

**above,**

$R_a^1$  is piperidyl having amino protective group, tetrahydropyridyl having amino protective group, azetidyl having amino protective group or tetrahydroisoquinolyl having amino protective group,


$R_B^1$  is piperidyl, tetrahydropyridyl, azetidyl or tetrahydroisoquinolyl,

R<sub>2</sub> is protected carboxy, and

$\text{HN} \bigcirc$  is piperidyl or tetrahydroisoquinolyl.

The starting compound (IV) or a salt thereof is novel and can be prepared by the following schemes.

**Process A**




(II)

or its reactive derivative  
at the carboxy group  
or a salt thereof

(VI)

or its reactive derivative  
at the amino group  
or a salt thereof



(VII).  
or a salt thereof



by a conventional protecting group such as an esterified carboxy group, or the like, and concrete examples of the ester moiety in said esterified carboxy group may be the ones such as lower alkyl ester [e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, isopentyl ester, hexyl ester, isohexyl ester, 1-cyclopropylethyl ester, etc.] which may have suitable substituent(s), for example, lower alkanoyloxy(lower)alkyl ester [e.g.

10 acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, 1-acetoxylethyl ester, 1-propionyloxyethyl ester, pivaloyloxyethyl ester, 2-propionyloxyethyl ester, hexanoyloxymethyl ester, etc.], lower-alkanesulfonylethyl(lower)alkyl ester [e.g. 2-mesyloxyethyl ester, etc.] or mono(or di or tri)halo(lower)alkyl ester [e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.];

higher alkyl ester [e.g. heptyl ester, octyl ester, 3,5-dimethyloctyl ester, 3,7-dimethyloctyl ester, nonyl ester, decyl ester, undecyl ester, dodecyl ester, tridecyl ester, tetradecyl ester, pentadecyl ester, hexadecyl ester, heptadecyl ester, octadecyl ester, nonadecyl ester, adamantyl ester, etc.];

25 lower alkenyl ester [e.g. (C<sub>2</sub>-C<sub>6</sub>)alkenyl ester (e.g. vinyl ester, allyl ester, etc.)]; lower alkynyl ester [e.g. (C<sub>2</sub>-C<sub>6</sub>)alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.)];

30 ar(lower)alkyl ester which may have one or more suitable substituent(s) [e.g. phenyl(lower)alkyl ester which may have 1 to 4 lower alkoxy, halogen, nitro, hydroxy, lower alkyl, phenyl, or halo(lower)alkyl, (e.g. benzyl ester, 4-methoxybenzyl ester, 4-chlorobenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester,

35

4-hydroxy-3,5-di-tert-butylbenzyl ester, 4-trifluoromethylbenzyl ester, etc.); aryl ester which may have one or more suitable substituent(s) [e.g. phenyl ester which may have 1 to 4 lower alkyl, or halogen, (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, 4-tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.), indanyl ester, etc.];

5 cycloalkyloxycarbonyloxy(lower)alkyl ester which may have lower alkyl (e.g., cyclopentyloxycarbonyloxymethyl ester, cyclohexyloxycarbonyloxymethyl ester, cycloheptyloxycarbonyloxymethyl ester, 1-methylcyclohexyloxycarbonyloxymethyl ester, 1-(or 2)-[cyclopentyloxycarbonyloxy]ethyl ester, 1-(or 2)-[cyclohexyloxycarbonyloxy]ethyl ester, 1-(or 2)-[cycloheptyloxycarbonyloxy]ethyl ester, etc.); (5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl)(lower)alkyl ester [e.g., (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl ester, 1-(or 2)-(5-methyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, 1-(or 2)-(5-ethyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, 1-(or 2)-(5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.]; or the like,

20 in which the preferred one may be lower alkyl ester, ar(lower)alkyl ester, aryl ester which may have one or more suitable substituent(s) cycloalkyloxycarbonyloxy-(lower)alkyl ester or lower alkanoyloxy(lower)alkyl ester, and the more preferred one may be methyl ester, ethyl ester, butyl ester, pentyl ester, isopentyl ester, isohexyl ester, phenethyl ester, phenyl ester, indanyl ester, pivaloyloxymethyl ester or

30 1-cyclohexyloxycarbonyloxylethyl ester.

Suitable "lower alkanyl-ylidene" may include straight or branched one such as methine, 1-ethanyl-2-ylidene,

35

dioxol-4-yl](lower)alkyl [e.g. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, etc.] or the like; and the like.

Suitable "acyl group" and "acyl" may include

5 aliphatic acyl, aromatic acyl, arylaliphatic acyl and heterocyclic-aliphatic acyl derived from carboxylic acid, carbonic acid, carbamic acid, sulfonic acid, and the like.

Suitable example of said "acyl group" may be

10 illustrated as follows :

aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);

20 lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.);

lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.);

lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); or the like;

25 aromatic acyl such as

aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.);

ar(lower)alkanoyl [e.g., phenyl(C<sub>1</sub>-C<sub>6</sub>)alkanoyl (e.g.,

phenylacetyl, phenylpropanoyl, phenylbutanoyl,

30 phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.),

naphthyl(C<sub>1</sub>-C<sub>6</sub>)alkanoyl (e.g., naphthylacetyl,

naphthylpropanoyl, naphthylbutanoyl, etc), etc.);

ar(lower)alkenoyl [e.g., phenyl(C<sub>3</sub>-C<sub>6</sub>)alkenoyl (e.g.,

phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl,

35 phenylpentenoyl, phenylhexenoyl, etc.), naphthyl(C<sub>3</sub>-C<sub>6</sub>)-

1-propanyl-3-ylidene, 2-methyl-1-propanyl-3-ylidene, 7-pentanyl-5-ylidene, 1-hexanyl-6-ylidene and the like.

5 Suitable "lower alkenylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, 1-ethylethylene, 2-ethylpropylene, and the like, in which the preferred one may be (C<sub>1</sub>-C<sub>4</sub>)-alkylene, and the more preferred one may be ethylene and propylene.

Suitable "lower alkenylene" may include straight or branched one having 2 to 6 carbon atom(s) such as

vinylene, 1 or 2-propenylene, 1 or 2 or 3-butenylene, 1 or

15 2 or 3-pentenylene, 1 or 2 or 3-hexenylene, 1 or 2-

methylvinylene, 1 or 2-ethylvinylene, 1 or 2 or 3-

methylpropenylene, 1 or 2 or 3-ethylpropenylene, 1 or 2 or

3 or 4-methyl-1 or 2-butenylene, or the like, in which the

preferred one may be (C<sub>2</sub>-C<sub>4</sub>)alkenylene, and the more

20 preferred one may be vinylene, 1-propenylene,

1-methylvinylene and 2-methylvinylene.

Suitable "cyclo(lower)alkylene" may be

cyclopropylene, cyclobutylene, cyclopentylene,

cyclohexylene or the like, in which the preferred one may be

25 be cyclo(C<sub>3</sub>-C<sub>6</sub>)alkylene, and the most preferred one may be cyclopropylene.

Suitable "arylene" may be phenylene, naphthylene,

anthrylene or the like, in which the preferred one may be

1,2-phenylene, 1,3-phenylene and 1,4-phenylene.

Suitable "amino protective group" may include acyl

30 group as explained below, a conventional protecting group

such as ar(lower)alkyl which may have 1 to 3 suitable

substituent(s) (e.g. benzyl, phenethyl, 1-phenylethyl,

35 benzhydryl, trityl, etc.), [5-(lower)alkyl-2-oxo-1,3-



alkenyl (e.g., naphthylpropenyl, naphthylbutenyl, etc.), etc.);

ar(lower)alkoxycarbonyl (e.g., phenyl(C<sub>1</sub>-C<sub>6</sub>)-alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.);

5 aryloxycarbonyl (e.g., phenoxycarbonyl,

naphthylloxycarbonyl, etc.);

aryloxy(lower)alkanoyl (e.g., phenoxyacetyl,

phenoxypropionyl, etc.);

arylcaramoyl (e.g., phenylcaramoyl, etc.);

10 arylthiocaramoyl (e.g., phenylthiocaramoyl, etc.);

arylglyoxyloyl (e.g., phenylglyoxyloyl,

naphthylglyoxyloyl, etc.);

arylsulfonyl which may have 1 to 4 lower alkyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like;

15 heterocyclic acyl such as

heterocycliccarbonyl;

heterocyclic(lower)alkanoyl (e.g., heterocyclicacetyl,

heterocyclicpropanoyl, heterocyclicbutanoyl,

heterocyclicpentanoyl, heterocyclichexanoyl; etc.);

20 heterocyclic(lower)alkenyl (e.g., heterocyclicpropenyl,

heterocyclicbutenyl, heterocyclicpentenyl,

heterocyclichexenyl, etc.);

heterocyclicglyoxyloyl; or the like; and the like.

heterocyclicglyoxyloyl" in the terms

Suitable "heterocyclic moiety" in the terms

25 "heterocycliccarbonyl", "heterocyclic(lower)alkyl",

"heterocyclic(lower)alkanoyl" and "heterocyclicglyoxyloyl"

as mentioned above, and "heterocyclic group" mean

saturated or unsaturated monocyclic or polycyclic

heterocyclic group containing at least one hetero-atom

30 such as an oxygen, sulfur, nitrogen atom and the like, in

which the preferable heterocyclic group may be

heterocyclic group such as

unsaturated 3 to 8-membered (more preferably 5 or

6-membered) heteromonocyclic group containing 1 to 4

35 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl,

imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

5 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;

10 unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indoliziny, benzimidazolyl, quinolyl, dihydroquinolyl, isoquinolyl, indazolyl, quinoxalinyl, dihydroquinoxalinyl, benzotriazolyl, etc.;

15 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.;

25 unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2

35

amino; amino protective group as mentioned above; hydroxy; protected hydroxy as mentioned below; cyano; nitro; carboxy; protected carboxy as mentioned above; sulfo; sulfamoyl; imino; oxo;

5 amino(lower)alkyl (e.g., aminomethyl, aminoethyl, etc.); carbamoyloxy; hydroxy(lower)alkyl (e.g., hydroxymethyl, 1 or 2-hydroxyethyl, 1 or 2 or 3-hydroxypropyl, etc.), or the like.

Suitable "protected hydroxy" may include acyl as mentioned above, phenyl(lower)alkyl which may have one or more suitable substituent(s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri(lower)alkylsilyl (e.g., trimethylsilyl, t-butyltrimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.

15 The more preferred example of "amino protective group" may be lower alkoxy carbonyl or ar(lower)alkoxy carbonyl and the most preferred one may be t-butoxy carbonyl or benzyloxy carbonyl.

20 Suitable "lower alkylene" in the term "lower alkylene which may have one or more suitable substituent(s)" can be referred to the ones as exemplified above.

25 Suitable example of "suitable substituent(s)" in the term "lower alkylene which may have one or more suitable substituent(s)" may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, etc.); lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, t-butoxy, pentyloxy, neopentyloxy, t-pentyloxy, hexyloxy, etc.);

30 lower alkenyl [e.g. (C<sub>2</sub>-C<sub>6</sub>)alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl,

35

sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl, dihydrodithionyl, etc.;

5 unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;

10 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;

15 unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like.

20 The acyl moiety as mentioned above may have one to ten, same or different, suitable substituent(s) such as lower alkyl (e.g., methyl, ethyl, propyl, etc.); lower alkoxy (e.g., methoxy, ethoxy, propoxy, etc.); lower alkylthio (e.g., methylthio, ethylthio, etc.); lower alkylamino (e.g., methylamino, ethylamino, propylamino, etc.);

30 cyclo(lower)alkyl [e.g. cyclo(C<sub>3</sub>-C<sub>6</sub>)alkyl (e.g., cyclopentyl, cyclohexyl, etc.)]; cyclo(lower)alkenyl [e.g. cyclo(C<sub>3</sub>-C<sub>6</sub>)alkenyl (e.g., cyclohexenyl, cyclohexadienyl, etc)];

halogen (e.g., fluorine, chlorine, bromine, iodine);

35

etc.);  
 lower alkynyl (e.g. (C<sub>2</sub>-C<sub>6</sub>)alkynyl (e.g., ethynyl,  
 1-propynyl, propargyl, 1-methylpropargyl,  
 1-ethylpropargyl, 1 or 2 or 3-butynyl, 1 or 2 or 3 or 4-  
 pentynyl, 1 or 2 or 3 or 4 or 5 hexynyl, etc.);  
 mono(or di or tri)halo(lower)alkyl (e.g., fluoromethyl,  
 difluoromethyl, trifluoromethyl, chloromethyl,  
 dichloromethyl, trichloromethyl, bromomethyl,  
 dibromomethyl, tribromomethyl, 1 or  
 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl,  
 1,1-difluoroethyl, 2,2-difluoroethyl, etc.);  
 halogen (e.g., chlorine, bromine, fluorine, iodine);  
 carboxy; protected carboxy as mentioned above; hydroxy;  
 protected hydroxy as mentioned above;  
 aryl (e.g., phenyl, naphthyl, etc.);  
 heterocyclic group as mentioned above (e.g. unsaturated 3  
 to 8-membered (more preferably 5 or 6-membered)  
 heteromonocyclic group containing 1 to 2 oxygen atom(s)  
 and 1 to 3 nitrogen atom(s) for example, oxazolyl,  
 isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-  
 oxadiazolyl, 1,2,5-oxadiazolyl, etc.),  
 unsaturated 3 to 8-membered (more preferably 5 or 6-  
 membered) heteromonocyclic group containing 1 to 4  
 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl,  
 imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl,  
 pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-  
 triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.),  
 tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.),  
 etc.), in which said heteromonocyclic group as mentioned  
 above may have one or more, same or different, suitable  
 substituent(s) such as lower alkyl (e.g., methyl, ethyl,  
 propyl, etc.), lower alkoxy (e.g., methoxy, ethoxy,  
 propoxy, etc.), or the like);  
 ar(lower)alkyl such as phenyl(lower)alkyl (e.g., benzyl,  
 phenethyl, phenylpropyl, etc.);

ar(lower)alkyl having one or more suitable substituent(s)  
 such as ar(lower)alkyl having one or more (preferably 1 to  
 4) lower alkoxy, halogen, cyano, halo(lower)alkyl, lower  
 alkylene dioxy or the like;  
 carboxy(lower)alkyl; protected carboxy(lower)alkyl;  
 nitro; amino;  
 protected amino, i.e. amino protected by aforesaid "amino  
 protective group", preferably, acylamino, in which acyl  
 moiety can be aforementioned "acyl", such as aliphatic  
 acylamino such as lower or higher alkanoylamino which may  
 have one or more suitable substituent(s) (e.g.,  
 formylamino, acetylamino, trifluoroacetylamino,  
 propanoylamino, butanoylamino, 2-methylpropanoylamino,  
 pentanoylamino, 2,2-dimethylpropanoylamino, hexanoylamino,  
 heptanoylamino, octanoylamino, nonanoylamino,  
 decanoylamino, undecanoylamino, dodecanoylamino,  
 tridecanoylamino, tetradecanoylamino, pentadecanoylamino,  
 hexadecanoylamino, heptadecanoylamino, octadecanoylamino,  
 nonadecanoylamino, icosanoylamino, etc.),  
 cyclo(lower)alkylcarbonylamino (e.g. cyclo(C<sub>3</sub>-C<sub>6</sub>)-  
 alkylcarbonylamino (e.g. cyclopropylcarbonylamino,  
 cyclobutylcarbonylamino, cyclopentylcarbonylamino,  
 cyclohexylcarbonylamino, etc.)), lower or higher  
 alkoxycarbonylamino (e.g., methoxycarbonylamino,  
 ethoxycarbonylamino, t-butoxycarbonylamino,  
 pentyloxycarbonylamino, heptyloxycarbonylamino, etc.),  
 lower alkoxy(lower)alkanoylamino (e.g. methoxyacetylamino,  
 2- or 3-methoxypropionylamino, ethoxyacetylamino, 2- or 3-  
 ethoxypropionylamino, etc.),  
 lower alkynylcarbonylamino (e.g. (C<sub>2</sub>-C<sub>6</sub>)-  
 alkynylcarbonylamino (e.g. propargylcarbonylamino,  
 1-methylpropargylcarbonylamino,  
 1- or 2- or 3-butynylcarbonylamino, etc.),  
 lower or higher alkylsulfonylamino (e.g.,  
 methylsulfonylamino, ethylsulfonylamino,

propylsulfonylamino, n-butylsulfonylamino, sec-butylsulfonylamino, t-butylsulfonylamino, n-pentylsulfonylamino, neo-pentylsulfonylamino, hexylsulfonylamino, etc.),

5 lower or higher alkoxysulfonfylamino (e.g., methoxysulfonfylamino, ethoxysulfonfylamino, etc.), aroylamino which may have one or more (preferably 1 to 3) suitable substituent(s) (e.g. benzoylamino, toluoylamino, naphthoylamino, 2- or 3- or 4-hydroxybenzoylamino, 2- or naphthoylamino, 2- or 3- or 4-methoxybenzoylamino, 2- or 3- or 4-chlorobenzoylamino, 2- or 3- or 4-trifluorobenzoylamino, phenylbenzoylamino, etc.),

10 ar(lower)alkanoylamino [e.g., phenyl(C<sub>1</sub>-C<sub>6</sub>)alkanoylamino (e.g., phenylacetylamino, phenylpropanoylamino, phenylbutanoylamino, phenylisobutanoylamino, phenylpentanoylamino, phenylhexanoylamino, etc.), naphthyl(lower)alkanoylamino (e.g., naphthylacetylamino, naphthylpropanoylamino, naphthylbutanoylamino, etc.), etc.),

15 ar(lower)alkenoylamino [e.g., phenyl(C<sub>3</sub>-C<sub>6</sub>)alkenoylamino (e.g., phenylpropenoylamino, phenylbutenoylamino, phenylmethacryloylamino, phenylpentenoylamino, phenylhexenoylamino, etc.), naphthyl(C<sub>3</sub>-C<sub>6</sub>)alkenoylamino (e.g., naphthylpropenoylamino, naphthylbutenoylamino, etc.), etc.),

20 ar(lower)alkoxycarbonylamino [e.g., phenyl(C<sub>1</sub>-C<sub>6</sub>)alkoxy-carbonylamino (e.g. benzylloxycarbonylamino, phenethylloxycarbonylamino, etc.), etc.),

25 aryloxycarbonylamino (e.g., phenoxycarbonylamino, naphthylloxycarbonylamino, etc.),

30 aryloxy(lower)alkanoylamino (e.g., phenoxyacetylamino, phenoxypionylamino, etc.),

arylcarbamoyleamino (e.g., phenylcarbamoyleamino, etc.),

arylthiocarbamoyleamino (e.g., phenylthiocarbamoyleamino, etc.).

35 etc.).

arylglyoxyloylamino (e.g., phenylglyoxyloylamino, naphthylglyoxyloylamino, etc.),

arylsulfonfylamino (e.g. phenylsulfonfylamino, p-tolylsulfonfylamino, etc.), or the like;

5 di(lower)alkylamino (e.g., dimethylamino, diethylamino, diisopropylamino, ethylmethylamino, isopropylmethylamino, ethylmethylamino, ethylpropylamino, etc.);

hydroxy(lower)alkyl; protected hydroxy(lower)alkyl; acyl as mentioned above; cyano; mercapto; oxo;

10 lower alkylthio(lower)alkyl (e.g. methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, methylthioethyl, ethylthioethyl, etc.);

arylthio(lower)alkyl (e.g. phenylthiomethyl, phenylthioethyl, etc.);

15 arylsulfonyl(lower)alkyl (e.g. phenylsulfonylmethyl, phenylsulfonylethyl, p-tolylsulfonylmethyl, p-tolylsulfonylethyl, etc.);

lower alkylsulfonyl(lower)alkyl (e.g. methylsulfonylmethyl, ethylsulfonylmethyl, etc.);

20 propylsulfonylmethyl, etc.);

acylamino(lower)alkyl which may have one or more suitable substituent(s), in which acyl moiety can be aforementioned "acyl" [e.g., arylsulfonfylamino(lower)alkyl (e.g., phenylsulfonfylaminomethyl, phenylsulfonfylaminoethyl, p-tolylsulfonfylaminomethyl, p-tolylsulfonfylaminoethyl, etc.),

25 lower alkylsulfonfylamino(lower)alkyl (e.g., methylsulfonfylaminomethyl, ethylsulfonfylaminomethyl, propylsulfonfylaminomethyl, butylsulfonfylaminomethyl, t-butylsulfonfylaminomethyl, pentylsulfonfylaminoethyl, etc.), lower alkanoylamino(lower)alkyl which may have one or more suitable substituent(s) (e.g., acetylaminoethyl, acetylaminomethyl, trifluoroacetylaminoethyl, etc.), aroylamino(lower)alkyl

30 (e.g., benzoylaminoethyl, benzoylaminoethyl, naphthoylaminoethyl, etc.), etc.);

lower alkoxy(lower)alkyl (e.g., methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, propoxymethyl, propoxyethyl, butoxyethyl, pentyloxymethyl, hexyloxyethyl, etc.);

5 cyclo(lower)alkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.);  
ar(lower)alkoxy(lower)alkyl (e.g., benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, benzyloxypropyl, benzyloxyhexyl, phenethyloxymethyl, phenethyloxyethyl, etc.) and the like,

10 in which the more preferred "suitable substituent(s)" in the term "lower alkylene which may have one or more suitable substituent(s)" may be (C<sub>1</sub>-C<sub>6</sub>)alkyl; (C<sub>2</sub>-C<sub>6</sub>)alkynyl; phenyl; phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl; (C<sub>1</sub>-C<sub>6</sub>)alkanoylamino; aroylamino; 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) which may have lower alkyl;

15 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s);

20 phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl having 1 or 2 (C<sub>1</sub>-C<sub>6</sub>)alkoxy; (C<sub>1</sub>-C<sub>6</sub>)alkoxy(C<sub>1</sub>-C<sub>6</sub>)alkyl;

cyclo(C<sub>1</sub>-C<sub>6</sub>)alkyl; hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl; phenyl(C<sub>1</sub>-C<sub>6</sub>)alkoxy(C<sub>1</sub>-C<sub>6</sub>)alkyl;

25 (C<sub>1</sub>-C<sub>6</sub>)alkanoylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl having 1 to 3 halogen; aroylamino having 1 to 3 halo(lower)alkyl;

(C<sub>1</sub>-C<sub>6</sub>)alkanoylamino having 1 to 3 halo(lower)alkyl; aroylamino having (C<sub>1</sub>-C<sub>6</sub>)alkoxy;

aroylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl; or (C<sub>1</sub>-C<sub>6</sub>)alkanoylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl;

30 and the most preferred one may be methyl, ethynyl, phenyl, phenethyl, acetylamino, benzoylamino, 3- or 4- or 5-methyl isoxazolyl, triazolyl, 4-methoxyphenethyl, 3,4-dimethoxyphenethyl, methoxymethyl, cyclopropyl, hydroxymethyl, benzyloxymethyl,

35 trifluoroacetylaminoethyl, trifluorobenzoylamino,

lower alkylcarbonyl(lower)alkyl (e.g. methylcarbonylmethyl, ethylcarbonylmethyl, propylcarbonylmethyl, etc.);

5 aroyl(lower)alkyl (e.g. benzoylmethyl, naphthoylmethyl, toluoylmethyl, anisoylmethyl, etc.);

heterocyclic(lower)alkyl such as (lower)alkyl having heterocyclic group as exemplified above (e.g. (C<sub>1</sub>-C<sub>6</sub>)alkyl having unsaturated condensed heterocyclic group containing

1 to 4 nitrogen atom(s) (e.g. indolylethyl,

10 isoindolylethyl, indolylmethyl, indolizinylolethyl, benzimidazolylethyl, quinolylethyl,

dihydroquinolylethyl, isoquinolylethyl, indazolylethyl, quinoxalinylolethyl, dihydroquinoxalinylolethyl,

benzotriazolylethyl, etc.);

15 lower alkyl sulfamoyl(lower)alkyl (e.g. methylsulfamoylmethyl, ethylsulfamoylmethyl,

n-propylsulfamoylmethyl, isopropylsulfamoylmethyl,

n-butylsulfamoylmethyl, t-butylsulfamoylmethyl,

methylsulfamoylethyl, etc.);

20 arylsulfamoyl(lower)alkyl (e.g. phenylsulfamoylmethyl, tolylsulfamoylmethyl, phenylsulfamoylethyl,

naphthylsulfamoylmethyl, etc.);

lower alkylcarbamoyl(lower)alkyl (e.g.

methylcarbamoylmethyl, ethylcarbamoylmethyl,

25 n-propylcarbamoylmethyl, isopropylcarbamoylmethyl,

n-butylcarbamoylmethyl, t-butylcarbamoylmethyl,

methylcarbamoylethyl, etc.);

arylcaramoyl(lower)alkyl (e.g. phenylcarbamoylmethyl,

tolylcarbamoylmethyl, phenylcarbamoylethyl,

30 naphthylcarbamoylmethyl, etc.);

ar(lower)alkylcarbamoyl which may have one or more

suitable substituent(s) (e.g. phenyl(C<sub>1</sub>-C<sub>6</sub>)alkylcarbamoyl


which may have 1 to 3 lower alkoxy (e.g.

2-methoxyphenethylcarbamoyl, 3-methoxyphenethylcarbamoyl,

35 4-methoxyphenethylcarbamoyl, etc.);

trifluoroacetylamino, methoxybenzoylamino, benzoylaminoethyl or acetylaminoethyl.

In the compound (I) as explained above, the preferred one is the following compound (I-A) :



wherein

R<sup>1</sup> is piperidyl, piperidyl having amino protective group, tetrahydropyridyl, tetrahydropyridyl having amino protective group, azetidyl, azetidyl having amino protective group, tetrahydroisoquinolyl, or tetrahydroisoquinolyl having amino protective group,

R<sup>2</sup> is carboxy or protected carboxy,

A<sup>1</sup> is lower alkenylene,

A<sup>2</sup> is lower alkylene,

lower alkylene which may have 1 to 3 suitable substituent(s) selected from the group consisting of lower alkyl, lower alkynyl, aryl, ar(lower)alkyl which may have 1 to 3 lower alkoxy, lower alkanoylamino which may have 1 to 3 halogen, aroylamino which may have 1 to 3 halo(lower)alkyl, heterocyclic group which may have 1 to 3 lower alkyl, lower alkoxy(lower)alkyl, cyclo(lower)alkyl, hydroxy(lower)alkyl, ar(lower)alkoxy(lower)alkyl and lower alkanoylamino(lower)alkyl which may have 1 to 3 halogen or arylene,

$\text{--}\text{N}\text{--}$  is piperidinediyl or tetrahydroisoquinolinediyl,

and

m is an integer of 1,

and the more preferred one is the aforementioned compound

(I-A), wherein

R<sup>1</sup> is piperidyl, piperidyl having amino protective group, tetrahydropyridyl, tetrahydropyridyl having amino protective group, azetidyl, azetidyl having amino protective group, tetrahydroisoquinolyl or tetrahydroisoquinolyl having amino protective group,

R<sup>2</sup> is carboxy or protected carboxy,

A<sup>1</sup> is lower alkenylene,

A<sup>2</sup> is lower alkylene,

lower alkylene which has one suitable substituent selected from the group consisting of lower alkyl, lower alkynyl, aryl, ar(lower)alkyl which may have 1 or 2 lower alkoxy, lower alkanoylamino which may have 3 halogens, aroylamino which may have one tri-halo(lower)alkyl, 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) which may have one lower alkyl, 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), lower alkoxy(lower)alkyl, cyclo(lower)alkyl, hydroxy(lower)alkyl, ar(lower)alkoxy(lower)alkyl and lower alkanoylamino(lower)alkyl which may have 3 halogens or phenylene,

$\text{--}\text{N}\text{--}$  is piperidinediyl or tetrahydroisoquinolinediyl

and

m is an integer of 1,

and the much more preferred one is the aforementioned compound (I-A), wherein

R<sup>1</sup> is piperidyl or tetrahydropyridyl,

R<sup>2</sup> is carboxy or protected carboxy,

A<sup>1</sup> is lower alkenylene,

A<sup>2</sup> is lower alkylene or lower alkylene which has one

suitable substituent selected from the group

consisting of lower alkyl, lower alkynyl, phenyl, phenyl(lower)alkyl which may have 1 or 2 lower

alkoxy, lower alkanoylamino, benzoylamino which may have one tri-halo(lower)alkyl, isoxazolyl which has one lower alkyl, triazolyl and phenyl(lower)alkoxy(lower)alkyl,

 is piperidinediyl, and

m is an integer of 1, and the most preferred one is the aforementioned compound (I-A), wherein



R<sup>1</sup> is 4-piperidyl or 4-tetrahydropyridyl,

R<sup>2</sup> is carboxy or protected carboxy,

A<sup>1</sup> is vinylene,


A<sup>2</sup> is lower alkylene or lower alkylene which has one

substituent selected from the group consisting of methyl, ethynyl, phenyl, phenethyl, acetylamino, benzoylamino, isoxazolyl having methyl, triazolyl, methoxyphenethyl, dimethoxyphenethyl, benzyloxymethyl and trifluorobenzoylamino,

 is , and

m is an integer of 1.

In the compound (I) as explained above, another preferred one is the following compound (I-B) :



wherein


R<sup>1</sup> is piperidyl,

R<sup>2</sup> is pentyloxycarbonyl, isopentyloxycarbonyl,

isohexyloxycarbonyl, phenethyloxycarbonyl,

phenyloxycarbonyl or indanyloxycarbonyl,

A<sup>1</sup> is lower alkylene,  
A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of lower alkynyl and lower alkanoylamino,

 is piperidinediyl, and

m is an integer of 1, and the much more preferred one is the aforementioned compound (I-B), wherein

R<sup>1</sup> is 4-piperidyl,



R<sup>2</sup> is pentyloxycarbonyl, isopentyloxycarbonyl,

isohexyloxycarbonyl, phenethyloxycarbonyl,

phenyloxycarbonyl or indanyloxycarbonyl,


A<sup>1</sup> is ethylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of ethynyl and acetylamino,

 is , and

m is an integer of 1.

In the compound (I) as explained above, another preferred one is the following compound (I-C) :




wherein

R<sup>1</sup> is piperidyl or piperidyl having amino protective group,

R<sup>2</sup> is carboxy or protected carboxy,


A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of 5 or 6-membered



m is an integer of 1.

In the compound (I) as explained above, another preferred one is the following compound (I-D) :



wherein

R<sup>1</sup> is tetrahydropyridyl or tetrahydropyridyl having amino protective group,

R<sup>2</sup> is carboxy or protected carboxy,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of lower alkynyl and 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) having lower alkyl,

---N--- is piperidinediyl, and

m is an integer of 1,

and the more preferred one is the aforementioned compound (I-D), wherein

R<sup>1</sup> is tetrahydropyridyl,

R<sup>2</sup> is carboxy,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of lower alkynyl and isoxazolyl having lower alkyl,

---N--- is piperidinediyl, and

heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) having lower alkyl, phenyl(lower)alkoxy(lower)alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, cyclo(lower)alkyl, benzoylamino(lower)alkyl, lower alkanoylamino(lower)alkyl, tri-halo(lower)-alkanylamino, benzoylamino having tri-halo(lower)-alkyl and tri-halo(lower)alkanoylamino(lower)alkyl or arylene,

---N--- is piperidinediyl, and

m is an integer of 1, and the more preferred one is the aforementioned compound

(I-C), wherein

R<sup>1</sup> is piperidyl,

R<sup>2</sup> is carboxy,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of isoxazolyl having lower alkyl, tri-halo(lower)alkylbenzoylamino,

benzoylamino(lower)alkyl,

tri-halo(lower)alkanoylamino(lower)alkyl,

---N--- is piperidinediyl, and

m is an integer of 1,

and the most preferred one is the aforementioned compound (I-C), wherein

R<sup>1</sup> is 4-piperidyl,

R<sup>2</sup> is carboxy,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of isoxazolyl having methyl, trifluorobenzoylamino, benzoylaminoethyl and trifluoroacetylaminomethyl,



- 31 -

m is an integer of 1, and the most preferred one is the aforementioned compound (I-D), wherein  
 $R^1$  is 4-tetrahydropyridyl,  
 $R^2$  is carboxy,  
 $A^1$  is lower alkylene,  
 $A^2$  is lower alkylene which has one substituent selected from the group consisting of ethynyl and isoxazolyl having methyl,



m is an integer of 1.

The processes for preparing the object compound (I) of the present invention are explained in detail in the following.

### Process 1

The object compound (I) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (III) or its reactive derivative at the amino group or a salt thereof.

Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic

- 32 -

carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole, tetrazole or 1-hydroxy-1H-benzotriazole; or an activated ester [e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl  $[(CH_3)_2N=C-]$  ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivative can optionally be selected from them according to the kind of the compound (II) to be used.

Suitable salts of the compound (II) and its reactive derivative can be referred to the ones as exemplified for the compound (I).

Suitable reactive derivative at the amino group of the compound (III) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound such as bis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide, bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (III) with phosphorus trichloride or phosgene, and the

or the like.

The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.

## Process 2

The object compound (I) or a salt thereof can be prepared by reacting a compound (IV) or its reactive derivative at the carboxy group or a salt thereof with a compound (V) or its reactive derivative at the amino group or a salt thereof.

This reaction can be carried out in a similar manner to that of Process 1 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. reactive derivative, solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

## Process 3

The object compound (Ib) or a salt thereof can be prepared by subjecting a compound (Ia) or a salt thereof to elimination reaction of amino protective group.

This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate

like.

Suitable salts of the compound (III) and its reactive derivative can be referred to the ones as exemplified for the compound (I).

The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.

In this reaction, when the compound (II) in used in a free acid form or its salt form, the reaction is preferable carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonylbis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkylphosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzoxazolium salt; 2-ethyl-5-(m-sulfohenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, methanesulfonyl chloride, etc.;

thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].

The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction.

Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal

platinum, platinum oxide, platinum wire, etc.), palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium, sulfate, palladium on barium

carbonate, etc.], nickel catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

The present invention includes within the scope of the invention the case that protected carboxy in R<sup>2</sup> is transformed into carboxy.

#### Process 4

The object compound (Id) or a salt thereof can be prepared by subjecting a compound (Ic) or a salt thereof to elimination reaction of the carboxy protective group.

This reaction can be carried out in a similar manner to that of Process 3 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. base, acid, catalyst, solvent, reaction temperature, etc.] of

this reaction are to be referred to those as explained in Process 3.

#### Process 5

5 The object compound (If) or a salt thereof can be prepared by subjecting the compound (Ie) or a salt thereof to protecting reaction of carboxy.

This reaction can be carried out according to a conventional manner such as the ones described in Examples 10 or the similar manners thereto.

The processes for preparing the starting compound (IV) is explained in detail in the following.

#### 15 Process A

The object compound (VII) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (VI) or its reactive derivative at the amino group or a salt thereof.

20 This reaction can be carried out in a similar manner to that of Process 1 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. reactive derivative, solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

#### Process B

The object compound (IV) or a salt thereof can be prepared by subjecting a compound (VII) or a salt thereof to elimination reaction of the carboxy protective group.

30 This reaction can be carried out in a similar manner to that of Process 3 mentioned in the above, and therefore the reaction mode and reaction conditions [e.g. base, acid, catalyst, solvent, reaction temperature, etc.] of

35

this reaction are to be referred to those as explained in Process 3.

The present invention includes within the scope of the invention the case that amino protective group in R<sup>1</sup> is transformed into amino.

5 When the object compound (I) obtained by the above-mentioned processes is in a free form, it can be converted into a salt form in a conventional manner. On the other hand, when the object compound (I) thus obtained is in a salt form, it can be converted into a free form or another salt form also in a conventional manner.

15 The compounds obtained by the above Processes 1 to 5 and A to B can be isolated and purified by a conventional method such as pulverization, recrystallization, column-chromatography, reprecipitation or the like.

20 It is to be noted that each of the object compound (I) may include one or more stereoisomer such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s) and all such isomers and mixture thereof are included within the scope of this invention.

25 The object compound (I) or a pharmaceutically acceptable salt thereof include solvated compound [e.g., enclosure compound (e.g., hydrate, etc.)].

The object compound (I) or a pharmaceutically acceptable salt thereof include both its crystal form and non-crystal form.

30 Now in order to show the utility of the object compound (I), some pharmacological test data of the representative compound (I) of the present invention are shown in the following.

35

- 39 -

Test 1 : Effect on platelet aggregation induced by  
adenosine diphosphate (ADP)

Test Compound

5 (1) the compound of Example 25

Test Method

10 platelet rich plasma (PRP) which contains  $3 \times 10^8$   
platelets/ml was prepared from human blood. To the 225  $\mu$ l  
of PRP, 25  $\mu$ l of drug solution\* was added, and then  
15 stirred for 2 minutes at 37°C. To the solution 5  $\mu$ l of  
ADP (final 2.5  $\mu$ M) was added as an aggregation inducer.  
Aggregation was measured by using an aggregometer (NBS  
HEMA-TRACER 801). Activity of inhibitor (test compound)  
was expressed as IC<sub>50</sub> value i.e. dose required for  
complete inhibition of platelet aggregation.

Drug solution\* --- Test compound was dissolved in  
water.

20 Test Result

Test Compound	IC <sub>50</sub> ( $\mu$ M)
(1)	0.085

25 The pharmaceutical composition of the present  
invention can be used in the form of a pharmaceutical  
preparation, for example, in solid, semisolid or liquid  
form, which contains the object compound (I) or a  
pharmaceutically acceptable salt thereof, as an active  
30 ingredient in admixture with an organic or inorganic  
carrier or excipient suitable for rectal, pulmonary (nasal  
or buccal inhalation), nasal, ocular, external (topical),  
oral or parenteral (including subcutaneous, intravenous  
and intramuscular) administrations or insufflation.

The active ingredient may be compounded, for example,  
with the usual non-toxic, pharmaceutically acceptable  
carriers for tablets, pellets, troches, capsules,  
suppositories, creams, ointments, aerosols, powders for  
insufflation, solutions, emulsions, suspensions, and any  
other form suitable for use. And, if necessary, in  
addition, auxiliary, stabilizing, thickening and coloring  
agents and perfumes may be used.

10 The object compound (I) or a pharmaceutically  
acceptable salt thereof is/are included in the  
pharmaceutical composition in an amount sufficient to  
produce the desired effect upon the process or condition  
of the diseases.

15 The pharmaceutical composition of the present  
invention can be manufactured by the conventional method  
in this field of the art. If necessary, the technique  
generally used in this field of the art for improving the  
bioavailability of a drug can be applied to the  
20 pharmaceutical composition of the present invention.

For applying the composition to a human being or an  
animal, it is preferable to apply it by intravenous  
(including i.v. infusion), intramuscular, pulmonary, or  
oral administration, or insufflation including aerosols  
from metered dose inhalator, nebulizer or dry powder  
inhalator.

30 While the dosage of therapeutically effective amount  
of the object compound (I) varies from and also depends  
upon the age and condition of each individual patient to  
be treated, in the case of intravenous administration, a  
daily dose of 0.001-100 mg of the object compound (I) per  
35 kg weight of a human being or an animal, in the case of

filtrate was concentrated in vacuo to give ethyl 3-amino-2(S)-(benzoylamino)propionate (0.25 g).

mp : 59°C

IR (Nujol) : 3320, 1730, 1630 cm<sup>-1</sup>

NMR (DMSO-d<sub>6</sub>, δ) : 1.19 (3H, t, J=7.0Hz), 2.93-2.97 (2H, m), 4.11 (2H, q, J=7.1Hz), 4.36-4.45 (1H, m), 7.44-7.56 (3H, m), 7.87-7.92 (2H, m), 8.59 (1H, d, J=7.0Hz)

MASS (m/z) : 237 (M<sup>+</sup>+1)

### Preparation 3

tert-butyldimethylsilyl chloride (1.42 g) was added to a mixture of 4(S)-ethynyl-2-azetidinone (0.78 g) in dichloromethane (10 ml) and ethyldiisopropylamine (2.14 ml) at room temperature. The reaction mixture was stirred overnight, then evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with n-hexane - ethyl acetate (9:1) to give 1-tert-butyldimethylsilyl-4(S)-ethynyl-2-azetidinone (1.4 g) as a colorless oil.

IR (Nujol) : 3280, 1730 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.28 (3H, s), 0.29 (3H, s), 0.98 (9H, s), 2.45 (1H, d, J=2.0Hz), 3.10 (3H, dd, J=3.0 and 15.1Hz), 3.40 (3H, dd, J=5.7 and 15.1Hz), 4.10-4.15 (1H, m)

MASS (m/z) : 210 (M<sup>+</sup>+1)

### Preparation 4

A solution of phenylisocyanate (0.93 ml) in benzene (5 ml) was added to a mixture of 1-tert-butyldimethylsilyl-4(S)-ethynyl-2-azetidinone (1.0 g) in benzene (10 ml), nitroethane (0.35 ml), and triethylamine (0.1 ml) in benzene (5 ml) at room temperature. The reaction mixture was refluxed for 8 hours, then evaporated in vacuo. The residue was purified by column

intramuscular administration, a daily dose of 0.001-100 mg of the object compound (I) per kg weight of a human being or an animal, in case of oral administration, a daily dose of 0.001-200 mg of the object compound (I) per kg weight of a human being or an animal in generally given for the prevention and/or the treatment of aforesaid diseases in a human being or an animal.

The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

### Preparation 1

To a solution of ethyl 3 azido-2(S)-aminopropionate hydrochloride (0.3 g) in dichloromethane (3 ml) was added triethylamine (0.47 ml) and benzoyl chloride (0.2 ml) under stirring at 0°C. After stirring at ambient temperature for 2 hours, the mixture was poured into water and extracted with dichloromethane. The extract was washed with water, saturated aq. NaHCO<sub>3</sub>, water and brine, and dried over magnesium sulfate, and evaporated in vacuo. The residue was recrystallized from diethyl ether to give ethyl 3 azido-2(S)-(benzoylamino)propionate (0.35 g).

mp : 56°C

IR (Nujol) : 3260, 2090, 1730, 1640 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.34 (3H, t, J=7.1Hz), 3.88 (2H, qd, J=9.0 and 3.3Hz), 4.32 (2H, d, J=7.1Hz), 4.91-4.98 (1H, m), 6.96-7.04 (1H, m), 7.42-7.59 (3H, m), 7.81-7.86 (2H, m)

MASS (m/z) : 263 (M<sup>+</sup>+1)

### Preparation 2

A mixture of ethyl 3-azido-2(S)-(benzoylamino)propionate (0.35 g) and 10% Pd-C (0.07 g) in ethanol (4 ml) was hydrogenated at an atmospheric pressure for 2 hours. After the catalyst was removed by filtration, the

chromatography on silica gel eluting with n-hexane - ethyl acetate (9:1) to give 1-tert-butyltrimethylsilyl-4(S)-(3-methyl-5-isoxazolyl)-2-azetidinone (0.96 g) as a colorless oil.

5 IR (Film) : 3120, 1740, 1605  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.05 (3H, s), 0.77 (3H, s), 0.91

(9H, s), 2.31 (3H, s), 3.22 (3H, dd, J=3.0 and

15.3Hz), 3.51 (3H, dd, J=5.8 and 15.3Hz), 4.66

(3H, dd, J=3.0 and 5.8Hz), 6.11 (1H, s)

10 MASS (m/z) : 267 ( $\text{M}^+ + 1$ )

#### Preparation 5

A solution of 1-tert-butyltrimethylsilyl-4(S)-(3-methyl-5-isoxazolyl)-2-azetidinone (0.9 g) in EtOH (10 ml) was added HCl (16.9 mmol)/EtOH (4.2 ml) at room

15 temperature at 0°C. The reaction mixture was stirred at room temperature for 2 hours, then evaporated in vacuo.

The residue was recrystallized from diethyl ether to give 3(S)-(3-methyl-5-isoxazolyl)- $\beta$ -alanine ethyl ester

20 hydrochloride (0.67 g) as a white solid.

IR (Nujol) : 3400, 2000, 1715, 1605  $\text{cm}^{-1}$

NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ) : 1.61 (3H, t, J=7.2Hz), 2.25 (3H,

s), 3.03-2.98 (2H, m), 4.08 (2H, d, J=7.2Hz),

4.80-4.88 (1H, m), 6.60 (1H, s), 9.14 (2H, br)

25 MASS (m/z) : 199 ( $\text{M}^+$  free+1)

#### Preparation 6

To a mixture of ethyl (R)-nipecotinate (1.86 g), 3-[1-(tert-butoxycarbonyl)-4-piperidyl]-(E)-acrylic acid (3.2 g) and 1-hydroxybenzotriazole (1.60 g) in dimethylformamide (20 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (2.16 ml) at 0°C. The reaction mixture was stirred overnight at room

30 temperature, and then poured into water. The whole was extracted with ethyl acetate, washed with aqueous

saturated  $\text{NaHCO}_3$ , water, and brine, dried over  $\text{MgSO}_4$ , and evaporated in vacuo, subsequently. The residue was

purified by column chromatography on silica gel eluting with  $\text{CHCl}_3$ -MeOH (99:1) to give ethyl (R)-1-[3-(1-tert-

5 butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-

piperidinecarboxylate as a colorless oil (4.46 g).

IR (Film) : 3450, 2940, 2860, 1725, 1680, 1620  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.27 (3H, t, J=7.1Hz), 1.26-1.46

(2H, m), 1.46 (9H, s), 1.52-1.82 (8H, m), 2.02-

2.14 (1H, m), 2.21-2.36 (1H, m), 2.44-2.56 (1H,

m), 2.69-2.83 (2H, m), 3.02-3.10 (1H, m), 4.08-

4.17 (2H, m), 4.15 (2H, q, J=7.1Hz), 6.27 (1H,

d, J=15.1Hz), 6.81 (1H, dd, J=6.7 and 15.1Hz)

#### Preparation 7

A solution of LiOH (0.32 g) in  $\text{H}_2\text{O}$  (20 ml) was added to a solution of ethyl (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidinecarboxylate (4.46 g) in tetrahydrofuran (20 ml)-EtOH (20 ml) at 0°C. The

20 reaction mixture was stirred for 3 hours at the same condition, and the solvent was evaporated in vacuo. The

residue was resolved in ethyl acetate - water, and acidified with 10% aq.  $\text{KHSO}_4$ . The whole was washed with

water, brine, dried over  $\text{MgSO}_4$ , and evaporated in vacuo, subsequently. The residue was recrystallized from diethyl

25 ether to give (R)-1-[3-(1-tert-butoxycarbonyl-4-

piperidyl)-(E)-acryloyl]-3-piperidinecarboxylic acid as a white solid (3.07 g).

mp : 128-129°C

IR (Film) : 1720, 1680, 1660  $\text{cm}^{-1}$

30 NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ) : 1.08-1.31 (2H, m), 1.39 (9H, s),

1.65-1.70 (5H, m), 1.84-1.99 (1H, m), 2.24-2.41

(2H, m), 2.74-2.82 (2H, m), 3.04 (1H, m), 3.32-

3.46 (2H, m), 3.85-3.98 (3H, m), 6.43 (1H, d,

J=15.8Hz), 6.60 (1H, d, J=5.4 and 15.8Hz), 12.4

Preparation 8

A mixture of 1-tert-butyltrimethylsilyl-4(S)-ethynyl-2-azetidinone (3.0 g) and trimethylsilylazide (15 ml) was heated at 80°C for 20 hours. The reaction mixture was allowed to room temperature and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with n-hexane ethyl acetate = (1:1) to give 1-tert-butyltrimethylsilyl-4(S)-(2H-1,2,3-triazol-4-yl)-2-azetidinone (0.3 g, 8.3%) as a pale yellow solid.

IR (Nujol) : 3180, 3050, 1710  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.35 (3H, s), 0.19 (3H, s), 0.85

(9H, s), 3.20 (1H, dd,  $J=2.9$  and 15.5Hz), 3.58

(1H, dd,  $J=5.7$  and 15.5Hz), 4.86 (1H, dd,  $J=2.9$  and 5.7Hz), 7.75 (1H, s)

MASS (m/z) : 253 ( $M^+$ )

Preparation 9

1-tert-Butyltrimethylsilyl-4(S)-(2H-1,2,3-triazol-4-yl)-2-azetidinone (0.3 g) was added to 6N HCl/EtOH (10 ml). The mixture was stirred for 1 hour, and then evaporated in vacuo. The crystalline solid was washed with diethyl ether to give 3(S)-(2H-1,2,3-triazol-4-yl)- $\beta$ -alanine ethyl ester hydrochloride (0.25 g, 94.4%) as a white solid.

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.04 (3H, t,  $J=7.1\text{Hz}$ ), 3.11 (2H, d,  $J=7.0\text{Hz}$ ), 4.97 (1H, t,  $J=7.0\text{Hz}$ ), 7.93 (1H, s)

MASS (m/z) : 184 ( $M^++1$ )

Preparation 10

To a solution of trimethylsulfoxonium iodide (1.16 g, 5.25 mmol) in dimethylsulfoxide (10 ml) was added sodium hydride (60% dispersion in oil, 210 mg, 5.25 mmol) under 0°C, and the solution was stirred at room temperature for 10 minutes. To the resulting mixture was added a solution of 3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acrylic acid

(1H, s)

MASS (m/z) : 367 ( $M^++1$ )



methyl ester (1.37 g, 5.09 mmol) was added dropwise under 0°C, and it was stirred for 1 hour at room temperature and for 2 hours at 50°C. After cooling to 0°C, saturated aqueous ammonium chloride was added to quench the reaction. The mixture was extracted with diethyl ether (50 ml x 2), and the organic phase was washed with brine, dried over MgSO<sub>4</sub>, filtered and evaporated in vacuo. The residue was purified by column chromatography (n-hexane/ethyl acetate = 7/1) to give 2-(1-tert-butoxycarbonyl-4-piperidyl)-(1R\*,2S\*)-cyclopropane-1-carboxylic acid methyl ester.

IR (Neat) : 1730, 1690 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.70-1.00 (2H, m), 1.10-1.50 (5H, m), 1.45 (9H, s), 1.60-2.00 (2H, m), 2.50-2.75 (2H, m), 3.66 (3H, s), 3.90-4.20 (2H, m)

MASS (m/z) : 184 (M<sup>+</sup>+1-Boc)

The following compounds [Preparations 11 to 21] were obtained according to a similar manner to that of

#### Preparation 6.

#### Preparation 11

Ethyl (R)-1-[3-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridyl)-(E)-acryloyl]-3-piperidinecarboxylate

IR (Film) : 1730, 1690, 1640, 1620, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.26 (3H, t, J=7.1Hz), 1.47 (9H, s), 1.66-1.78 (2H, m), 2.02-2.17 (2H, m), 2.30 (2H, br), 2.42-2.56 (1H, br), 2.85-3.18 (2H, br), 3.54-3.59 (2H, m), 3.84-3.95 (2H, br), 4.07 (2H, br), 4.15 (2H, d, J=7.1Hz), 6.01 (1H, br), 6.21-6.45 (1H, m), 7.28 (1H, d, J=15.0Hz)

#### Preparation 12

Ethyl (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-

(Z)-acryloyl]-3-piperidinecarboxylate

IR (Film) : 1720, 1690, 1630, 1615 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.17-1.38 (2H, m), 1.26 (3H, t, J=7.2Hz), 1.46 (9H, s), 1.65-1.77 (4H, m), 2.04-

2.11 (1H, m), 2.42-2.52 (1H, m), 2.70-3.45 (5H, m), 3.76-3.91 (1H, m), 4.04-4.60 (5H, m), 3.94-4.24 (2H, m), 5.64-5.77 (1H, m), 5.96, 6.04 (total 1H, d, J=11.6Hz)

#### Preparation 13

Ethyl (S)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidinecarboxylate

IR (Film) : 2910, 1850, 1720, 1680, 1650, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.26 (3H, t, J=7.1Hz), 1.30-1.63 (3H, m), 1.46 (9H, s), 1.69-1.88 (4H, m), 2.03-2.14 (1H, m), 2.21-2.39 (1H, m), 2.42-2.54 (1H, m), 2.70-2.82 (2H, m), 3.03-3.14 (1H, m), 3.35-3.54 (1H, m), 3.83-3.95 (1H, m), 4.08-4.75 (5H, m), 6.30 (1H, d, J=15.2Hz), 6.81 (1H, dd, J=15.2 and 6.7Hz)

MASS (m/z) : 395 (M<sup>+</sup>+1)

#### Preparation 14

Ethyl (R)-1-[3-(1-tert-butoxycarbonyl-3-azetidiny)-

(E)-acryloyl]-3-piperidinecarboxylate

IR (Neat) : 1700 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.26 (3H, t, J=7.1Hz), 1.43 (9H, s), 1.50-2.20 (4H, m), 2.20-3.20 (3H, m), 3.20-3.60 (1H, m), 3.65-4.05 (5H, m), 4.05-4.25 (3H, m), 4.40-4.75 (1H, br), 6.20-6.45 (1H, m), 6.98 (1H, dd, J=15.0 and 8.2Hz)

MASS (m/z) : 367 (M<sup>+</sup>+1)

#### Preparation 15

Ethyl (R)-1-[4-(1-tert-butoxycarbonyl-3-azetidiny)-

- 50 -

- Ethyl (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-3-methyl-(E)-acryloyl]-3-piperidinecarboxylate  
 IR (Neat) : 1730, 1690, 1630  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.25-1.60 (2H, m), 1.26 (3H, t,  $J=7.1\text{Hz}$ ), 1.46 (9H, s), 1.60-1.80 (4H, m), 1.83 (3H, s), 1.90-2.20 (3H, m), 2.30-2.55 (1H, m), 2.70 (2H, t,  $J=11.9\text{Hz}$ ), 2.80-3.40 (2H, m), 3.60-3.95 (1H, m), 4.00-4.35 (4H, m), 4.45-4.75 (1H, m), 5.78 (1H, d,  $J=13.6\text{Hz}$ )  
 MASS (m/z) : 409 ( $M^+ + 1$ )

- Preparation 20  
 Ethyl (R)-1-[4-(1-tert-butoxycarbonyl-3-piperidyl)-2-butenoyl]-3-piperidinecarboxylate  
 IR (Neat) : 1730, 1680  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.95-3.30 (16H, m), 1.45 (9H, s), 3.30-4.25 (8H, m), 4.50-4.80 (1H, m), 6.15-6.45 (1H, m), 6.75-6.90 (1H, m)  
 MASS (m/z) : 409 ( $M^+ + 1$ )

Preparation 21

- Ethyl (R)-1-[3-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridyl)propanoyl]-3-piperidinecarboxylate  
 IR (Film) : 1730, 1690, 1640  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.15-1.31 (3H, t,  $J=7.0\text{Hz}$ ), 1.46 (9H, s), 1.67-1.77 (3H, m), 2.04-2.07 (3H, m), 2.33-2.50 (5H, m), 2.98-3.11 (2H, m), 3.36-3.51 (2H, m), 3.76-3.85 (3H, m), 4.02-4.21 (3H, m), 5.38 (1H, br)

30 The following compounds [Preparation 22 to 33] were obtained according to a similar manner to that of Preparation 7.

35 Preparation 22

- 49 -

- (E)-2-butenoyl]-3-piperidinecarboxylate  
 IR (Neat) : 1690, 1650, 1620  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.27 (3H, t,  $J=7.1\text{Hz}$ ), 1.44 (9H, s), 1.45-1.95 (5H, m), 1.95-2.20 (1H, m), 2.35-2.75 (3H, m), 3.00-3.25 (1H, m), 3.35-4.25 (8H, m), 6.20-6.40 (1H, m), 6.67-6.82 (1H, m)  
 MASS (m/z) : 381 ( $M^+ + 1$ )

Preparation 16

- 10 Ethyl (R)-1-[(2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)carbonyl]-3-piperidinecarboxylate  
 IR (Nujol) : 1720, 1690, 1630  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.20-1.30 (3H, m), 1.49 (9H, m), 1.60-1.90 (3H, m), 2.05-2.20 (1H, m), 2.35-2.70 (1H, m), 2.75-2.95 (2H, m), 2.95-3.45 (4H, m), 3.65 (2H, t,  $J=5.9\text{Hz}$ ), 4.05-4.25 (2H, m), 4.58 (2H, s), 7.10-7.27 (3H, m)  
 MASS (m/z) : 417 ( $M^+ + 1$ )

20 Preparation 17

- Ethyl (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-methacryloyl]-3-piperidinecarboxylate

Preparation 18

- 25 Ethyl (R)-1-[2-(1-tert-butoxycarbonyl-4-piperidyl)-(1R\*,2S\*)-cyclopropan-1-yl-carbonyl]-3-piperidinecarboxylate  
 IR (Neat) : 1730, 1680, 1630  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.55-1.05 (2H, m), 1.05-1.35 (7H, m), 1.46 (9H, s), 1.50-1.95 (4H, m), 1.95-2.35 (1H, m), 2.35-3.65 (6H, m), 3.90-4.35 (6H, m), 4.45-4.85 (1H, m)  
 MASS (m/z) : 409 ( $M^+ + 1$ )

35 Preparation 19

(R)-1-[3-(1-tert-Butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridyl)-(E)-acryloyl]-3-piperidinecarboxylic acid

IR (Film) : 1730, 1690, 1640, 1620, 1600  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.47 (9H, s), 1.78 (2H, br), 2.09

(1H, br), 2.29 (2H, br), 2.55 (1H, br), 3.20

(2H, br), 3.54-3.60 (2H, m), 3.95 (2H, br),

4.07-4.11 (2H, m), 6.01 (1H, br), 6.28 (1H, br),

7.28 (1H, d,  $J=15.0\text{Hz}$ )

5

# Preparation 23

(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(Z)-

acryloyl]-3-piperidinecarboxylic acid

# Preparation 24

(S)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-

acryloyl]-3-piperidinecarboxylic acid

IR (Nujol) : 1705, 1680, 1660  $\text{cm}^{-1}$

NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ) : 1.08-1.31 (2H, m), 1.39 (9H, s),

1.39-1.74 (6H, m), 1.89-2.01 (1H, m), 2.24-2.44

(1H, m), 2.70-2.89 (2H, m), 2.97-3.12 (1H, m),

3.29-3.48 (1H, m), 3.80-4.01, 4.36-4.49 (total

4H, m), 6.43 (1H, d,  $J=15.5\text{Hz}$ ), 6.60 (1H, dd,

$J=15.5$  and  $5.5\text{Hz}$ ), 12.39 (1H, br)

MASS (m/z) : 367 ( $M^+ + 1$ )

25

# Preparation 25

(R)-1-[3-(1-tert-Butoxycarbonyl-3-azetidiny)-(E)-

acryloyl]-3-piperidinecarboxylic acid

IR (Neat) : 1700  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.43 (9H, s), 1.45-2.20 (3H, m),

2.20-2.85 (3H, m), 2.85-3.50 (2H, m), 3.60-4.20

(6H, m), 5.40-6.10 (1H, br), 6.20-6.50 (1H, m),

6.80-7.10 (1H, m)

30

# Preparation 26

(R)-1-[4-(1-tert-Butoxycarbonyl-3-azetidiny)-(E)-2-butenoyl]-3-piperidinecarboxylic acid

IR (Neat) : 1710, 1690  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.44 (9H, s), 1.45-2.20 (3H, m),

2.40-2.80 (4H, m), 2.90-3.95 (8H, m), 4.03 (2H,

t,  $J=8.5\text{Hz}$ ), 6.15-6.50 (1H, m), 6.70-6.84 (1H,

m)

MASS (m/z) : 353 ( $M^+ + 1$ )

5

# Preparation 27

(R)-1-[(2-tert-Butoxycarbonyl-1,2,3,4-tetrahydro-

isoquinolin-6-yl)carbonyl]-3-piperidinecarboxylic acid

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.35-1.90 (5H, m), 1.49 (9H, s),

2.00-2.25 (1H, m), 2.35-2.70 (1H, m), 2.84 (2H,

t,  $J=5.8\text{Hz}$ ), 2.95-3.40 (2H, m), 3.65 (2H, t,

$J=5.8\text{Hz}$ ), 4.58 (2H, s), 5.10-5.80 (1H, br),

7.00-7.25 (3H, m)

MASS (m/z) : 389 ( $M^+ + 1$ )

15

# Preparation 28

(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-

methacryloyl]-3-piperidinecarboxylic acid

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.15-1.45 (2H, m), 1.46 (9H, s),

1.50-1.95 (6H, m), 1.86 (3H, d,  $J=2.2\text{Hz}$ ), 2.00-

2.10 (1H, m), 2.30-2.65 (2H, m), 2.65-2.95 (2H,

m), 2.95-3.35 (2H, m), 3.80-4.25 (3H, m), 4.90-

5.80 (1H, br), 5.34 (1H, d,  $J=7.7\text{Hz}$ )

MASS (m/z) : 281 ( $M^+ + 1$ -Boc)

25

# Preparation 29

2-(1-tert-Butoxycarbonyl-4-piperidyl)-(1R\*,2S\*)-

cyclopropane-1-carboxylic acid

IR (Neat) : 1680  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.75-1.00 (2H, m), 1.15-1.60 (5H,

m), 1.46 (9H, s), 1.60-1.80 (2H, m), 2.50-2.75

35

The following compound was obtained according to a similar manner to that of Preparation 6.

#### Preparation 34

- 5 Methyl 2-[3-[1-(tert-butoxycarbonyl)-4-piperidyl]-(E)-acryloyl]-1,2,3,4-tetrahydroisoquinoline-4-carboxylate
- NMR (CDCl<sub>3</sub>, δ): 1.30-1.50 (2H, m), 1.46 (9H, s), 1.65-1.85 (2H, m), 2.20-2.50 (1H, m), 2.78 (2H, t-like), 3.50-4.00 (2H, m), 3.70 (3H, s), 4.00-4.30 (2H, m), 4.40-4.65 (2H, m), 5.00-5.25 (1H, m), 6.25-6.60 (1H, m), 6.88 (1H, dd, J=15.3 and 6.6Hz), 7.10-7.40 (4H, m)
- 10 MASS (m/z): 429 (M<sup>+</sup>+1)

MASS (m/z): 429 (M<sup>+</sup>+1)

- 15 The following compound was obtained according to a similar manner to that of Preparation 7.

#### Preparation 35

- 20 2-[3-[1-(tert-Butoxycarbonyl)-4-piperidyl]-(E)-acryloyl]-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid

#### Example 1

- To a mixture of (R)-1-[3-(1-tert-butoxycarbonyl)-4-piperidyl]-(E)-acryloyl]-3-piperidinecarboxylic acid (1 g), 3(S)-ethyl-β-alanine ethyl ester hydrochloride (0.48 g) and 1-hydroxybenzotriazole (0.37 g) in dimethylformamide (10 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.5 ml) at 0°C. The reaction mixture was stirred overnight at room temperature, and then poured into water. The whole was extracted with ethyl acetate, washed with aqueous saturated NaHCO<sub>3</sub>, water, and brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo, subsequently. The residue was purified by column chromatography on silica gel eluting with CHCl<sub>3</sub>-MeOH (99:1) to give N-[(R)-1-[3-(1-tert-
- 25
- 30
- 35

(2H, m), 3.90-4.25 (2H, m)

MASS (m/z): 170 (M<sup>+</sup>+1-Boc)

#### Preparation 30

- 5 (R)-1-[2-(1-tert-Butoxycarbonyl-4-piperidyl)-(1R\*,2S\*)-cyclopropan-1-yl-carbonyl]-3-piperidinecarboxylic acid
- IR (Neat): 1670 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ): 0.60-2.35 (11H, m), 1.45 (9H, s), 2.35-4.25 (10H, m), 6.15-7.20 (1H, br)
- 10 MASS (m/z): 381 (M<sup>+</sup>+1)

#### Preparation 31

- 15 (R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-3-methyl-(E)-acryloyl]-3-piperidinecarboxylic acid
- IR (Neat): 1730, 1690 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ): 1.25-1.60 (2H, m), 1.46 (9H, s), 1.60-1.95 (4H, m), 1.83 (3H, s), 1.95-2.20 (2H, m), 2.35-2.60 (1H, m), 2.60-2.80 (2H, m), 2.90-3.25 (2H, m), 3.25-3.55 (1H, m), 3.65-4.35 (3H, m), 4.40-4.65 (1H, m), 5.78 (1H, d, J=13.9Hz), 5.85-6.70 (1H, br)
- 20 MASS (m/z): 381 (M<sup>+</sup>+1)

#### Preparation 32

- 25 (R)-1-[4-(1-tert-Butoxycarbonyl-3-piperidyl)-2-butenoyl]-3-piperidinecarboxylic acid
- NMR (CDCl<sub>3</sub>, δ): 1.00-4.20 (21H, m), 1.45 (9H, s), 6.20-6.40 (1H, m), 6.65-6.88 (1H, m)
- 30 MASS (m/z): 381 (M<sup>+</sup>+1)

#### Preparation 33

- 35 (R)-1-[3-(1-tert-Butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridyl)propanoyl]-3-piperidinecarboxylic acid
- IR (Film): 1720, 1690 cm<sup>-1</sup>

butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine ethyl ester as a pale yellow oil (1.34 g).

IR (Film) : 3250, 2910, 2850, 1720, 1650, 1600  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.28 (3H, t,  $J=7.1\text{Hz}$ ), 1.25-1.57 (2H, m), 1.46 (9H, s), 1.70-1.80 (3H, m), 1.92-2.10 (2H, m), 2.24-2.40 (2H, m), 2.28 (1H, d,  $J=2.3\text{Hz}$ ), 2.70-2.85 (4H, m), 3.22-3.41 (2H, m), 3.65-3.80 (1H, m), 4.07-4.25 (4H, m), 4.18 (2H, q,  $J=7.1\text{Hz}$ ), 5.05-5.17 (1H, m), 6.22 (1H, d,  $J=15.1\text{Hz}$ ), 6.83 (1H, dd,  $J=7.1$  and  $15.1\text{Hz}$ ), 7.02-7.18 (1H, m)  
 MASS (m/z) : 490 ( $M^+ + 1$ )

15 The following compounds [Examples 2 to 7] were

obtained according to a similar manner to that of Example 1.

#### Example 2

20 N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-(3-methyl-5-isoxazolyl)- $\beta$ -alanine ethyl ester.

IR (Film) : 3360, 1730, 1640  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.09-1.25 (3H, m), 1.26 (3H, t,  $J=7.2\text{Hz}$ ), 1.45 (9H, s), 1.53-1.71 (6H, m), 1.91-1.95 (2H, m), 2.26 (3H, s), 2.39-2.46 (3H, m), 2.61-2.72 (2H, m), 2.87-2.93 (1H, m), 3.10 (1H, br), 3.36-3.50 (2H, m), 3.78 (1H, br), 3.96-4.07 (3H, m), 4.12 (2H, d,  $J=7.2\text{Hz}$ ), 5.57-5.78 (1H, m), 5.99 (1H, s)  
 MASS (m/z) : 549 ( $M^+$  free+1)

#### Example 3

35 N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-phenyl- $\beta$ -alanine methyl

ester

10 IR (Film) : 3000, 2930, 2860, 1740, 1670, 1650, 1600  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.24-1.56 (5H, m), 1.46 (9H, s), 1.68-1.90 (4H, m), 2.03-2.51 (3H, m), 2.69-2.90 (4H, m), 3.40-3.60 (1H, m), 3.60, 3.63 (total 3H, s), 3.70-3.88 (1H, m), 4.06-4.20 (2H, m), 5.37-5.47 (1H, m), 6.15-6.28 (1H, m), 6.78 (1H, dd,  $J=15.2$  and  $6.5\text{Hz}$ ), 7.26-7.51 (6H, m)  
 MASS (m/z) : 528 ( $M^+ + 1$ )

#### Example 4

15 N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-(acetylamino)- $\beta$ -alanine ethyl ester  
 IR (Film) : 2975, 2930, 2860  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.28 (3H, t,  $J=7.1\text{Hz}$ ), 1.25-1.60 (6H, m), 1.46 (9H, s), 1.69-1.81 (2H, m), 2.07 (3H, s), 2.21-2.52 (3H, m), 2.70-2.84 (2H, m), 3.33-3.73 (4H, m), 3.95-4.27 (6H, m), 4.64-4.72 (1H, m), 6.27 (1H, d,  $J=15.3\text{Hz}$ ), 6.82 (1H, dd,  $J=15.3$  and  $6.7\text{Hz}$ ), 7.01-7.27 (1H, m)  
 MASS (m/z) : 523 ( $M^+ + 1$ )

#### Example 5

25 N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-methyl- $\beta$ -alanine methyl ester  
 IR (Film) : 3060, 2970, 2930, 2850, 1725, 1645, 1600  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.22 (3H, t,  $J=6.8\text{Hz}$ ), 1.28-1.60 (4H, m), 1.46 (9H, s), 1.68-1.80 (3H, m), 1.86-2.03 (2H, m), 2.23-2.40 (3H, m), 2.50 (2H, d,  $J=5.5\text{Hz}$ ), 2.70-2.84 (2H, m), 3.32-3.56 (2H, m), 3.68 (3H, s), 4.00-4.19 (3H, m), 4.30-4.42 (1H, s)

- ethynyl- $\beta$ -alanine ethyl ester (1.34 g) in tetrahydrofuran (10 ml) - EtOH (10 ml) at 0°C. The reaction mixture was stirred for 3 hours at the same condition, and the solvent was evaporated in vacuo. The residue was resolved in ethyl acetate - water, and acidified with 10% aq.  $\text{KHSO}_4$ . The whole was washed with water, brine, dried over  $\text{MgSO}_4$ , and evaporated in vacuo to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine (1.23 g).
- IR (Film) : 3270, 2920, 2850, 1720, 1650, 1600  $\text{cm}^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.12-1.35 (3H, m), 1.39 (9H, s), 1.50-1.80 (5H, m), 2.14-2.38 (2H, m), 2.56-3.20 (6H, m), 3.90-4.01 (4H, m), 4.17-4.38 (1H, m), 4.77-4.87 (1H, m), 6.42 (1H, d,  $J=15.1\text{Hz}$ ), 6.60 (1H, dd,  $J=6.4$  and  $15.1\text{Hz}$ ), 8.43 (1H, d,  $J=8.2\text{Hz}$ ), 12.4 (1H, br)  
 MASS (m/z) : 462 ( $M^+ + 1$ )

The following compounds [Examples 9 to 13] were

- obtained according to a similar manner to that of Example 8.

#### Example 9

- N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-acetylaminob- $\beta$ -alanine
- IR (Film) : 2930, 1720, 1650  $\text{cm}^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.11-1.32 (3H, m), 1.39 (9H, m), 1.39-1.99 (7H, m), 1.91 (3H, m), 2.12-2.40 (1H, m), 2.51-2.86 (3H, m), 3.32-3.57 (2H, m), 3.89-4.06 (3H, m), 4.23-4.45 (2H, m), 6.39-6.67 (2H, m), 7.95-8.12 (2H, m)  
 MASS (m/z) : 495 ( $M^+ + 1$ )

#### Example 10

- N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-

- m), 6.25 (1H, d,  $J=15.2\text{Hz}$ ), 6.82 (1H, dd,  $J=6.7$ , and  $15.2\text{Hz}$ )  
 MASS (m/z) : 466 ( $M^+ + 1$ )

#### Example 6

- N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-phenethyl- $\beta$ -alanine ethyl ester
- IR (Film) : 2960, 2920, 2850, 1720, 1670, 1650  $\text{cm}^{-1}$   
 NMR (CDCl $_3$ ,  $\delta$ ) : 1.25 (3H, t,  $J=7.1\text{Hz}$ ), 1.30-1.59 (2H, m), 1.46 (9H, s), 1.66-2.16 (8H, m), 2.22-2.40 (2H, m), 2.48-2.83 (6H, m), 3.24-3.68 (3H, m), 4.01-4.37 (6H, m), 6.23 (1H, d,  $J=15.2\text{Hz}$ ), 6.81 (1H, dd,  $J=6.6$  and  $15.2\text{Hz}$ ), 7.13-7.32 (6H, m)  
 MASS (m/z) : 570 ( $M^+ + 1$ )

#### Example 7

- N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-benzoylamino- $\beta$ -alanine ethyl ester
- IR (Film) : 2980, 2930, 2860, 1740, 1670, 1655, 1600  $\text{cm}^{-1}$   
 NMR (CDCl $_3$ ,  $\delta$ ) : 1.11-1.33 (2H, m), 1.30 (3H, t,  $J=7.1\text{Hz}$ ), 1.46 (9H, s), 1.46-1.83 (6H, m), 2.09-2.55 (3H, m), 2.63-2.78 (2H, m), 3.26-3.72 (4H, m), 4.00-4.24 (5H, m), 4.82-4.90 (1H, m), 6.18 (1H, d,  $J=15.1\text{Hz}$ ), 6.67 (1H, dd,  $J=6.3$  and  $15.1\text{Hz}$ ), 7.33-7.65 (4H, m), 7.79-8.00 (3H, m)  
 MASS (m/z) : 585 ( $M^+ + 1$ )

#### Example 8

- A solution of LiOH (79 mg) in  $\text{H}_2\text{O}$  (10 ml) was added to a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-

acryloyl]-3-piperidylcarbonyl]-3(R)-methyl-β-alanine

IR (Film) : 2950, 2850, 1705, 1650, 1600  $\text{cm}^{-1}$

NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.06 (3H, d, J=6.6Hz), 1.17-1.31 (2H, m), 1.39 (9H, s), 1.51-1.85 (5H, m), 2.07-2.40 (4H, m), 2.58-3.13 (5H, m), 3.91-4.40 (5H, m), 6.42 (1H, d, J=15.1Hz), 6.60 (1H, dd, J=6.4 and 15.1Hz), 7.83 (1H, d, J=7.9Hz), 12.10-12.20 (1H, br)

MASS (m/z) : 452 ( $M^+$ +1)

10

#### Example 11

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-

acryloyl]-3-piperidylcarbonyl]-3(R)-phenethyl-β-alanine

IR (Film) : 2920, 2850, 1710, 1645  $\text{cm}^{-1}$

NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.11-1.32 (4H, m), 1.39 (9H, s), 1.60-1.89 (6H, m), 2.15-2.35 (2H, m), 2.38 (2H, d, J=6.8Hz), 2.55-3.21 (6H, m), 3.89-4.03 (4H, m), 4.20-4.40 (1H, m), 6.43 (1H, d, J=15.1Hz), 6.61 (1H, dd, J=6.3 and 15.1Hz), 7.15-7.30 (5H, m), 7.87 (1H, d, J=8.4Hz), 12.10 (1H, s)

MASS (m/z) : 542 ( $M^+$ +1)

20

#### Example 12

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-

acryloyl]-3-piperidylcarbonyl]-2(S)-benzoylamino-β-alanine

IR (Film) : 2930, 1725, 1635, 1600  $\text{cm}^{-1}$

NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.13-1.30 (2H, m), 1.39 (9H, s), 1.49-1.86 (6H, m), 2.16-2.36 (2H, m), 2.60-3.17 (4H, m), 3.38-3.69 (2H, m), 3.87-4.01 (3H, m), 4.19-4.59 (2H, m), 6.33-6.44 (1H, m), 6.59 (1H, dd, J=6.4 and 15.0Hz), 7.45-7.56 (3H, m), 7.83-7.87 (2H, m), 8.13-8.22 (1H, m), 8.58-8.64 (1H, m)

MASS (m/z) : 557 ( $M^+$ +1)

35

#### Example 13

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-phenyl-β-alanine

IR (Film) : 3000, 2960, 2930, 2855, 1715, 1650  $\text{cm}^{-1}$

NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.09-1.39 (2H, m), 1.39 (9H, s), 1.48-1.91 (6H, m), 2.14-2.37 (2H, m), 2.57-2.83 (6H, m), 3.87-4.01 (3H, m), 4.15-4.43 (1H, m), 5.18 (1H, q, J=7.6Hz), 6.34-6.66 (2H, m), 7.19-7.31 (5H, m), 8.41 (1H, d, J=8.4Hz), 12.17-12.26 (1H, br)

MASS (m/z) : 514 ( $M^+$ +1)

10

#### Example 14

To a mixture of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine (0.5 g), 4-methyl-1-pentanol (0.15 ml) and N,N-dimethylaminopyridine (13 mg) in dichloromethane (5 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.23 g) at 0°C. After stirring at an

ambient temperature overnight, the solution was evaporated in vacuo. The residue was poured into water and extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrogen carbonate, water and brine, dried over magnesium sulfate, and evaporated in vacuo,

subsequently. The residue was purified by column chromatography on silica gel eluting with  $\text{CHCl}_3$ :MeOH (100:1) to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine isohexyl ester (0.59 g) as an oil.

IR (Film) : 2930, 2860, 1735, 1680, 1630  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.89 (6H, d, J=6.6Hz), 0.97-1.29 (5H, m), 1.45 (9H, s), 1.50-2.15 (11H, m), 2.27 (1H, d, J=2.2Hz), 2.36 (3H, t, J=7.8Hz), 2.62-2.72 (5H, m), 3.29-3.40 (2H, m), 3.51 (1H, m), 4.10 (2H, t, J=6.8Hz), 4.03-4.20 (2H, m), 5.04-

35

propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine phenyl ester

IR (Film) : 3000, 2930, 2855, 1750, 1660, 1620  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.97-1.19 (2H, m), 1.45 (9H, s),  
 1.31-2.13 (11H, m), 2.29-2.40 (3H, m), 2.36 (1H, d,  $J=2.0\text{Hz}$ ), 2.68-2.73 (2H, m), 2.92-3.02 (2H, m), 3.24-3.72 (2H, m), 3.82-3.91 (1H, m), 4.02-4.12 (2H, m), 5.20-5.31 (1H, m), 7.12 (2H, d,  $J=8.1\text{Hz}$ ), 7.18-7.26 (1H, m), 7.35-7.42 (2H, m)  
 MASS (m/z) : 540 ( $M^+ + 1$ )

### Example 18

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine 5-indanyl ester

IR (Film) : 2930, 2850, 1750, 1660, 1640  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.97-1.18 (2H, m), 1.45 (9H, s), 1.45-1.94 (11H, m), 2.09 (2H, d,  $J=7.4\text{Hz}$ ), 2.30-2.37 (3H, m), 2.36 (1H, d,  $J=2.3\text{Hz}$ ), 2.59-2.72 (2H, m), 2.84-2.94 (6H, m), 3.23-3.69 (2H, m), 3.86-3.95 (1H, m), 4.01-4.11 (2H, m), 5.19-5.31 (1H, m), 6.82-6.87 (1H, m), 6.95 (1H, s), 7.19 (1H, d,  $J=8.0\text{Hz}$ )  
 MASS (m/z) : 580 ( $M^+ + 1$ )

### Example 19

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-methyl- $\beta$ -alanine (0.97 g) in ethyl acetate (10 ml) was added 4N HCl in ethyl acetate (5.37 ml) at room temperature, and the reaction mixture was stirred for 2 hours. The resulting precipitates were collected by filtration to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-methyl-

5.16 (1H, m), 6.77 and 7.01 (total 1H, d,  $J=8.6\text{Hz}$ )  
 MASS (m/z) : 548 ( $M^+ + 1$ )

The following compounds [Examples 15 to 18] were obtained according to a similar manner to that of Example 14.

### Example 15

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine isopentyl ester

IR (Film) : 3000, 2940, 2860, 1730, 1660, 1620  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 0.93 (6H, d,  $J=6.5\text{Hz}$ ), 1.02-1.21 (2H, m), 1.45 (9H, s), 1.49-1.72 (9H, m), 1.91-2.12 (2H, m), 2.27 (1H, d,  $J=2.2\text{Hz}$ ), 2.32-2.40 (3H, m), 2.60-2.77 (4H, m), 3.20-3.65 (3H, m), 4.04-4.11 (4H, m), 4.15 (2H, t,  $J=6.7\text{Hz}$ ), 5.03-5.16 (1H, m), 6.71, 7.01 (total 1H, d,  $J=8.4\text{Hz}$ )  
 MASS (m/z) : 534 ( $M^+ + 1$ )

### Example 16

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine phenethyl ester

IR (Film) : 2920, 2850, 1725, 1660, 1630  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.01-1.20 (2H, m), 1.36-2.00 (14H, m), 1.57 (9H, s), 2.25 (1H, d,  $J=2.2\text{Hz}$ ), 2.31-2.41 (2H, m), 2.59-2.75 (5H, m), 2.97 (2H, t,  $J=6.8\text{Hz}$ ), 4.02-4.14 (2H, m), 4.29-4.40 (2H, m), 7.17-7.32 (6H, m)  
 MASS (m/z) : 468 ( $M^+ - \text{Boc} + 1$ )

### Example 17

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-



- 63 -

$\beta$ -alanine hydrochloride (0.83 g).

IR (KBr pellet): 2945, 2870, 1726, 1657  $\text{cm}^{-1}$

NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 1.06 (3H, d,  $J=6.5\text{Hz}$ ), 1.21-1.39 (1H, m), 1.47-1.91 (7H, m), 2.10-2.48 (4H, m), 2.58-3.14 (4H, m), 3.20-3.29 (2H, m), 3.87-4.12 (2H, m), 4.15-4.42 (1H, m), 6.45 (1H, d,  $J=15.2\text{Hz}$ ), 6.58 (1H, dd,  $J=5.4$  and  $15.2\text{Hz}$ ), 7.86-7.95 (1H, m), 8.84-8.98 (1H, br), 9.10-9.21 (1H, br)

10 MASS (m/z): 352 ( $M^+$  free+1)

#### Example 20

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine (1.23 g) in ethyl acetate (12 ml) was added 4N HCl in ethyl acetate (6.66 ml) at room temperature, and the reaction mixture was stirred for 2 hours. The precipitates were filtered, washed with diethyl ether and purified by preparative HPLC eluting with 0.1% trifluoroacetic acid -  $\text{CH}_3\text{CN}$  (9:1), then the fractions containing the object compound were concentrated in vacuo. The residue was resolved in water, neutralized with 1N aq. NaOH, desalted by using the resin of HP-20 eluting with isopropanol -  $\text{H}_2\text{O}$  (1:1), freeze-dried to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine as a white powder (0.7 g).

IR (Film): 3200, 1660, 1580  $\text{cm}^{-1}$

NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 1.19-1.41 (2H, m), 1.59-1.88 (5H, m), 2.14-2.32 (4H, m), 2.51-2.76 (4H, m), 2.89-3.17 (4H, m), 3.89-4.42 (2H, m), 4.60-4.71 (1H, m), 6.36 (1H, d,  $J=15.1\text{Hz}$ ), 6.57 (1H, dd,  $J=6.4$  and  $15.1\text{Hz}$ ), 8.85 (1H, br)

MASS (m/z): 362 ( $M^+$ +1)

Elemental Analysis Calcd. for  $\text{C}_{19}\text{H}_{27}\text{N}_3\text{O}_4 \cdot 1.1\text{H}_2\text{O}$ :

35

- 64 -

C 59.86, H 7.72, N 11.02  
Found: C 59.70, H 7.63, N 10.91

5 The following compounds (Examples 21 and 22) were obtained according to a similar manner to that of Example 20.

#### Example 21

N-[(R)-1-[3-(4-Piperidyl)propionyl]-3-

10 piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine isohexyl ester  
IR (KBr pellet): 2953, 2936, 2868, 1736, 1657,  
1650, 1620  $\text{cm}^{-1}$

15 NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 0.86 (6H, d,  $J=6.6\text{Hz}$ ), 0.97-1.64 (18H, m), 2.24-2.69 (6H, m), 2.88-3.12 (2H, m), 3.20-3.28 (1H, m), 3.78-3.83 (2H, m), 4.01 (2H, t,  $J=6.6\text{Hz}$ ), 4.11-4.35 (1H, m), 4.80-4.92 (1H, m), 8.40-8.49 (1H, m)

MASS (m/z): 448 ( $M^+$ +1)

Elemental Analysis Calcd. for  $\text{C}_{25}\text{H}_{41}\text{N}_3\text{O}_4 \cdot \text{H}_2\text{O}$ :

20 C 64.49, H 9.31, N 9.02

Found: C 64.52, H 9.32, N 9.04

#### Example 22

N-[(R)-1-[3-(4-Piperidyl)propionyl]-3-

25 piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine isopentyl ester  
IR (KBr pellet): 3037, 2953, 2934, 2868, 1736,  
1641, 1626  $\text{cm}^{-1}$

NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 0.88 (6H, d,  $J=6.5\text{Hz}$ ), 0.97-1.77 (15H, m), 2.14-2.68 (6H, m), 2.87-3.12 (3H, m), 3.20-3.24 (1H, m), 3.68-3.84 (2H, m), 4.06 (2H, t,  $J=6.7\text{Hz}$ ), 4.13-4.34 (2H, m), 4.78-4.92 (1H, m), 8.40-8.51 (1H, m)

MASS (m/z): 434 ( $M^+$ +1)

35 Example 23

Example 25

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-phenethyl-β-alanine hydrochloride  
IR (KBr pellet): 3061, 3026, 2949, 2860, 1724,  
1653 cm<sup>-1</sup>

NMR (DMSO-d<sub>6</sub>, δ): 1.26-1.42 (1H, m), 1.49-1.85 (9H, m), 2.15-3.05 (10H, m), 3.18-3.31 (2H, m), 3.89-4.08 (2H, m), 4.20-4.42 (1H, m), 6.46 (1H, d, J=15.2Hz), 6.59 (1H, dd, J=5.3 and 15.2Hz), 7.16-7.30 (5H, m), 7.89-8.00 (1H, m), 8.88-9.00 (1H, br), 9.15-9.26 (1H, br)  
MASS (m/z): 442 (M<sup>+</sup> free+1)

[α] = -28.8° (C=1.0, MeOH)  
Elemental Analysis Calcd. for C<sub>25</sub>H<sub>35</sub>N<sub>3</sub>O<sub>4</sub>HCl · 3.5H<sub>2</sub>O:  
C 56.50, H 8.01, N 7.77

Found: C 56.56, H 7.77, N 7.57

Example 26

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-acetylamino-β-alanine hydrochloride

IR (KBr pellet): 3076, 2953, 2864, 1728, 1657 cm<sup>-1</sup>  
NMR (DMSO-d<sub>6</sub>, δ): 1.21-1.99 (10H, m), 1.85 (3H, s), 2.11-2.51 (2H, m), 2.57-3.11 (2H, m), 3.18-3.32 (2H, m), 3.35-3.48 (1H, m), 3.90-4.07 (1H, m), 4.17-4.45 (3H, m), 6.40-6.65 (2H, m), 8.07-8.27 (2H, m), 8.73-8.89 (1H, br), 9.00-9.13 (1H, br)  
MASS (m/z): 395 (M<sup>+</sup> free+1)  
[α] = -29.2° (C=1.0, MeOH)

Example 27

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-benzoylamino-β-alanine hydrochloride

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine phenethyl ester (0.53 g) in ethyl acetate (5 ml) was added 4N HCl in ethyl acetate (2.33 ml) at room temperature, and the reaction mixture was stirred for 2 hours. The resulting precipitates were collected by filtration to give N-[(R)-1-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine phenethyl ester hydrochloride (0.46 g).

IR (KBr pellet): 3028, 2945, 2864, 2804, 1736,  
1651 cm<sup>-1</sup>

NMR (DMSO-d<sub>6</sub>, δ): 1.21-1.75 (11H, m), 2.30-2.35 (2H, m), 2.61-3.10 (8H, m), 2.88 (3H, t, J=6.8Hz), 3.17-3.29 (2H, m), 3.66-3.84 (1H, m), 4.24 (2H, d, J=7.0Hz), 4.69-4.92 (1H, m), 7.20-7.35 (5H, m), 8.45-8.55 (1H, m), 8.46-8.65 (1H, br), 8.81-8.93 (1H, br)  
MASS (m/z): 468 (M<sup>+</sup> free+1)

The following compounds [Examples 24 to 29] were obtained according to a similar manner to that of Example 23.

Example 24

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-phenyl-β-alanine hydrochloride

IR (Nujol): 1725, 1645 cm<sup>-1</sup>  
NMR (DMSO-d<sub>6</sub>, δ): 1.16-1.91 (7H, m), 2.20-2.50 (4H, m), 2.60-3.00 (5H, m), 3.19-3.31 (3H, m), 4.15-4.46 (1H, m), 5.18 (1H, q, J=7.7Hz), 6.44 (1H, d, J=15.3Hz), 6.59 (1H, dd, J=15.3 and 5.2Hz), 7.19-7.32 (5H, m), 8.47-8.60 (1H, m), 8.91-9.05 (1H, br), 9.18-9.30 (1H, br)  
MASS (m/z): 414 (M<sup>+</sup> free+1)

- 67 -

- 5 IR (KBr pellet) : 2970, 2868, 1728, 1655, 1603  $\text{cm}^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.14-1.99 (9H, m), 2.14-2.50 (2H, m), 2.57-3.11 (3H, m), 3.17-3.26 (2H, m), 3.37-3.50 (2H, m), 3.86-4.57 (3H, m), 6.43 (1H, d,  $J=15.4\text{Hz}$ ), 6.57 (1H, dd,  $J=15.4$  and  $5.5\text{Hz}$ ), 7.45-7.56 (3H, m), 7.89 (2H, d,  $J=6.6\text{Hz}$ ), 8.21-8.37 (1H, m), 8.62-8.86 (2H, m), 9.00-9.12 (1H, br)  
 MASS (m/z) : 457 ( $M^+$  free+1)  
 10  $[\alpha] = -45.3^\circ$  (C=1.0, MeOH)

Example 28

- N-[(R)-1-[3-(4-Piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine phenyl ester  
 15 IR (KBr pellet) : 3043, 2953, 2862, 1755, 1653, 1616  $\text{cm}^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.21-1.91 (12H, m), 2.06-2.38 (2H, m), 2.55-3.11 (7H, m), 3.13-3.28 (2H, m), 3.35-3.39 (1H, m), 3.67-3.85 (1H, m), 4.95-5.08 (1H, m), 7.11-7.44 (5H, m), 8.69 (1H, dd,  $J=16.1$  and  $8.3\text{Hz}$ ), 8.59-8.73 (1H, br), 8.88-9.00 (1H, br)  
 MASS (m/z) : 440 ( $M^+$  free+1)  
 25 Example 29  
 N-[(R)-1-[3-(4-Piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine 5-indanyl ester  
 IR (KBr pellet) : 2945, 2862, 2812, 1755, 1653, 1616  $\text{cm}^{-1}$   
 30 NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.22-1.86 (9H, m), 1.98-2.22 (2H, m), 2.27-2.40 (2H, m), 2.59-2.85 (11H, m), 3.15-3.26 (2H, m), 3.35-3.40 (1H, m), 3.69-3.85 (1H, m), 4.10-4.37 (1H, m), 4.92-5.04 (1H, m), 6.80-6.85 (2H, m), 6.94 (1H, s) 7.23 (2H, d,  $J=7.9\text{Hz}$ ), 8.40-8.52 (1H, m), 8.60-8.68 (1H, m),  
 35

- 68 -

8.63-8.80 (1H, br)  
 MASS (m/z) : 480 ( $M^+$  free+1)

Example 30

- 5 To the solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-(3-methyl-5-isoxazolyl)- $\beta$ -alanine ethyl ester (0.8 g) in MeOH (10 ml) was added 1N aqueous NaOH (2.3 ml) at  $0^\circ\text{C}$ . The reaction mixture was stirred at room temperature for 2 hours, and then the solvent was removed in vacuo. The residue was dissolved in ethyl acetate - water, and acidified with 10% aqueous  $\text{KHSO}_4$ . The organic layer was separated and evaporated in vacuo. The residue was dissolved in ethyl acetate (8 ml), and then a solution of 4N HCl in ethyl acetate (4 ml) was added. The whole was stirred at room temperature for 2 hours, and then the solvent was removed in vacuo. The residue was powdered from diethyl ether to give N-[(R)-1-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-3(S)-(3-methyl-5-isoxazolyl)- $\beta$ -alanine hydrochloride (0.46 g) as a white solid.  
 IR (KBr pellet) : 3446, 2931, 1734, 1652, 1608  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.35-1.78 (8H, m), 1.93-2.00 (3H, s), 2.26 (3H, s), 2.45-2.53 (3H, m), 2.80-3.25 (6H, m), 3.39-3.45 (2H, m), 3.77-3.83 (1H, m), 4.08-4.22 (1H, m), 5.44-5.51 (1H, m), 6.24 (1H, d,  $J=2.2\text{Hz}$ )  
 MASS (m/z) : 421 ( $M^+$  free+1)  
 25 Example 31  
 To a mixture of (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidinecarboxylic acid (2 g) and  $\beta$ -alanine ethyl ester hydrochloride (0.84 g) and 1-hydroxybenzotriazole (0.74 g) in dimethylformamide (20 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1  
 35

- 70 -

NMR (DMSO-d<sub>6</sub>, δ) : 1.14-1.31 (2H, m), 1.39 (9H, s), 1.50-1.85 (6H, m), 2.11-2.31 (2H, m), 2.37 (2H, t, J=6.8Hz), 2.56-3.29 (7H, m), 3.90-4.01 (2H, m), 4.17-4.43 (1H, m), 6.43 (1H, d, J=15.2Hz), 6.60 (1H, dd, J=15.2 and 6.3Hz), 7.99 (1H, t, J=5.4Hz), 12.13 (1H, br)

MASS (m/z) : 438 (M<sup>+</sup>+1)

Example 33

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine ethyl ester (0.8 g) in ethyl acetate (8 ml) was added 4N HCl in ethyl acetate (4.3 ml) at 0°C, and the reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was concentrated in vacuo, and resolved in water, neutralized with saturated aqueous NaHCO<sub>3</sub>, desalted by using the resin of HP-20 eluting with isopropanol-H<sub>2</sub>O (1:1), then freeze-dried to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine ethyl ester (458 mg).

IR (KBr pellet) : 3406, 2993, 2945, 2856, 2821, 2735, 1730, 1655 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.27 (3H, t, J=7.1Hz), 1.46-1.88 (6H, m), 1.92-2.07 (3H, m), 2.39-2.57 (2H, m), 2.60 (2H, t, J=6.2Hz), 2.96-3.30 (4H, m), 3.39-3.49 (4H, m), 3.95-4.38 (2H, m), 4.17 (2H, q, J=7.1Hz), 6.48 (1H, d, J=15.7Hz), 6.60-6.73 (1H, m)

MASS (m/z) : 366 (M<sup>+</sup>+1)

Example 34

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine (1.64 g) in ethyl acetate (16 ml) was added 4N HCl

- 69 -

ml) at 0°C. The reaction mixture was stirred overnight at room temperature, and then poured into water. The whole was extracted with ethyl acetate, washed with aqueous saturated NaHCO<sub>3</sub>, water, and brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo, subsequently. The residue was purified by column chromatography on silica gel eluting with CHCl<sub>3</sub>-MeOH (99:1) to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine ethyl ester as a colorless oil (2.54 g).

IR (Film) : 2960, 2930, 2850, 1725, 1650, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.27 (3H, t, J=7.1Hz), 1.31-1.40 (2H, m), 1.46 (9H, s), 1.63-1.78 (2H, m), 1.69-1.97 (6H, m), 2.20-2.37 (2H, m), 2.52 (2H, t, J=6.1Hz), 2.69-2.83 (2H, m), 3.28 (1H, dd, J=13.5 and 9.5Hz), 3.47-3.56 (2H, m), 4.07-4.17 (3H, m), 4.16 (2H, q, J=7.1Hz), 6.23 (1H, d, J=15.1Hz), 6.45-6.64 (1H, m), 6.81 (1H, dd, J=15.1 and 6.7Hz)

MASS (m/z) : 466 (M<sup>+</sup>+1)

Example 32

A solution of LiOH (0.18 g) in water (10 ml) was added to a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine ethyl ester (1.74 g) in the mixture of tetrahydrofuran (10 ml) and ethanol (10 ml) at 0°C. The reaction mixture was stirred for overnight at room temperature, and the solvent was evaporated in vacuo. The residue was resolved in ethyl acetate-water, and acidified with 10% aqueous KHSO<sub>4</sub>. The whole was washed with water, brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine as a colorless oil (1.64 g).

IR (Film) : 2930, 2855, 1720, 1625 cm<sup>-1</sup>

in ethyl acetate (9.37 ml) at 0°C, and the reaction mixture was stirred for 2 hours at room temperature. The precipitates were filtered, washed with ether and resolved in water, neutralized with saturated aqueous NaHCO<sub>3</sub>, desalted by using the resin of HP-20 eluting with isopropanol-H<sub>2</sub>O (1:1), then freeze-dried to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine as a white powder (690 mg).

IR (KBr pellet): 3392, 3074, 2943, 2862, 2746,

2522, 1652 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ): 1.42-2.09 (9H, m), 2.39 (2H, t, J=6.8Hz), 2.43-2.70 (2H, m), 2.94-3.16 (3H, m), 3.20-3.51 (5H, m) 3.97-4.38 (2H, m), 6.47 (1H, d, J=15.5Hz), 6.59-6.72 (1H, m)

MASS (m/z): 339 (M<sup>+</sup>+1)

[α]<sub>D</sub><sup>20</sup> = -43.17° (C=1.0, MeOH)

### Example 35

To a mixture of 3(R)-(3,4-dimethoxyphenethyl)-β-alanine methyl ester (0.87 g), (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidinecarboxylic acid (1.19 g) and i-hydroxybenzotriazole (0.44 g) in dimethylformamide was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.59 ml) at 0°C. The reaction mixture was stirred overnight at room temperature, and then poured into water. The whole was extracted with ethyl acetate, washed with aqueous saturated NaHCO<sub>3</sub>, water, and brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo, subsequently. The residue was purified by column chromatography on silica gel eluting with ethyl acetate: n-hexane = (5:1) to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)-β-alanine methyl ester as a colorless oil (1.83 g).

IR (Film): 2980, 2930, 2850, 1730, 1650, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ): 1.26-1.40 (2H, m), 1.46 (9H, s), 1.68-1.91 (7H, m), 2.22-2.40 (3H, m), 2.49-2.82 (6H, m), 3.35-3.69 (2H, m), 3.65 (3H, s), 3.85 (3H, s), 3.87 (3H, s), 3.94-4.17 (3H, m), 4.26-4.37 (1H, m), 6.18-6.36 (2H, m), 6.72-6.86 (5H, m)

MASS (m/z): 616 (M<sup>+</sup>+1)

The following compounds [Examples 36 to 64] were obtained according to a similar manner to that of Example 35.

### Example 36

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

- N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl-3(R)-(4-methoxyphenethyl)]-β-alanine methyl ester
- IR (Film) : 2930, 2840, 1725, 1680, 1660, 1600 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ) : 1.30-1.40 (2H, m), 1.46 (9H, s), 1.44-1.95 (8H, m), 2.19-2.39 (3H, m), 2.48-2.84 (6H, m), 3.32-3.70 (5H, m), 3.78 (3H, s), 3.97-4.35 (4H, m), 6.16-6.35, 6.74-6.86 (total 2H, m), 6.78 (3H, q, J=6.9Hz), 7.09 (2H, d, J=8.5Hz)
- MASS (m/z) : 586 (M<sup>+</sup>+1)

10

Example 40

- N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-methoxymethyl-β-alanine methyl ester
- IR (Film) : 2955, 2850, 1720, 1640, 1600 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ) : 1.15-1.77 (9H, m), 1.46 (9H, s), 1.89-2.07 (2H, m), 2.23-2.38 (2H, m), 2.59 (2H, d, J=6.1Hz), 2.70-2.81 (3H, m), 3.20-3.51 (2H, m), 3.34 (3H, s), 3.96-4.29 (3H, m), 4.36-4.50 (1H, m), 3.68 (3H, m), 6.23 (1H, d, J=15.3Hz), 6.82 (1H, dd, J=15.3 and 6.7Hz)
- MASS (m/z) : 496 (M<sup>+</sup>+1)

15

20

Example 41

- N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-ethynyl-β-alanine ethyl ester
- IR (Film) : 3250, 2960, 2920, 2850, 1710, 1650, 1600 cm<sup>-1</sup>

25

30

- NMR (CDCl<sub>3</sub>, δ) : 1.14-1.61 (6H, m), 1.46 (9H, s), 1.69-1.80 (3H, m), 1.90-2.05 (2H, m), 2.23-2.40 (2H, m), 2.28 (1H, d, J=2.4Hz), 2.61-2.81 (4H, m), 3.27-3.38 (2H, m), 3.65-3.80 (1H, m), 4.07-4.24 (5H, m), 5.04-5.17 (1H, m), 6.24 (1H, d,

35

- IR (Film) : 3260, 1730, 1690, 1640, 1620 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ) : 1.24-1.31 (3H, m), 1.47 (9H, s), 1.50-1.55 (2H, br), 1.88-2.04 (2H, m), 2.27 (1H, d, J=2.4Hz), 2.35 (3H, br), 2.68-2.71 (2H, m), 3.40 (2H, br), 3.54-3.60 (2H, m), 3.65-3.75 (1H, m), 4.07-4.18 (6H, m), 5.09 (1H, br), 6.03 (1H, br), 7.28 (1H, d, J=15.0Hz)

5

Example 37

- N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(Z)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester
- IR (Film) : 3250, 1720, 1690, 1640, 1600 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ) : 1.26 (3H, t, J=7.2Hz), 1.20-1.46 (2H, m), 1.46 (9H, s), 1.65-1.77 (4H, m), 1.90-2.13 (3H, m), 2.29 (1H, d, J=2.4Hz), 2.35 (1H, br), 2.73-2.91 (5H, m), 3.18-3.30 (2H, m), 3.67-3.94 (1H, m), 3.94-4.24 (2H, m), 4.18 (2H, t, J=7.2Hz), 5.09-5.11 (1H, m), 5.67-5.77 (1H, m), 5.93-6.04 (1H, m)
- MASS (m/z) : 490 (M<sup>+</sup>+1)

10

15

20

Example 38

- N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-(3-methyl-5-isoxazolyl)-β-alanine ethyl ester
- IR (Film) : 3420, 3250, 1730, 1670, 1660, 1590 cm<sup>-1</sup>
- NMR (CDCl<sub>3</sub>, δ) : 1.20-1.29 (6H, m), 1.46 (9H, s), 1.71-1.77 (4H, m), 1.90 (1H, br), 2.26 (3H, s), 2.30-2.45 (2H, m), 2.70-2.90 (4H, m), 3.39-3.65 (2H, m), 4.06-4.17 (6H, m), 5.54-5.58 (1H, m), 6.00 (1H, s), 6.23 (1H, d, J=15.5Hz), 6.82 (1H, dd, J=6.6 and 15.5Hz)

25

30

Example 39

35

- 75 -

J=15.0Hz), 6.82 (1H, dd, J=15.0 and 6.7Hz),  
7.03-7.23 (1H, m)  
MASS (m/z) : 490 (M<sup>+</sup>+1)

**Example 42**

N-[(S)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-ethynyl-β-alanine ethyl ester

IR (Film) : 2960, 2925, 2850, 1715, 1650, 1600 cm<sup>-1</sup>  
NMR (CDCl<sub>3</sub>, δ) : 1.28 (3H, t, J=7.1Hz), 1.22-1.60 (4H, m), 1.46 (9H, s), 1.69-1.77 (4H, m), 1.89-2.05 (1H, m), 2.23-2.40 (2H, m), 2.28 (1H, d, J=2.4Hz), 2.69-2.82 (4H, m), 3.25-3.43 (2H, m), 3.65-3.78 (1H, m), 4.10-4.20 (4H, m), 5.04-5.15 (1H, m), 6.30 (1H, d, J=15.2Hz), 6.82 (1H, dd, J=15.2 and 6.6Hz), 6.61-6.77, 7.05-7.15 (total 1H, m)

MASS (m/z) : 490 (M<sup>+</sup>+1)

**Example 43**

N-[1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-4-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Film) : 3030, 2970, 2825, 2850, 1730, 1645, 1600 cm<sup>-1</sup>  
NMR (CDCl<sub>3</sub>, δ) : 1.29 (3H, t, J=7.1Hz), 1.25-1.50 (2H, m), 1.46 (9H, s), 1.57-1.79 (3H, m), 1.84-1.96 (2H, m), 2.20-2.44 (2H, m), 2.28 (1H, d, J=2.4Hz), 2.68-2.82 (6H, m), 2.99-3.15 (1H, m), 3.95-4.24 (5H, m), 4.54-4.68 (1H, m), 5.06-5.16 (1H, m), 6.22 (1H, d, J=15.2Hz), 6.60 (1H, d, J=8.7Hz), 6.80 (1H, dd, J=15.2 and 6.7Hz)  
MASS (m/z) : 490 (M<sup>+</sup>+1)

**Example 44**

- 76 -

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-trifluoroacetylaminomethyl-β-alanine tert-butyl ester

**Example 45**

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-(4-trifluoromethylbenzoylamino)-β-alanine ethyl ester

IR (Nujol) : 1730 cm<sup>-1</sup>  
NMR (CDCl<sub>3</sub>, δ) : 1.05-1.40 (2H, m), 1.29 (3H, t, J=7.3Hz), 1.45 (9H, s), 1.45-1.75 (4H, m), 2.05-2.45 (2H, m), 2.45-2.85 (3H, m), 3.20-3.60 (3H, m), 3.60-3.95 (2H, m), 3.95-4.30 (6H, m), 4.75-4.95 (1H, m), 6.18 (1H, d, J=15.3Hz), 6.64 (1H, dd, J=15.3 and 6.4Hz), 7.72 (3H, d-like), 7.85-8.25 (3H, m)  
MASS (m/z) : 653 (M<sup>+</sup>+1)

**Example 46**

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-trifluoroacetylaminomethyl-β-alanine ethyl ester

NMR (CDCl<sub>3</sub>, δ) : 1.20-1.40 (2H, m), 1.26 (3H, t, J=7.2Hz), 1.50-1.95 (6H, m), 2.10-2.45 (2H, m), 2.45-2.90 (3H, m), 3.20-3.55 (2H, m), 3.55-3.90 (1H, m), 3.95-4.45 (7H, m), 4.60-4.80 (1H, m), 6.21 (1H, d, J=15.3Hz), 6.81 (1H, dd, J=15.2 and 6.6Hz), 8.30-8.55 (1H, br)  
MASS (m/z) : 577 (M<sup>+</sup>+1)

**Example 47**

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-3-azetidiny)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Neat) : 1660 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.29 (3H, t, J=7.1Hz), 1.35-1.60 (1H, m), 1.44 (9H, s), 1.60-2.15 (2H, m), 2.15-2.45 (2H, m), 2.50-2.85 (3H, m), 3.10-3.50 (3H, m), 3.55-4.05 (5H, m), 4.05-4.30 (5H, m), 5.00-5.20 (1H, m), 6.20-6.40 (1H, m), 6.60-6.85 (1H, br), 7.00 (1H, dd, J=15.0 and 8.2Hz)

MASS (m/z) : 462 (M<sup>+</sup>+1)

5

Example 48

10 N-[(R)-1-[4-(1-tert-Butoxycarbonyl-3-azetidiny)]-(E)-2-butenoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

NMR (CDCl<sub>3</sub>, δ) : 1.28 (3H, t, J=7.1Hz), 1.35-2.00 (7H, m), 1.43 (9H, s), 2.20-2.85 (6H, m), 2.28 (1H, d, J=2.4Hz), 3.05-3.85 (4H, m), 4.02 (2H, t, J=8.5Hz), 4.10-4.23 (2H, m), 5.05-5.15 (1H, m), 6.15-6.40 (1H, m), 6.68-6.83 (1H, m), 6.85-7.15 (1H, m)

MASS (m/z) : 476 (M<sup>+</sup>+1)

20

Example 49

N-[(R)-1-[(2-tert-Butoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)carbonyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Nujol) : 1670 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.28 (3H, t, J=7.1Hz), 1.35-2.15 (6H, m), 1.49 (9H, s), 2.29 (1H, d, J=2.3Hz), 2.35-3.00 (5H, m), 3.00-3.60 (2H, m), 3.65 (2H, t, J=5.8Hz), 4.05-4.40 (1H, m), 4.18 (2H, q, J=7.1Hz), 4.58 (2H, s), 5.00-5.25 (1H, m), 7.05-7.25 (3H, m)

MASS (m/z) : 512 (M<sup>+</sup>+1)

30

Example 50

35 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-

methacryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Neat) : 1730, 1660 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.15-1.55 (2H, m), 1.29 (3H, t, J=7.1Hz), 1.46 (9H, s), 1.55-1.80 (5H, m), 1.80-2.05 (2H, m), 1.87 (3H, d, J=1.4Hz), 2.20-2.55 (2H, m), 2.28 (3H, d, J=2.4Hz), 2.55-2.90 (4H, m), 3.00-3.50 (1H, m), 3.50-3.95 (1H, m), 4.00-4.20 (2H, m), 4.19 (2H, q, J=7.1Hz), 5.00-5.20 (1H, m), 5.33 (1H, d, J=9.1Hz)

10

Example 51

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3,3-dimethyl-β-alanine ethyl ester

15 NMR (CDCl<sub>3</sub>, δ) : 1.26 (3H, t, J=7.1Hz), 1.25-1.40 (2H, m), 1.41 (3H, s), 1.33 (3H, s), 1.41 (9H, s), 1.50-1.75 (5H, m), 1.80-2.05 (2H, m), 2.10-2.40 (2H, m), 2.60-2.85 (4H, m), 3.10-3.35 (2H, m), 3.60-3.90 (1H, m), 4.00-4.35 (2H, m), 4.13 (2H, q, J=7.1Hz), 6.05-6.45 (2H, m), 6.81 (1H, dd, J=15.3 and 6.7Hz)

MASS (m/z) : 494 (M<sup>+</sup>+1)

20

Example 52

25 N-[(R)-1-[2-[1-tert-Butoxycarbonyl-4-piperidyl]-(1R<sup>+</sup>,2S<sup>+</sup>)-cyclopropan-1-yl]carbonyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (Neat) : 1730, 1660 cm<sup>-1</sup>

30 NMR (CDCl<sub>3</sub>, δ) : 0.60-1.05 (3H, m), 1.05-1.40 (9H, m), 1.45 (9H, s), 1.50-1.85 (8H, m), 1.85-2.20 (2H, m), 2.20-2.50 (2H, m), 2.50-2.90 (4H, m), 3.15-3.55 (2H, m), 3.60-4.30 (6H, m), 5.00-5.20 (1H, m)

MASS (m/z) : 504 (M<sup>+</sup>+1)

35



Example 53

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-3-methyl-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine ethyl ester

- 5 IR (Neat) : 1740, 1670, 1610  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.29 (3H, t,  $J=7.1\text{Hz}$ ), 1.30-1.55 (2H, m), 1.46 (9H, s), 1.55-1.80 (2H, m), 1.84 (3H, s), 1.85-2.25 (2H, m), 2.25-2.45 (1H, m), 2.26 (1H, d,  $J=2.4\text{Hz}$ ), 2.55-2.85 (5H, m), 3.05-3.40 (2H, m), 3.50-3.80 (1H, m), 4.05-4.35 (4H, m), 5.00-5.20 (1H, m), 5.70-5.90 (1H, m)
- 10

Example 54

N-[(R)-1-[4-(1-tert-Butoxycarbonyl-3-piperidyl)-(E)-2-butenoyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine ethyl ester

- 15 IR (Neat) : 1730, 1680, 1660  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.00-2.40 (12H, m), 1.28 (3H, m), 1.45 (9H, s), 2.40-2.90 (5H, m), 3.05-3.45 (3H, m), 3.50-4.30 (4H, m), 4.18 (2H, q,  $J=7.1\text{Hz}$ ), 5.00-5.20 (1H, m), 6.27 (1H, d,  $J=15.0\text{Hz}$ ), 6.65-7.00 (1H, m)
- 20 MASS (m/z) : 504 ( $M^+ + 1$ )

Example 55

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]- $\beta$ -alanine 1-(cyclohexyloxycarbonyloxy)ethyl ester

- 25 IR (Film) : 2930, 2850, 1750, 1650, 1600  $\text{cm}^{-1}$   
 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.26-1.58 (15H, m), 1.51 (9H, s), 1.69-1.81 (6H, m), 1.89-2.00 (4H, m), 2.20-2.38 (2H, m), 2.55 (2H, t,  $J=6.0\text{Hz}$ ), 2.70-2.84 (2H, m), 3.20-3.34 (1H, m), 3.44-3.61 (2H, m), 4.07-4.17 (2H, m), 4.57-4.91 (1H, m), 6.25 (1H, d,  $J=15.3\text{Hz}$ ), 6.69-6.79 (1H, m), 6.81 (1H, dd,
- 30
- 35

$J=15.3$  and  $6.7\text{Hz}$ )

MASS (m/z) : 608 ( $M^+ + 1$ )

Example 56

5 Methyl 3-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]aminobenzoate

IR (Film) : 3070, 3000, 2940, 2850, 1710, 1680, 1650, 1600  $\text{cm}^{-1}$

- 10 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.29-1.47 (2H, m), 1.45 (9H, s), 1.57-2.00 (5H, m), 2.21-2.40 (2H, m), 2.59-2.84 (3H, m), 3.54-3.61 (2H, m), 3.90 (3H, s), 3.90-3.96 (2H, m), 4.05-4.17 (2H, m), 6.24 (1H, d,  $J=15.3\text{Hz}$ ), 6.90 (1H, dd,  $J=15.1$  and  $6.4\text{Hz}$ ), 7.38 (1H, t,  $J=8.0\text{Hz}$ ), 7.75-7.86 (2H, m), 8.27 (1H, s), 9.25 (1H, s)
- 15 MASS (m/z) : 500 ( $M^+ + 1$ )

Example 57

20 Ethyl 4-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]aminobenzoate

IR (Film) : 3100, 2980, 2930, 2850, 1700, 1660, 1600  $\text{cm}^{-1}$

- 25 NMR ( $\text{CDCl}_3$ ,  $\delta$ ) : 1.26-1.46 (2H, m), 1.39 (3H, t,  $J=7.1\text{Hz}$ ), 1.46 (9H, s), 1.57-1.79 (5H, m), 2.21-2.45 (2H, m), 2.66-2.84 (3H, m), 3.48-3.80 (3H, m), 4.06-4.23 (3H, m), 4.36 (2H, q,  $J=7.1\text{Hz}$ ), 6.23 (1H, d,  $J=14.4\text{Hz}$ ), 6.84-6.95 (1H, m), 7.73 (2H, d,  $J=8.6\text{Hz}$ ), 8.00 (2H, d,  $J=8.6\text{Hz}$ ), 9.36 (1H, s)
- 30 MASS (m/z) : 514 ( $M^+ + 1$ )

Example 58

Methyl 2-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]aminobenzoate

IR (Film) : 2960, 2925, 2850, 1720, 1650, 1600  $\text{cm}^{-1}$

35

NMR (CDCl<sub>3</sub>, δ) : 1.26-1.46 (2H, m), 1.46 (9H, s),  
 1.70-1.91 (6H, m), 2.13-2.37 (2H, m), 2.45-2.60  
 (1H, m), 2.68-2.84 (2H, m), 2.90-3.46 (2H, m),  
 3.94 (3H, s), 4.04-4.19 (3H, m), 6.34 (1H, d,  
 J=15.2Hz), 6.84 (1H, dd, J=15.2 and 2.6Hz),  
 7.05-7.14 (total 1H, m), 7.51-7.60 (1H, m),  
 8.03-8.07 (1H, m), 8.69 (1H, d, J=8.5Hz), 11.19-  
 11.34 (1H, m)

MASS (m/z) : 500 (M<sup>+</sup>+1)

10

Example 59

Methyl 3-[(R)-1-[3-(1-tert-butoxycarbonyl-4-

piperidyl)propanoyl]-3-piperidylcarbonyl]aminobenzoate

IR (Film) : 2930, 1715, 1660, 1610 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.97-1.19 (2H, m), 1.45 (9H, s),  
 1.52-1.95 (9H, m), 2.27-2.45 (3H, m), 2.53-2.74  
 (3H, m), 3.38-3.59 (1H, m), 3.70-3.80 (1H, m),  
 3.91 (3H, s), 4.00-4.12 (3H, m), 7.38 (1H, t,  
 J=7.9Hz), 7.75-7.84 (2H, m), 8.26 (1H, s), 8.89  
 (1H, s)

MASS (m/z) : 402 (M<sup>+</sup>-Boc+1)

20

Example 60

Ethyl 4-[(R)-1-[3-(1-tert-butoxycarbonyl-4-

piperidyl)propanoyl]-3-piperidylcarbonyl]aminobenzoate

IR (Film) : 2960, 2930, 2850, 1680, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.98-1.18 (2H, m), 1.38 (3H, t,  
 J=7.1Hz), 1.44 (9H, s), 1.51-1.97 (8H, m), 2.25-  
 2.45 (3H, m), 2.53-2.69 (3H, m), 3.46-3.54 (2H,  
 m), 3.76-3.84 (1H, m), 3.93-4.10 (3H, m), 4.35  
 (2H, q, J=7.1Hz), 7.70 (2H, d, J=8.7Hz), 7.99  
 (2H, d, J=8.7Hz), 9.20 (1H, s)

MASS (m/z) : 416 (M<sup>+</sup>-Boc+1)

30

35 Example 61

Methyl 2-[(R)-1-[3-(1-tert-butoxycarbonyl-4-

piperidyl)propanoyl]-3-piperidylcarbonyl]aminobenzoate

IR (Film) : 3260, 2960, 2920, 2850, 1715, 1670,  
 1620, 1610 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.02-1.22 (2H, m), 1.45 (9H, s),  
 1.57-1.93 (7H, m), 2.37-3.40 (9H, m), 3.94 (3H,  
 s), 4.00-4.15 (3H, m), 4.39-4.89 (1H, m), 7.05-  
 7.17 (1H, m), 7.51-7.60 (1H, m), 8.01-8.10 (1H,  
 m), 8.67-8.72 (1H, m), 11.18-11.33 (1H, m)

MASS (m/z) : 502 (M<sup>+</sup>-Boc+1)

10

Example 62

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-

propanoyl]-3-piperidylcarbonyl]-3(s)-methoxymethyl-β-

alanine methyl ester

IR (Film) : 2910, 2850, 1725, 1670, 1620 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.03-1.26 (2H, m), 1.45 (9H, s),  
 1.37-2.07 (6H, m), 2.20-2.42 (4H, m), 2.54-2.73  
 (6H, m), 3.19-3.48 (5H, m), 3.34 (3H, s), 3.67  
 (3H, s), 4.03-4.16 (3H, m), 4.33-4.49 (1H, m),  
 6.31-6.67 (1H, m)

MASS (m/z) : 498 (M<sup>+</sup>+1)

20

Example 63

N-[(R)-1-[3-(1-tert-butoxycarbonyl-1,2,3,6-

tetrahydro-4-pyridyl)propanoyl]-3-piperidylcarbonyl]-3(S)-

ethynyl-β-alanine ethyl ester

IR (Film) : 3260, 1730, 1600 (br) cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.25-1.32 (4H, m), 1.46 (9H, s),  
 1.70-1.75 (4H, br), 1.99-2.05 (4H, m), 2.27 (1H,  
 d, J=2.4Hz), 2.35-2.41 (4H, br), 2.67-2.71 (2H,  
 m), 3.28-3.31 (2H, m), 3.46-3.52 (2H, m), 3.85  
 (2H, br), 4.07-4.19 (2H, m), 5.09 (1H, br), 5.38  
 (1H, br)

30

35

Example 64

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridyl)propanoyl]-3-piperidylcarbonyl]-3(S)-

(3-methyl-5-isoxazolyl)- $\beta$ -alanine ethyl ester

IR (Film): 3260, 1720, 1650 (br)  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ): 1.21-1.30 (4H, m), 1.46 (9H, s),

1.55-2.07 (6H, m), 2.62 (3H, s), 2.20-2.50 (4H,

m), 2.88-2.96 (2H, m), 3.22-3.52 (4H, m), 3.85

(1H, br), 3.98 (1H, br), 4.13 (3H, q,  $J=7.1\text{Hz}$ ),

5.38 (1H, br), 5.51-5.61 (1H, m), 5.99 (1H, br)

MASS (m/z): 447 ( $M^+ + 1$ -Boc)

Example 65

To a solution of N-tert-butoxycarbonyl-2-

15 hydroxymethyl- $\beta$ -alanine ethyl ester (0.5 g) in ethyl

acetate (5 ml) was added 4N HCl in ethyl acetate (5.05 ml)

at 0°C, and the reaction mixture was stirred for 2 hours

at room temperature. The reaction mixture was

concentrated in vacuo. The residue, (R)-1-[3-(1-tert-

20 butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-

piperidinecarboxylic acid (0.74 g) and

1-hydroxybenzotriazole (0.27 g) was dissolved in

dimethylformamide (5 ml), and 1-ethyl-3-

dimethylaminopropylcarbodiimide (0.55 ml) was added under

25 stirring at 0°C. After stirring at ambient temperature

for overnight, the mixture was poured into water. The

whole was extracted with ethyl acetate, washed with

aqueous saturated  $\text{NaHCO}_3$ , water, and brine, dried over

$\text{MgSO}_4$ , and evaporated in vacuo, subsequently. The residue

30 was purified by column chromatography on silica gel

eluting with  $\text{CHCl}_3:\text{MeOH} = (99:1)$  to give N-[(R)-1-[3-(1-

tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-2-hydroxymethyl- $\beta$ -alanine ethyl ester

as a colorless oil (0.37 g, 36.9%).

IR (Film): 2970, 2930, 2850, 1720, 1645, 1600  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ): 1.28 (3H, t,  $J=7.1\text{Hz}$ ), 1.32-1.46

(2H, m), 1.46 (9H, s), 1.53-2.14 (8H, m), 2.23-

2.48 (2H, m), 2.70-2.81 (3H, m), 3.34-3.85 (5H,

m), 3.99-4.19 (3H, m), 4.17 (2H, q,  $J=7.1\text{Hz}$ ),

6.23 (1H, d,  $J=15.1\text{Hz}$ ), 6.82 (1H, dd,  $J=15.2$  and

6.7Hz), 6.88-7.01 (1H, m)

MASS (m/z): 496 ( $M^+ + 1$ )

The following compounds [Examples 66 to 72] were  
10 obtained according to a similar manner to that of Example  
65.

Example 66

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-  
15 acryloyl]-3-piperidylcarbonyl]-2-benzoyloxymethyl- $\beta$ -alanine  
ethyl ester

IR (Film): 2980, 2940, 2870, 1730, 1680, 1660  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ): 1.26 (3H, t,  $J=7.1\text{Hz}$ ), 1.25-1.46

(5H, m), 1.46 (9H, s), 1.63-1.91 (4H, m), 2.16-

2.35 (2H, m), 2.68-2.88 (3H, m), 3.13-3.24 (1H,

m), 3.52-3.80 (5H, m), 4.05-4.19 (3H, m), 4.17

(2H, q,  $J=7.1\text{Hz}$ ), 4.50 (2H, s), 6.23 (1H, d,

$J=15.2\text{Hz}$ ), 6.44-6.53 (1H, m), 6.80 (1H, dd,

$J=15.2$  and 6.7Hz), 7.27-7.35 (5H, m)

MASS (m/z): 586 ( $M^+ + 1$ )

Example 67

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-  
25 benzoyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine ethyl  
ester

IR (Film): 3000, 2970, 2860, 1725, 1670, 1620  $\text{cm}^{-1}$

NMR ( $\text{CDCl}_3$ ,  $\delta$ ): 1.28 (3H, t,  $J=7.1\text{Hz}$ ), 1.20-1.31

(1H, m), 1.48 (9H, s), 1.40-2.04 (11H, m), 2.28

(1H, d,  $J=2.3\text{Hz}$ ), 2.34-2.89 (6H, m), 4.11-4.31

(5H, m), 5.06-5.16 (1H, m), 7.21-7.54 (4H, m)

35

- 86 -

J=7.1Hz), 1.45 (9H, s), 1.53-1.78 (6H, m), 1.85-2.13 (3H, m), 2.32-2.40 (4H, m), 2.60-2.79 (3H, m), 3.24-3.96 (8H, m), 4.02-4.15 (2H, m), 4.17 (2H, q, J=7.1Hz), 6.29-6.40, 6.77-6.88 (total 1H, m)  
 MASS (m/z) : 498 (M<sup>+</sup>+1)

5

Example 71

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-benzoylaminoethyl-β-alanine ethyl ester  
 IR (Film) : 3070, 2975, 2930, 2850, 1725, 1640 cm<sup>-1</sup>  
 NMR (CDCl<sub>3</sub>, δ) : 1.00-1.33 (3H, m), 1.30 (3H, t, J=7.1Hz), 1.45 (9H, s), 1.52-1.83 (7H, m), 1.90-2.12 (2H, m), 2.53-2.44 (3H, m), 2.60-2.73 (2H, m), 2.83-2.95 (1H, m), 3.12-3.41 (3H, m), 4.02-4.14 (6H, m), 4.20 (2H, q, J=7.1Hz), 6.92-7.04 (1H, m), 7.42-7.57 (4H, m), 7.83-7.86 (2H, m)  
 MASS (m/z) : 601 (M<sup>+</sup>+1)

15

Example 72

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-acetylaminoethyl-β-alanine ethyl ester  
 IR (Film) : 2920, 2850, 1720, 1650 cm<sup>-1</sup>  
 NMR (CDCl<sub>3</sub>, δ) : 1.01-1.21 (2H, m), 1.28 (3H, t, J=7.1Hz), 1.45 (9H, s), 1.37-1.98 (11H, m), 2.02 (3H, s), 2.27-2.43 (3H, m), 2.62-2.84 (3H, m), 3.05-3.36 (3H, m), 3.73-4.23 (8H, m), 6.89-7.04 (1H, m)  
 MASS (m/z) : 539 (M<sup>+</sup>+1)

30

Example 73

A mixture of N-benzyl-3-cyclopropyl-β-alanine (1.35 g), 10% Pd-C (0.27 g) and ammonium formate (1.72 g) in

35

- 85 -

MASS (m/z) : 540 (M<sup>+</sup>+1)

Example 68

N-[(R)-1-[4-(1-tert-Butoxycarbonyl-4-piperidyl)-benzoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester  
 IR (Film) : 3400, 2960, 2925, 2850, 1730, 1665, 1615 cm<sup>-1</sup>  
 NMR (CDCl<sub>3</sub>, δ) : 1.26 (3H, t, J=7.1Hz), 1.48 (9H, s), 1.57-2.04 (11H, m), 2.28 (1H, d, J=2.4Hz), 2.36-2.86 (6H, m), 7.12 (2H, q, J=7.1Hz), 4.20-4.28 (3H, m), 5.07-5.17 (1H, m), 7.23 (2H, d, J=8.2Hz), 7.27 (1H, s), 7.35 (2H, d, J=8.2Hz)  
 MASS (m/z) : 540 (M<sup>+</sup>+1)

15

Example 69

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-benzoyloxymethyl-β-alanine ethyl ester  
 IR (Film) : 2980, 2930, 2860, 1735, 1660, 1635 cm<sup>-1</sup>  
 NMR (CDCl<sub>3</sub>, δ) : 1.01-1.20 (2H, m), 1.26 (3H, t, J=7.1Hz), 1.35-1.73 (10H, m), 1.45 (9H, s), 1.79-1.91 (1H, m), 2.30-2.40 (2H, m), 2.60-2.73 (2H, m), 2.81-2.94 (2H, m), 3.06-3.23 (1H, m), 3.54-3.64 (3H, m), 3.68-3.79 (2H, m), 4.01-4.12 (3H, m), 4.17 (2H, q, J=7.1Hz), 4.51 (2H, s), 7.26-7.36 (5H, m)  
 MASS (m/z) : 588 (M<sup>+</sup>+1)

20

25

Example 70

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-hydroxymethyl-β-alanine ethyl ester  
 IR (Film) : 2970, 2930, 2855, 1710, 1660, 1620 cm<sup>-1</sup>  
 NMR (CDCl<sub>3</sub>, δ) : 1.01-1.26 (2H, m), 1.28 (3H, t,

35

ethanol (15 ml) was hydrogenated at atmospheric pressure for 2 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo. The residue, (R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidinecarboxylic acid (2 g) and 1-hydroxybenzotriazole (0.74 g) was dissolved in dimethylformamide (20 ml), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1 ml) was added under stirring at 0°C. After stirring at ambient temperature for overnight, the mixture was poured into water. The whole was extracted with ethyl acetate, washed with aqueous saturated NaHCO<sub>3</sub>, water, and brine, and dried over MgSO<sub>4</sub>, and evaporated in vacuo, subsequently. The residue was purified by column chromatography on silica gel eluting with n-hexane:AcOEt = (1:2) to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-cyclopropyl-β-alanine methyl ester as a colorless oil (2.58 g, 93.5%).

IR (Film) : 3300, 3080, 2980, 2930, 2960, 1725,

1650, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.20-0.57 (4H, m), 0.92-1.09 (1H, m), 1.22-1.57 (8H, m), 1.46 (9H, s), 1.69-1.81 (3H, m), 1.85-2.05 (1H, m), 2.21-2.39 (2H, m), 2.57-2.83 (4H, m), 3.25-3.73 (3H, m), 4.07-4.18 (5H, m), 6.23 (1H, d, J=15.3Hz), 6.82 (1H, dd, J=15.3 and 6.6Hz), 6.79-6.93 (1H, m)

MASS (m/z) : 506 (M<sup>+</sup>+1)

The following compound was obtained according to a similar manner to that of Example 73.

#### Example 74

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-3-cyclopropyl-β-alanine ethyl ester

IR (Film) : 2980, 2920, 2850, 1715, 1650, 1620 cm<sup>-1</sup>  
NMR (CDCl<sub>3</sub>, δ) : 0.20-0.57 (4H, m), 0.96-1.20 (2H, m), 1.23-1.31 (4H, m), 1.40-1.74 (9H, m), 1.45 (9H, s), 1.89-2.41 (4H, m), 2.56-2.75 (4H, m), 3.20-3.39 (1H, m), 3.49-3.65 (2H, m), 3.85-4.20 (5H, m), 6.50-6.84 (1H, m)  
MASS (m/z) : 508 (M<sup>+</sup>+1)

#### Example 75

A solution of LiOH (0.11 g) in H<sub>2</sub>O (10 ml) was added to a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)-β-alanine methyl ester (1.83 g) in tetrahydrofuran (10 ml)-EtOH (10 ml) at 0°C. The reaction mixture was stirred for 3 hours at room temperature, and the solvent was evaporated in vacuo. The residue was resolved in ethyl acetate-water, and acidified with 10% aq. KHSO<sub>4</sub>. The whole was washed with water and brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)-β-alanine as a colorless oil (1.33 g, 74.4%).

IR (Film) : 2980, 2930, 2850, 1720, 1645 cm<sup>-1</sup>

NMR (DMSO<sub>3</sub>, δ) : 1.18-1.33 (2H, m), 1.39 (9H, s), 1.64-1.91 (8H, m), 2.17-2.46 (5H, m), 2.57-3.19 (4H, m), 3.70 (3H, s), 3.73 (3H, s), 3.90-4.08 (5H, m), 4.17-4.46 (1H, m), 6.43 (1H, d, J=15.1Hz), 6.61 (1H, dd, J=15.1 and 6.4Hz), 6.45-6.85 (3H, m), 7.83 (1H, d, J=8.4Hz), 12.09 (1H, s)

MASS (m/z) : 602 (M<sup>+</sup>+1)

The following compounds [Examples 76 to 102] were obtained according to a similar manner to that of Example 75.

J=8.4Hz), 12.08 (1H, br)

MASS (m/z) : 478 (M<sup>+</sup>+1)

### Example 79

- 5 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2-hydroxymethyl-β-alanine
- IR (Film) : 3300, 2930, 2870, 1720, 1650, 1600 cm<sup>-1</sup>
- NMR (DMSO-d<sub>6</sub>, δ) : 1.08-1.44 (6H, m), 1.39 (9H, s), 1.50-1.87 (5H, m), 2.11-2.40 (2H, m), 2.57-3.25 (5H, m), 3.53 (2H, d, J=5.7Hz), 3.90-4.01 (3H, m), 4.18-4.42 (1H, m), 6.40-6.68 (2H, m), 7.95-8.00 (1H, m)
- MASS (m/z) : 468 (M<sup>+</sup>+1)

### Example 80

- 15 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-ethynyl-β-alanine
- IR (Film) : 3270, 2925, 2855, 1720, 1650, 1600 cm<sup>-1</sup>
- NMR (DMSO-d<sub>6</sub>, δ) : 1.17-1.32 (2H, m), 1.37 (9H, s), 1.39-1.86 (7H, m), 2.11-2.40 (2H, m), 2.55-3.11 (6H, m), 3.21 (1H, d, J=2.3Hz), 3.90-3.98 (2H, m), 4.13-4.45 (1H, m), 4.75-4.88 (1H, m), 6.42 (1H, d, J=15.3Hz), 6.60 (1H, dd, J=15.3 and 6.3Hz), 8.43 (1H, d, J=8.0Hz)
- MASS (m/z) : 462 (M<sup>+</sup>+1)

### Example 81

- 30 N-[(S)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-ethynyl-β-alanine
- IR (Film) : 3260, 2925, 2850, 1720, 1645 cm<sup>-1</sup>
- NMR (DMSO-d<sub>6</sub>, δ) : 1.17-1.32 (2H, m), 1.39 (9H, s), 1.39-1.85 (6H, m), 2.10-2.40 (2H, m), 2.55-2.83 (6H, m), 3.21 (1H, d, J=2.3Hz), 3.91-4.01 (3H, m), 4.14-4.44 (1H, m), 4.76-4.89 (1H, m), 6.42 (1H, d, J=15.2Hz), 6.55-6.64 (1H, m), 8.42 (1H, d, J=15.2Hz)

### Example 76

- 5 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(4-methoxyphenethyl)-β-alanine
- IR (Film) : 2950, 2890, 2820, 1690, 1630 cm<sup>-1</sup>
- NMR (DMSO-d<sub>6</sub>, δ) : 1.18-1.47 (4H, m), 1.39 (9H, s), 1.60-1.95 (8H, m), 2.11-2.44 (5H, m), 2.57-2.84 (3H, m), 3.71 (3H, s), 3.90-4.08 (4H, m), 4.21-4.44 (1H, m), 6.43 (1H, d, J=15.2Hz), 6.66 (1H, dd, J=15.2 and 6.4Hz), 6.82 (2H, d, J=8.6Hz), 7.07 (2H, d, J=8.6Hz), 7.83 (1H, d, J=8.4Hz), 12.08 (1H, br)
- MASS (m/z) : 572 (M<sup>+</sup>+1)

### Example 77

- 15 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-methoxymethyl-β-alanine
- IR (Film) : 3000, 2955, 2900, 1720, 1660 cm<sup>-1</sup>
- NMR (DMSO-d<sub>6</sub>, δ) : 1.06-1.33 (2H, m), 1.39 (9H, s), 1.55-1.83 (7H, m), 2.15-2.41 (6H, m), 2.64-2.84 (2H, m), 3.23 (3H, s), 3.77-3.97 (4H, m), 4.11-4.40 (2H, m), 6.42 (1H, d, J=15.2Hz), 6.55-6.66 (1H, m), 7.84-7.93 (1H, m)
- MASS (m/z) : 482 (M<sup>+</sup>+1)

### Example 78

- 30 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-cyclopropyl-β-alanine
- IR (Film) : 3280, 2980, 2920, 2850, 1700, 1640 cm<sup>-1</sup>
- NMR (DMSO-d<sub>6</sub>, δ) : 0.08-0.43 (2H, m), 1.17-1.32 (2H, m), 1.29-1.85 (13H, m), 1.29 (9H, s), 2.11-2.45 (3H, m), 2.59-3.04 (2H, m), 3.51-3.70 (1H, m), 3.90-4.08 (3H, m), 6.43 (1H, d, J=15.2Hz), 6.60 (1H, dd, J=15.2 and 6.5Hz), 7.82 (1H, d, J=15.2Hz)

$d$ ,  $J=8.2\text{Hz}$ )

MASS (m/z) : 462 ( $M^+ + 1$ )

### Example 82

- 5 N-[1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-4-piperidylcarbonyl]-3-(S)-ethynyl- $\beta$ -alanine
- IR (Film) : 3220, 2925, 2880, 1715, 1645, 1600  $\text{cm}^{-1}$
- NMR (DMSO- $d_6$ ,  $\delta$ ) : 1.10-1.51 (4H, m), 1.39 (9H, s), 1.65-1.71 (4H, m), 2.23-2.43 (2H, m), 2.57 (2H,  $d$ ,  $J=7.3\text{Hz}$ ), 2.65-2.87 (3H, m), 2.93-3.10 (1H,  $d$ ,  $J=7.3\text{Hz}$ ), 3.19 (1H,  $d$ ,  $J=2.3\text{Hz}$ ), 3.91-4.13 (3H, m), 4.28-4.41 (1H, m), 4.75-4.89 (1H, m), 6.42 (1H,  $d$ ,  $J=15.2\text{Hz}$ ), 6.61 (1H,  $dd$ ,  $J=15.2$  and  $6.4\text{Hz}$ ), 8.32 (1H,  $d$ ,  $J=8.2\text{Hz}$ )
- 15 MASS (m/z) : 462 ( $M^+ + 1$ )

### Example 83

- 20 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-3-azetidinyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-(S)-ethynyl- $\beta$ -alanine
- NMR (CDCl<sub>3</sub>,  $\delta$ ) : 1.44 (9H, s), 1.45-2.20 (4H, m), 2.20-2.55 (2H, m), 2.55-2.90 (3H, m), 3.05-3.40 (3H, m), 3.40-4.05 (4H, m), 4.20-4.70 (1H, m), 5.00-5.20 (1H, m), 6.20-6.45 (1H, m), 6.60-7.20 (2H, m), 7.35-7.65 (1H, m)
- 25 MASS (m/z) : 334 ( $M^+ + 1$ -Boc)

### Example 84

- 30 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-methacryloyl]-3-piperidylcarbonyl]-3-(S)-ethynyl- $\beta$ -alanine
- IR (Neat) : 1730, 1650  $\text{cm}^{-1}$
- NMR (CDCl<sub>3</sub>,  $\delta$ ) : 1.10-1.40 (2H, m), 1.40-2.20 (7H, m), 1.49 (9H, s), 1.84 (3H,  $d$ ,  $J=1.4\text{Hz}$ ), 2.27 (1H,  $d$ ,  $J=2.4\text{Hz}$ ), 2.35-3.20 (7H, m), 3.85-4.20 (3H, m), 4.45-4.85 (1H, m), 4.95-5.15 (1H, m), 5.15-5.30 (1H, m)
- 35

### Example 85

- 5 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3,3-dimethyl- $\beta$ -alanine
- IR (Film) : 1730, 1650  $\text{cm}^{-1}$
- NMR (CDCl<sub>3</sub>,  $\delta$ ) : 1.39 (6H, s), 1.46 (9H, s), 1.50-2.45 (11H, m), 2.45-3.05 (4H, m), 3.05-3.40 (1H, m), 3.60-4.70 (6H, m), 6.10-6.60 (1H, m), 6.60-6.95 (1H, m)

### Example 86

- 10 N-[(R)-1-[2-(1-tert-Butoxycarbonyl-4-piperidyl)-(1R\*,2S\*)-cyclopropan-1-yl-carbonyl]-3-piperidylcarbonyl]-3-(S)-ethynyl- $\beta$ -alanine
- IR (Neat) : 1720, 1650  $\text{cm}^{-1}$
- 15 NMR (CDCl<sub>3</sub>,  $\delta$ ) : 0.50-1.35 (6H, m), 1.35-2.20 (10H, m), 1.45 (9H, s), 2.20-2.45 (2H, m), 2.45-3.10 (4H, m), 3.10-4.60 (7H, m), 4.95-5.20 (1H, m), 6.45-6.95 (1H, br)
- 20 MASS (m/z) : 476 ( $M^+ + 1$ )

### Example 87

- 25 N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-3-methyl-(E)-acryloyl]-3-piperidylcarbonyl]-3-(S)-ethynyl- $\beta$ -alanine
- IR (Nujol) : 1660  $\text{cm}^{-1}$
- NMR (CDCl<sub>3</sub>,  $\delta$ ) : 1.15-1.60 (2H, m), 1.47 (9H, s), 1.60-2.45 (9H, m), 2.45-2.90 (5H, m), 2.90-3.25 (2H, m), 3.45-4.70 (6H, m), 4.90-5.20 (1H, m), 5.74 (1H, s)
- 30 MASS (m/z) : 476 ( $M^+ + 1$ )

### Example 88

- 35 3-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]aminobenzoic acid
- IR (Film) : 3250, 3000, 2925, 2850, 1700, 1650  $\text{cm}^{-1}$

acryloyl]-3-piperidylcarbonyl]-2-benzoyloxymethyl-β-alanine  
 IR (Film) : 3300, 2960, 2930, 2860, 1720, 1670,  
 1650 cm<sup>-1</sup>

NMR (DMSO-d<sub>6</sub>, δ) : 1.10-1.33 (2H, m), 1.39 (9H, s),  
 1.39-1.83 (8H, m), 2.12-2.40 (2H, m), 2.57-2.84  
 (4H, m), 3.20-3.30 (1H, m), 3.57 (2H, d,  
 J=6.1Hz), 3.88-4.01 (3H, m), 4.18-4.41 (1H, m),  
 4.46 (2H, s), 6.42 (1H, d, J=15.2Hz), 6.60 (1H,  
 dd, J=15.2 and 6.4Hz), 7.27-7.38 (5H, m), 7.93-  
 8.00 (1H, m), 12.31 (1H, br)

MASS (m/z) : 558 (M<sup>+</sup>+1)

10

Example 92

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-  
 benzoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine  
 IR (Film) : 3380, 3000, 2930, 2860, 1720, 1650,  
 1620 cm<sup>-1</sup>

NMR (DMSO-d<sub>6</sub>, δ) : 1.33-1.99 (8H, m), 1.41 (9H, s),  
 2.24-2.80 (2H, m), 2.55-2.80 (6H, m), 3.19 (1H,  
 d, J=2.3Hz), 3.40-3.63 (1H, m), 4.01-4.12 (2H,  
 m), 4.27-4.45 (1H, m), 4.74-4.87 (1H, m), 7.13-  
 7.21 (2H, m), 7.26-7.37 (2H, m), 8.33-8.46 (1H,  
 m), 12.33-12.47 (1H, br)

MASS (m/z) : 512 (M<sup>+</sup>+1)

25

Example 93

N-[(R)-1-[4-(1-tert-Butoxycarbonyl-4-piperidyl)-  
 benzoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine

IR (Film) : 3350, 2925, 2850, 1720, 1655, 1605 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 1.41 (9H, s), 1.41-1.91 (10H, m),  
 2.22-2.40 (1H, m), 2.51-3.00 (7H, m), 3.18 (1H,  
 d, J=2.3Hz), 4.01-4.12 (2H, m), 4.74-4.86 (1H,  
 m), 7.30 (4H, s), 8.37-8.48 (1H, m), 12.35-12.41  
 (1H, br)

MASS (m/z) : 512 (M<sup>+</sup>+1)

35

NMR (DMSO-d<sub>6</sub>, δ) : 1.09-1.49 (3H, m), 1.39 (9H, s),  
 1.38-1.81 (4H, m), 1.91-2.03 (1H, m), 2.20-2.46  
 (2H, m), 2.64-2.86 (3H, m), 2.97-3.15 (1H, m),  
 3.87-4.11 (3H, m), 4.13-4.53 (1H, m), 6.43-6.69  
 (2H, m), 7.42 (1H, t, J=7.9Hz), 7.62 (1H, d,  
 J=7.7Hz), 7.82 (1H, d, J=8.0Hz), 8.24 (1H, s),  
 10.17 (1H, s)

MASS (m/z) : 486 (M<sup>+</sup>+1)

5

Example 89

4-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-  
 acryloyl]-3-piperidylcarbonyl]aminobenzoic acid  
 IR (Film) : 3000, 2925, 2850, 1700, 1670, 1650 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 1.14-1.49 (3H, m), 1.39 (9H, s),  
 1.39-1.80 (5H, m), 1.91-2.03 (1H, m), 2.22-2.37  
 (1H, m), 2.63-2.84 (3H, m), 2.97-3.21 (1H, m),  
 3.87-4.12 (3H, m), 4.18-4.35 (1H, m), 6.42-6.69  
 (2H, m), 7.71 (2H, d, J=8.7Hz), 7.79 (2H, d,  
 J=8.7Hz), 10.29 (1H, s), 12.41-12.60 (1H, br)

MASS (m/z) : 486 (M<sup>+</sup>+1)

20

Example 90

2-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-  
 acryloyl]-3-piperidylcarbonyl]aminobenzoic acid  
 IR (Film) : 3000, 2930, 2860, 1720, 1660, 1600 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 1.11-1.53 (5H, m), 1.39 (9H, s),  
 1.91-2.48 (4H, m), 2.60-3.10 (6H, m), 3.86-4.14  
 (4H, m), 6.46 (1H, d, J=7.1Hz), 6.55-6.69 (1H,  
 m), 7.15 (1H, t, J=7.1Hz), 7.58 (1H, t,  
 J=7.1Hz), 7.98 (1H, d, J=8.1Hz), 8.44 (1H, d,  
 J=8.1Hz), 11.30 (1H, br)

MASS (m/z) : 486 (M<sup>+</sup>+1)

30

Example 91

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-

35



- 95 -

Example 94

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-3(S)-methoxymethyl-β-alanine

IR (Film) : 2950, 2900, 1730, 1660, 1640 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 0.87-1.08 (2H, m), 1.38 (9H, s), 1.26-1.83 (9H, m), 2.11-2.41 (6H, m), 2.55-2.74 (2H, m), 2.84-3.14 (2H, m), 3.24 (3H, s), 3.71-3.95 (4H, m), 4.13-4.35 (2H, m), 7.82-7.91 (1H, m), 12.06-12.29 (1H, br)  
 MASS (m/z) : 384 (M<sup>+</sup>-Boc+1)

5

10

Example 95

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-3-cyclopropyl-β-alanine

IR (Film) : 3400, 3000, 2910, 2855, 1700, 1640, 1620 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 0.11-0.46 (4H, m), 0.84-1.08 (3H, m), 1.23-1.44 (5H, m), 1.38 (9H, s), 1.53-1.82 (5H, m), 2.11-2.45 (5H, m), 2.51-2.75 (2H, m), 2.86-3.09 (1H, m), 3.56-3.80 (2H, m), 3.86-3.97 (2H, m), 4.13-4.39 (1H, m), 7.80-7.90 (1H, m)  
 MASS (m/z) : 480 (M<sup>+</sup>+1)

15

20

Example 96

3-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]aminobenzoic acid

IR (Film) : 3260, 3000, 2930, 2850, 1700, 1660, 1600 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 0.84-1.07 (1H, m), 1.39 (9H, s), 1.37-1.50 (4H, m), 1.60-1.80 (5H, m), 1.91-1.99 (1H, m), 2.31-2.41 (2H, m), 2.51-2.79 (4H, m), 2.93-3.31 (1H, m), 3.79-4.00 (3H, m), 4.12-4.51 (1H, m), 7.42 (1H, d, J=7.6Hz), 7.62 (1H, d, J=7.6Hz), 7.76-7.85 (1H, m), 8.23 (1H, s), 10.16

30

35

- 96 -

(1H, d, J=3.7Hz)  
 MASS (m/z) : 388 (M<sup>+</sup>-Boc+1)

Example 97

4-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]aminobenzoic acid

IR (Film) : 2930, 2850, 1760, 1600 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 0.87-1.05 (1H, m), 1.38 (9H, s), 1.37-1.50 (5H, m), 1.60-1.80 (4H, m), 1.91-2.04 (1H, m), 2.31-2.40 (2H, m), 2.51-2.79 (4H, m), 2.95-3.22 (1H, m), 3.77-3.96 (3H, m), 4.12-4.49 (1H, m), 7.70 (2H, d, J=8.0Hz), 7.89 (2H, d, J=8.4Hz), 10.28 (1H, s)  
 MASS (m/z) : 388 (M<sup>+</sup>-Boc+1)

5

10

15

Example 98

2-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]aminobenzoic acid

IR (Film) : 2925, 2855, 1720, 1660, 1600 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 0.83-1.09 (2H, m), 1.38 (9H, s), 1.38-1.78 (6H, m), 1.99-2.16 (1H, m), 2.26-2.41 (3H, m), 2.58-3.06 (5H, m), 3.68-4.56 (6H, m), 7.15 (1H, t, J=7.4Hz), 7.51-7.60 (1H, m), 7.9 (1H, d, J=8.9Hz), 8.41 (1H, t, J=7.3Hz)  
 MASS (m/z) : 488 (M<sup>+</sup>+1)

20

25

Example 99

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-benzylloxymethyl-β-alanine

IR (Film) : 3400, 2930, 2855, 1720, 1660, 1630 cm<sup>-1</sup>  
 NMR (DMSO-d<sub>6</sub>, δ) : 0.83-1.09 (2H, m), 1.23-1.49 (8H, m), 1.38 (9H, s), 1.52-1.85 (4H, m), 2.25-2.37 (2H, m), 2.57-2.77 (4H, m), 2.93-3.11 (1H, m), 3.55-3.62 (2H, m), 3.69-3.97 (3H, m), 4.18-4.40

30

35

- 98 -

3.44 (4H, m), 3.76-4.39 (4H, m), 7.89-8.03 (2H, m)

MASS (m/z) : 511 ( $M^{+}+1$ )

### 5 Example 103

To a mixture of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine (0.6 g), n-pentylalcohol (0.16 ml) and N,N-dimethylaminopyridine (16 mg) in dichloromethane (6 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (0.27 g) at 0°C. After stirring at room temperature for overnight, the solution was evaporated in vacuo. The residue was poured into water and extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrogencarbonate, water and brine, dried over  $MgSO_4$ , and evaporated in vacuo, subsequently. The residue was purified by column chromatography on silica gel eluting with AcOEt:Hexane = (1:1) to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine n-pentyl ester as a colorless oil (0.65 g, 94.0%).

IR (Film) : 2900, 2825, 1710, 1640, 1600  $cm^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 0.89-0.97 (3H, m), 1.26-1.40 (7H, m), 1.46 (9H, s), 1.61-1.79 (6H, m), 1.92-2.05 (1H, m), 2.28 (1H, d, J=2.3Hz), 2.24-2.38 (2H, m), 2.68-2.83 (4H, m), 3.23-3.39 (2H, m), 3.64-4.26 (6H, m), 5.05-5.16 (1H, m), 6.22 (1H, d, J=15.2Hz), 6.82 (1H, dd, J=15.2 and 6.6Hz), 7.07-7.16 (1H, m)

MASS (m/z) : 532 ( $M^{+}+1$ )

The following compounds [Examples 104 to 107] were obtained according to a similar manner to that of Example 103.

- 97 -

(1H, m), 4.46 (2H, s), 7.26-7.37 (5H, m), 7.89-7.99 (1H, m)

MASS (m/z) : 560 ( $M^{+}+1$ )

### 5 Example 100

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-hydroxymethyl- $\beta$ -alanine  
 IR (Film) : 2930, 2860, 1720, 1660, 1620  $cm^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 0.86-1.08 (2H, m), 1.38 (9H, s), 1.58-1.85 (11H, m), 2.13-2.37 (3H, m), 2.51-3.25 (5H, m), 3.53 (2H, d, J=5.1Hz), 3.71-3.96 (4H, m), 4.13-4.39 (1H, m), 7.94-8.03 (1H, m)

MASS (m/z) : 470 ( $M^{+}+1$ )

### 15 Example 101

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-benzoylaminoethyl- $\beta$ -alanine  
 IR (Film) : 3280, 3050, 2920, 2850, 1710, 1620  $cm^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 0.84-1.05 (2H, m), 1.38 (9H, s), 1.35-1.46 (4H, m), 1.60-1.70 (4H, m), 1.76-1.86 (1H, m), 2.27-2.38 (2H, m), 2.51-3.15 (6H, m), 3.24-3.52 (4H, m), 3.74-3.95 (3H, m), 4.13-4.40 (1H, m), 7.43-7.54 (3H, m), 7.81-7.84 (2H, m), 8.00-8.11 (1H, m), 8.51-8.60 (1H, m)

MASS (m/z) : 573 ( $M^{+}+1$ )

### Example 102

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-propanoyl]-3-piperidylcarbonyl]-2-acetylaminoethyl- $\beta$ -alanine  
 IR (Film) : 3325, 2920, 2850, 1720, 1640  $cm^{-1}$   
 NMR (DMSO- $d_6$ ,  $\delta$ ) : 0.86-4.08 (2H, m), 1.17 (9H, s), 1.17-1.47 (4H, m), 1.60-1.71 (5H, m), 1.91 (3H, s), 2.28-2.40 (2H, m), 2.51-2.94 (6H, m), 3.14-

35

- 99 -

Example 104

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine n-butyl ester

5 NMR (CDCl<sub>3</sub>, δ) : 0.96 (3H, t, J=7.3Hz), 1.33 (2H, d, J=7.3Hz), 1.36-1.45 (3H, m), 1.46 (9H, s), 1.56-1.77 (4H, s), 1.90-2.05 (2H, m), 2.20-2.31 (2H, m), 2.28 (1H, d, J=2.4Hz), 2.60-2.81 (4H, m), 4.06-4.18 (5H, m), 5.05-5.13 (1H, m), 6.23 (1H, d, J=15.1Hz), 6.82 (1H, dd, J=6.7 and 15.1Hz)

10 MASS (m/z) : 518 (M<sup>+</sup>+1)

Example 105

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine phenethyl ester

15 IR (Film) : 2930, 2850, 1730, 1650, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.26-1.40 (2H, m), 1.46 (9H, s), 1.45-1.89 (8H, m), 1.95-2.04 (1H, m), 2.20-2.39 (1H, m), 2.25 (1H, d, J=2.4Hz), 2.67-2.91 (4H, m), 2.97 (2H, t, J=7.0Hz), 3.20-3.41 (1H, m), 4.07-4.17 (3H, m), 4.36 (2H, t, J=7.0Hz), 5.01-5.13 (1H, m), 6.23 (1H, d, J=15.2Hz), 6.82 (1H, dd, J=15.2 and 6.7Hz), 7.21-7.51 (6H, m)

25 MASS (m/z) : 566 (M<sup>+</sup>+1)

Example 106

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-β-alanine n-butyl ester

30 IR (Film) : 2920, 2855, 1725, 1680, 1650, 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.94 (3H, t, J=7.2Hz), 1.27-1.79 (12H, m), 1.46 (9H, s), 1.90-2.01 (1H, m), 2.23-2.36 (2H, m), 2.52 (2H, t, J=6.1Hz), 2.70-2.81 (2H, m), 3.29 (1H, dd, J=13.5 and 9.3Hz), 3.65-3.76 (3H, m), 4.10 (2H, t, J=6.6Hz), 4.00-4.20

35

- 100 -

(3H, m), 6.22 (1H, d, J=15.2Hz), 6.55-6.68 (1H, m), 6.81 (1H, dd, J=15.2 and 6.7Hz)

MASS (m/z) : 494 (M<sup>+</sup>+1)

5 Example 107

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)propanoyl]-3-piperidyl-carbonyl]-2(S)-acetylamino-β-alanine n-pentyl ester

10 IR (Film) : 2910, 2850, 1720, 1640 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 0.91 (3H, t, J=6.6Hz), 1.00-1.22 (2H, m), 1.31-1.36 (4H, m), 1.45 (9H, s), 1.40-1.77 (13H, m), 2.04-2.09 (3H, m), 2.34-2.51 (3H, m), 2.60-2.74 (2H, m), 3.20-3.49 (2H, m), 3.57-3.75 (2H, m), 4.02-4.25 (5H, m), 4.57-4.80 (1H, m), 6.88-7.20 (1H, m)

15 MASS (m/z) : 467 (M<sup>+</sup>-Boc+1)

Example 108

20 To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine (0.5 g) in dimethylformamide (5 ml) was added K<sub>2</sub>CO<sub>3</sub> (75 mg) under stirring at 0°C, stirred for 15 minutes, and pivalic acid iodomethyl ester (0.61 g) in dimethylformamide (3 ml) was added to the mixture. After stirring at room temperature for 1 hour, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo, subsequently. The residue was purified by column chromatography on silica gel eluting with CHCl<sub>3</sub>:MeOH = (98:2) to give N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine

30 pivaloyloxymethyl ester as a colorless oil (0.37 g, 59.3%).

35 IR (Film) : 2960, 2920, 2850, 1745, 1650, 1600 cm<sup>-1</sup>

- 101 -

NMR (CDCl<sub>3</sub>, δ) : 1.22 (9H, s), 1.32-1.60 (3H, m),  
 1.46 (9H, s), 1.69-1.80 (3H, m), 1.89-2.03 (2H,  
 m), 2.16-2.40 (5H, m), 2.28 (1H, d, J=2.4Hz),  
 2.70-2.85 (4H, m), 3.33-3.51 (1H, m), 4.04-4.18  
 (3H, m), 5.04-5.17 (1H, m), 5.77 (2H, s), 6.24  
 (1H, d, J=15.1Hz), 6.83 (1H, dd, J=15.1 and 6.6Hz)

MASS (m/z) : 576 (M<sup>+</sup>+1)

5

The following compound was obtained according to a  
 similar manner to that of Example 108.

10

Example 109

N-[(R)-1-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-  
 acryloyl]-3-piperidylcarbonyl]-β-alanine pivaloyloxymethyl

15 ester

IR (Film) : 2960, 2930 2855, 1750, 1670, 1650,  
 1600 cm<sup>-1</sup>

NMR (CDCl<sub>3</sub>, δ) : 1.21 (9H, s), 1.21-2.05 (8H, m),  
 1.46 (9H, s), 2.21-2.39 (2H, m), 2.58 (2H, t,  
 J=6.1Hz), 2.70-2.83 (2H, m), 3.23-3.78 (5H, m),  
 4.07-4.20 (3H, m), 5.76 (2H, d, J=2.4Hz), 6.22  
 (1H, d, J=15.2Hz), 6.65-6.79 (1H, m), 6.81 (1H,  
 dd, J=15.2 and 6.7Hz)

20

MASS (m/z) : 552 (M<sup>+</sup>+1)

25

Example 110

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-  
 4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2-  
 hydroxymethyl-β-alanine (0.24 g) in ethyl acetate (2 ml)  
 was added 4N HCl in ethyl acetate (1.3 ml) at 0°C, and the  
 reaction mixture was stirred for 2 hours at room  
 temperature. The precipitates were filtered and washed  
 with diethyl ether to give N-[(R)-1-[3-(4-piperidyl)-(E)-  
 acryloyl]-3-piperidylcarbonyl]-2-hydroxymethyl-β-alanine  
 hydrochloride (0.17 g, 82.0%).

35

- 102 -

IR (KBr pellet) : 3440, 2947, 2866, 1728, 1659 cm<sup>-1</sup>  
 NMR (D<sub>2</sub>O, δ) : 1.40-1.83 (7H, m), 1.92-2.08 (4H, m),  
 2.40-2.69 (4H, m), 2.78-2.92 (2H, m), 2.99-3.29  
 (3H, m), 3.38-3.55 (3H, m), 3.78 (2H, d,  
 J=5.9Hz), 3.92-4.18 (1H, m), 4.25-4.37 (1H, m),  
 6.46 (1H, dd, J=15.8Hz), 6.58-6.71 (1H, m)

MASS (m/z) : 368 (M<sup>+</sup>free+1)

5

The following compounds [Examples 111 to 124] were  
 obtained according to a similar manner to that of Example  
110.

10

Example 111

N-[(1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

15 piperidylcarbonyl]-3(S)-ethyl-β-alanine hydrochloride

IR (KBr pellet) : 2954, 2729, 2360, 2337, 1724,  
 1655 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.52-1.75 (4H, m), 1.84-1.93 (2H, m),  
 2.01-2.07 (2H, m), 2.51-2.68 (2H, m), 2.74 (1H,  
 d, J=2.3Hz), 2.85 (2H, dd, J=7.0 and 2.9Hz),  
 3.00-3.25 (3H, m), 3.40-3.51 (2H, m), 4.08-4.20  
 (1H, m), 4.39-4.49 (1H, m), 4.64-4.98 (3H, m),  
 6.46 (1H, d, J=15.6Hz), 6.64 (1H, dd, J=15.6 and  
 6.2Hz)

20

MASS (m/z) : 362 (M<sup>+</sup>free+1)  
 [α]<sub>D</sub><sup>25</sup> = -37.97° (C=1.0, MeOH)

25

Example 112

3-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

30 piperidylcarbonyl]aminobenzoic acid hydrochloride

IR (KBr pellet) : 2951, 2862, 2729, 1711, 1655 cm<sup>-1</sup>  
 NMR (D<sub>2</sub>O, δ) : 1.50-2.10 (10H, m), 2.36-2.76 (2H,  
 m), 2.91-3.70 (5H, m), 3.84-4.49 (2H, m), 6.46  
 (1H, dd, J=15.5 and 2.2Hz), 6.56-6.72 (1H, m),  
 7.48 (1H, td, J=7.9 and 2.2Hz), 7.66 (1H, d,

35

- 103 -

$J=8.3\text{Hz}$ ), 7.79 (1H, d,  $J=6.6\text{Hz}$ ), 8.01 (1H, d,  $J=1.8\text{Hz}$ )

MASS (m/z) : 386 ( $M^+$ free+1)

**Example 113**

4-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]aminobenzoic acid hydrochloride

IR (KBr pellet) : 3425, 2947, 2862, 2729, 1691,

1655  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.47-2.10 (8H, m), 2.29-2.79 (3H, m),  
2.89-4.46 (8H, m), 6.39-6.72 (2H, m), 7.56 (2H,  
d,  $J=8.7\text{Hz}$ ), 7.97 (2H, dd,  $J=8.8$  and  $2.1\text{Hz}$ )

MASS (m/z) : 386 ( $M^+$ free+1)

$[\alpha]_D^{25} = -34.70^\circ$  (C=1.0, MeOH)

15

**Example 114**

2-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]aminobenzoic acid hydrochloride

IR (KBr pellet) : 3425, 2947, 2862, 2821, 2727,

1692, 1657  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.51-2.16 (9H, m), 2.40-2.80 (2H, m),  
2.95-3.50 (6H, m), 3.62-4.08 (2H, m), 6.44-6.69  
(2H, m), 7.26-7.36 (1H, m), 7.53-7.66 (1H, m),

7.87-8.03 (2H, m)

MASS (m/z) : 386 ( $M^+$ free+1)

$[\alpha]_D^{25} = -7.53^\circ$  (C=1.0, MeOH)

25

**Example 115**

N-[(R)-1-[3-(4-Piperidyl)benzoyl]-3-

piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine

IR (KBr pellet) : 2721, 1728, 1655, 1599, 1579  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.32-1.47 (1H, m), 1.54-1.99 (8H, m),

2.33-2.46 (1H, m), 2.54-2.65 (3H, m), 2.80-3.07

(5H, m), 3.19 (1H, d,  $J=2.0\text{Hz}$ ), 3.30-3.40 (2H,

m), 4.32-4.44 (1H, m), 4.73-4.87 (1H, m), 7.21-

35

- 104 -

7.45 (4H, m), 8.49-8.57 (1H, m)

MASS (m/z) : 412 ( $M^+$ free+1)

$[\alpha]_D^{25} = -40.47^\circ$  (C=1.0, MeOH)

**Example 116**

N-[(R)-1-[4-(4-Piperidyl)benzoyl]-3-

piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine

IR (KBr pellet) : 2929, 1728, 1649, 1605  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.30-1.97 (9H, m), 2.25-2.41 (1H, m),

2.54-2.64 (2H, m), 2.82-3.08 (5H, m), 3.19 (1H,

d,  $J=2.3\text{Hz}$ ), 3.29-3.41 (2H, m), 4.24-4.44 (1H,

m), 4.75-4.87 (1H, m), 7.29 (2H, d,  $J=8.3\text{Hz}$ ),

7.35 (2H, d,  $J=8.3\text{Hz}$ ), 8.43-8.51 (1H, m), 8.95-

9.11 (2H, br)

MASS (m/z) : 412 ( $M^+$ free+1)

$[\alpha]_D^{25} = 49.77^\circ$  (C=1.0, MeOH)

15

**Example 117**

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine phenethyl ester

hydrochloride

IR (KBr pellet) : 3412, 3278, 3028, 2951, 2864,

2725, 1734, 1655  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.46-2.27 (9H, m), 2.41-3.43 (12H, m),

3.56-3.72 (2H, m), 4.10-4.64 (4H, m), 6.53-6.88

(2H, m), 7.25-7.35 (5H, m)

MASS (m/z) : 466 ( $M^+$ free+1)

25

**Example 118**

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]- $\beta$ -alanine n-butyl ester hydrochloride

IR (KBr pellet) : 3415, 3059, 2956, 2870, 2725,

1730, 1653  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 0.90 (3H, t,  $J=7.3\text{Hz}$ ), 1.25-1.85

(10H, m), 1.93-2.09 (3H, m), 2.39-2.69 (2H, m),

35

- 106 -

piperidylcarbonyl]aminobenzoic acid hydrochloride  
 IR (KBr pellet) : 3444, 2949, 2866, 2731, 1713,  
 1684, 1653, 1614  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.23-1.69 (7H, m), 1.81-2.11 (6H, m),  
 2.42-2.75 (3H, m), 2.85-3.31 (3H, m), 3.37-3.56  
 (2H, m), 3.79-4.36 (2H, m), 7.48 (1H, td,  $J=7.9$   
 and 2.9Hz), 7.64-7.69 (1H, m), 7.76-7.80 (1H,  
 m), 8.02 (1H, s)  
 MASS (m/z) : 388 ( $\text{M}^+$ +1)

Example 122

4-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-  
 piperidylcarbonyl]aminobenzoic acid hydrochloride  
 IR (KBr pellet) : 3101, 2947, 2862, 1691  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.28-1.69 (6H, m), 1.77-2.09 (5H, m),  
 2.40-2.78 (4H, m), 2.84-2.98 (2H, m), 3.11-3.46  
 (4H, m), 3.78-4.31 (2H, m), 7.58 (2H, dd,  $J=8.7$   
 and 1.4Hz), 8.00 (2H, dd,  $J=8.7$  and 1.8Hz)  
 MASS (m/z) : 388 ( $\text{M}^+$ free+1)  
 $[\alpha]_{\text{D}}^{25} = -24.4^\circ$  (C=1.0, MeOH)

Example 123

2-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-  
 piperidylcarbonyl]aminobenzoic acid hydrochloride  
 IR (KBr pellet) : 3417, 2947, 2862, 2731, 1686,  
 1609  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.28-2.09 (11H, m), 2.49-2.76 (2H,  
 m), 2.86-3.49 (6H, m), 3.51-4.40 (4H, m), 7.30  
 (1H, t,  $J=7.5\text{Hz}$ ), 7.62 (1H, t,  $J=7.9\text{Hz}$ ), 7.89-  
 8.02 (2H, m)  
 MASS (m/z) : 388 ( $\text{M}^+$ free+1)  
 $[\alpha]_{\text{D}}^{25} = -8.85^\circ$  (C=1.0, MeOH)

Example 124

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-

- 105 -

2.57 (2H, t,  $J=6.4\text{Hz}$ ), 2.92-3.27 (2H, m), 3.10  
 (2H, td,  $J=12.7$  and  $2.8\text{Hz}$ ), 3.32-3.53 (4H, m),  
 3.93-4.40 (2H, m), 4.12 (2H, t,  $J=6.5\text{Hz}$ ), 6.48  
 (1H, d,  $J=15.5\text{Hz}$ ), 6.66 (1H, dd,  $J=15.5$  and  
 6.2Hz)  
 MASS (m/z) : 394 ( $\text{M}^+$ free+1)

Example 119

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-  
 piperidylcarbonyl]- $\beta$ -alanine 1-(cyclohexyloxy)carbonyl)-  
 ethyl ester hydrochloride  
 IR (KBr pellet) : 3425, 3377, 3271, 3070, 2941,  
 2862, 2810, 2729, 1757, 1653  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.19-2.08 (18H, m), 1.50 (3H, d,  
 $J=5.3\text{Hz}$ ), 2.34-2.62 (5H, m), 2.80-2.93 (1H, m),  
 3.03-3.15 (3H, m), 3.25-3.63 (4H, m), 4.00-4.49  
 (2H, m), 4.56-4.66 (1H, m), 6.49 (1H, d,  
 $J=15.6\text{Hz}$ ), 6.66 (1H, dd,  $J=15.6$  and  $6.2\text{Hz}$ ),  
 6.61-6.71 (1H, m)  
 MASS (m/z) : 508 ( $\text{M}^+$ free+1)

Example 120

(-)-N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-  
 piperidylcarbonyl]-3-cyclopropyl- $\beta$ -alanine hydrochloride  
 IR (KBr pellet) : 3444, 3392, 3076, 3008, 2949,  
 2866, 2731, 1732, 1716, 1649, 1622  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 0.24-0.34 (2H, m), 0.93-1.09 (1H, m),  
 1.36-1.84 (9H, m), 1.91-2.03 (3H, m), 2.32-2.82  
 (9H, m), 2.92-3.03 (3H, m), 3.11-3.46 (2H, m),  
 3.53-3.65 (1H, m), 3.76-3.93 (1H, m), 4.08-4.27  
 (1H, m)  
 MASS (m/z) : 380 ( $\text{M}^+$ free+1)

Example 121

3-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-

Example 126

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(4-methoxyphenethyl)-β-alanine

IR (Nujol) : 3445, 1645, 1600 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.41-2.05 (10H, m), 2.18-2.68 (4H, m), 2.40 (2H, d, J=7.3Hz), 2.97-3.12 (4H, m), 3.23-3.50 (3H, m), 3.82 (3H, s), 3.85 (3H, s), 3.87-4.20 (3H, m), 6.38-6.68 (2H, m), 6.80-6.98 (3H, m)

5

MASS (m/z) : 472 (M<sup>+</sup>+1)

10

Elemental Analysis Calcd. for C<sub>26</sub>H<sub>37</sub>N<sub>3</sub>O<sub>5</sub>·0.3H<sub>2</sub>O :

C 65.47, H 7.94, N 8.81

Found : C 65.36, H 7.92, N 8.92

Example 127

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-methoxymethyl-β-alanine

IR (KBr pellet) : 2939, 2862, 1652 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.45-1.88 (6H, m), 1.93-2.12 (3H, m), 2.26-2.67 (4H, m), 2.92-3.23 (3H, m), 3.36 (3H, s), 3.31-3.49 (4H, m), 3.90-4.20 (2H, m), 4.27-4.39 (2H, m), 6.47 (1H, d, J=15.7Hz), 6.59-6.72 (1H, m)

20

MASS (m/z) : 382 (M<sup>+</sup>+1)

25

Example 128

(-)-N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3-cyclopropyl-β-alanine

IR (KBr pellet) : 3444, 3392, 3082, 3012, 2949, 2862, 1653 cm<sup>-1</sup>

30

NMR (D<sub>2</sub>O, δ) : 0.20-0.32 (2H, m), 0.39-0.59 (2H, m), 0.93-1.01 (1H, m), 1.45-2.08 (9H, m), 2.40-2.67 (4H, m), 2.96-3.65 (7H, m), 3.88-4.27 (2H, m), 6.48 (1H, d, J=15.7Hz), 6.65 (1H, dt, J=15.7 and 5.89Hz)

35

piperidylcarbonyl]-2-hydroxymethyl-β-alanine hydrochloride

IR (KBr pellet) : 3419, 3064, 2945, 2866, 1726, 1643, 1620 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.36-2.09 (13H, m), 2.38-2.53 (3H, m), 2.81-3.03 (4H, m), 3.12-3.52 (5H, m), 3.78 (2H, d, J=5.9Hz), 3.86-3.93 (1H, m), 4.11-4.30 (1H, m)

5

MASS (m/z) : 370 (M<sup>+</sup>+1)

Example 125

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl)-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)-β-alanine (1.33 g) in ethyl acetate (10 ml) was added 4N HCl in 1,4-dioxane (5.53 ml) at 0°C, and the reaction mixture was stirred for 3 hours at room temperature. The precipitates were filtered, washed with diethyl ether and resolved in water, neutralized with saturated aqueous NaHCO<sub>3</sub>, desalted by using the resin of HP-20 eluting with isopropanol:H<sub>2</sub>O = (1:1), then freeze-dried to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(R)-(3,4-dimethoxyphenethyl)-β-alanine as a white powder (0.88 g, 79.4%)

20

IR (Nujol) : 3400, 1635, 1600 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.41-2.05 (10H, m), 2.18-2.68 (4H, m), 2.40 (2H, d, J=7.3Hz), 2.97-3.12 (4H, m), 3.23-3.50 (3H, m), 3.82 (3H, s), 3.85 (3H, s), 3.87-4.20 (3H, m), 6.38-6.68 (2H, m), 6.80-6.98 (3H, m)

25

MASS (m/z) : 502 (M<sup>+</sup>+1)

[α]<sub>D</sub><sup>20</sup> = -48.7° (C=1.0, MeOH)

30

The following compounds [Examples 126 to 143] were obtained according to a similar manner to that of Example 125.

35

Example 130

N-[(S)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-3(S)-ethynyl-β-alanine

IR (KBr pellet) : 3444, 3275, 2947, 2862, 1653 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 1.43-1.85 (6H, m), 1.93-2.10 (3H, m),

2.42-2.70 (5H, m), 3.03-3.51 (7H, m), 3.90-4.36

(2H, m), 6.48 (1H, d, J=15.6Hz), 6.59-6.72 (1H,

m)

MASS (m/z) : 362 (M<sup>+</sup>+1)[α]<sub>D</sub><sup>25</sup> = 25.4° (C=1.0, MeOH)Elemental Analysis Calcd. for C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>·1.9H<sub>2</sub>O :

C 57.68, H 7.85, N 10.62

Found : C 57.61, H 8.10, N 10.41

15 N-[(S)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-3(R)-ethynyl-β-alanine

IR (KBr pellet) : 3439, 3259, 3049, 2945, 2860,

1655 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 1.41-1.89 (6H, m), 1.99-2.09 (3H, m),

2.39-2.67 (5H, m), 3.01-3.15 (3H, m), 3.17-3.50

(4H, m), 3.92-4.37 (2H, m), 6.46 (1H, d,

J=15.7Hz), 6.59-6.67 (1H, m)

MASS (m/z) : 362 (M<sup>+</sup>+1)[α]<sub>D</sub><sup>25</sup> = 79.23° (C=1.0, MeOH)Elemental Analysis Calcd. for C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>·1.6H<sub>2</sub>O :

C 58.21, H 7.82, N 10.72

Found : C 58.35, H 8.23, N 10.48

Example 131

30 N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-2-benzoyloxymethyl-β-alanine

IR (KBr pellet) : 3514, 3433, 3317, 3265, 2939,

2860, 1657 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 1.37-2.09 (8H, m), 2.26-2.43 (1H, m),

2.45-2.63 (1H, m), 2.69-2.81 (1H, m), 2.85-3.28

35

MASS (m/z) : 378 (M<sup>+</sup>+1)[α]<sub>D</sub><sup>20</sup> = -73.6° (C=1.0, MeOH)Elemental Analysis Calcd. for C<sub>20</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>·0.2H<sub>2</sub>O :

C 58.09, H 8.53, N 10.16

Found : C 58.32, H 8.45, N 10.16

5 (+)-N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-3-cyclopropyl-β-alanine

IR (KBr pellet) : 3471, 3412, 3365, 3802, 3007,

2949, 2862, 1653 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 0.18-0.35 (2H, m), 0.38-0.58 (2H, m),

0.90-1.08 (1H, m), 1.42-2.12 (9H, m), 2.33-2.69

(4H, m), 3.01-3.66 (7H, m), 4.00-4.32 (2H, m),

6.47 (1H, d, J=15.6Hz), 6.59-6.72 (1H, m)

15 MASS (m/z) : 378 (M<sup>+</sup>+1)[α]<sub>D</sub><sup>20</sup> = -38.5° (C=1.0, MeOH)Elemental Analysis Calcd. for C<sub>20</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>·2.3H<sub>2</sub>O :

C 57.34, H 8.57, N 10.03

Found : C 57.26, H 8.73, N 9.86

Example 129

20 N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-3(R)-ethynyl-β-alanine

IR (KBr pellet) : 3415, 3271, 3051, 2947, 2860,

2748, 1655 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 1.41-1.87 (6H, m), 1.95-2.09 (3H, m),

2.39-2.70 (5H, m), 3.02-3.29 (4H, m), 3.40-3.50

(3H, m), 3.92-4.34 (2H, m), 6.47 (1H, d,

J=15.6Hz), 6.59-6.71 (1H, m)

30 MASS (m/z) : 362 (M<sup>+</sup>+1)[α]<sub>D</sub><sup>25</sup> = -29.27° (C=1.0, MeOH)Elemental Analysis Calcd. for C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>·1.5H<sub>2</sub>O :

C 58.75, H 7.78, N 10.82

Found : C 58.79, H 7.96, N 10.56

35



- 111 -

(4H, m), 3.35-3.50 (4H, m), 3.56-3.78 (2H, m),  
3.85-4.00 (1H, m), 4.08-4.33 (2H, m), 4.55 (2H,  
s), 6.35-6.70 (2H, m), 7.44 (5H, s)  
MASS (m/z) : 458 (M<sup>+</sup>+1)

5

Example 132

N-[(R)-1-[3-(4-Piperidyl)-(E)-methacryloyl]-3-  
piperidylcarbonyl]-3(S)-ethynyl-β-alanine

IR (Nujol) : 1750, 1670 cm<sup>-1</sup>

10 NMR (D<sub>2</sub>O, δ) : 1.05-1.90 (8H, m), 1.56 (3H, s),  
2.05-3.05 (8H, m), 2.37 (1H, d, J=2.2Hz), 3.05-  
3.25 (2H, m), 3.35-3.80 (2H, m), 3.80-4.05 (1H,  
m), 5.13 (1H, d, J=7.6Hz)

MASS (m/z) : 376 (M<sup>+</sup>+1)

15

Example 133

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-  
piperidylcarbonyl]-3,3-dimethyl-β-alanine

20 NMR (CDCl<sub>3</sub>, δ) : 1.25-2.15 (12H, m), 1.39 (6H, s),  
2.20-2.60 (5H, m), 2.75-3.10 (3H, m), 3.10-3.55  
(3H, m), 3.75-4.00 (1H, m), 4.05-4.35 (1H, m)

MASS (m/z) : 368 (M<sup>+</sup>+1)

Example 134

25 N-[(R)-1-[2-(4-Piperidyl)-(1R\*,2S\*)-cyclopropan-1-yl-  
carbonyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine

IR (Nujol) : 1600 cm<sup>-1</sup>

30 NMR (D<sub>2</sub>O, δ) : 0.45-0.70 (1H, m), 0.70-1.05 (3H, m),  
1.05-1.85 (9H, m), 1.85-2.45 (4H, m), 2.45-2.75  
(3H, m), 2.75-3.05 (1H, m), 3.05-3.25 (3H, m),  
3.70-4.10 (2H, m)

MASS (m/z) : 376 (M<sup>+</sup>+1)

Example 135

35 N-[(R)-3-(4-Piperidyl)-3-methyl-(E)-acryloyl]-3-

- 112 -

piperidylcarbonyl]-3(S)-ethynyl-β-alanine

IR (Nujol) : 1640 cm<sup>-1</sup>

5 NMR (D<sub>2</sub>O, δ) : 1.35-2.15 (9H, m), 1.76 (3H, s),  
2.20-2.55 (2H, m), 2.55-2.75 (3H, m), 2.85-3.60  
(6H, m), 3.65-4.00 (1H, m), 4.05-4.35 (1H, m),  
5.88 (1H, m)

MASS (m/z) : 376 (M<sup>+</sup>+1)

Example 136

10 N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-  
piperidylcarbonyl]-3(S)-ethynyl-β-alanine ethyl ester

IR (KBr pellet) : 3427, 3269, 3049, 2941, 2862,  
2742, 1732, 1655 cm<sup>-1</sup>

15 NMR (D<sub>2</sub>O, δ) : 1.10 (3H, t, J=7.2Hz), 1.32-1.68 (6H,  
m), 1.75-1.89 (3H, m), 2.23-2.54 (3H, m), 2.59-  
3.14 (6H, m), 3.23-3.30 (3H, m), 3.37-4.19 (2H,  
m), 4.03 (2H, q, J=7.2Hz), 4.76-4.86 (1H, m),  
6.30 (1H, d, J=15.6Hz), 6.43-6.57 (1H, m)

MASS (m/z) : 390 (M<sup>+</sup>+1)

20 Elemental Analysis Calcd. for C<sub>21</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>·2.7H<sub>2</sub>O :

C 57.57, H 8.37, N 9.59

Found : C 57.89, H 8.13, N 9.19

Example 137

25 N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-  
piperidylcarbonyl]-3(S)-ethynyl-β-alanine n-butyl ester

30 NMR (D<sub>2</sub>O, δ) : 0.92 (3H, t, J=7.2Hz), 1.24-1.41 (5H,  
m), 1.59-1.76 (2H, m), 2.18-2.30 (2H, m), 2.58-  
2.82 (5H, m), 3.11-3.18 (2H, m), 3.83 (2H, d,  
J=7.2Hz), 5.16-5.19 (1H, m), 6.15 (1H, d,  
J=15.4Hz), 6.25-6.40 (1H, m)

MASS (m/z) : 418 (M<sup>+</sup>+1)

Example 138

35 N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-

- 114 -

2.36-2.70 (4H, m), 2.77-3.04 (3H, m), 3.13-3.45 (7H, m), 3.83-4.00 (2H, m), 4.15-4.38 (2H, m)  
 MASS (m/z) : 411 ( $M^+$ +1)

**Example 142**

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-3,3-dimethyl- $\beta$ -alanine

NMR ( $D_2O$ ,  $\delta$ ) : 1.25-1.90 (8H, m), 1.39 (6H, s), 1.90-2.10 (3H, m), 2.20-2.65 (5H, m), 2.70-3.10 (3H, m), 3.10-3.55 (3H, m), 3.70-4.05 (1H, m), 4.15-4.40 (1H, m)  
 MASS (m/z) : 368 ( $M^+$ +1)

**Example 143**

N-[(R)-1-[3-(1,2,3,6-Tetrahydro-4-pyridyl)propanoyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine ethyl ester  
 NMR ( $D_2O$ ,  $\delta$ ) : 1.24 (3H, t,  $J=7.1$ Hz), 1.55-1.94 (5H, m), 2.24-2.65 (5H, m), 2.74 (1H, d,  $J=2.4$ Hz), 2.80-3.00 (6H, m), 3.30-3.42 (3H, m), 3.64 (1H, br), 3.83-3.90 (1H, m), 4.12-4.28 (1H, m), 4.17 (2H, q,  $J=7.1$ Hz), 5.48 (1H, br)  
 MASS (m/z) : 390 ( $M^+$ +1)

**Example 144**

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl)-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine n-pentyl ester (0.65 g) in ethyl acetate (6 ml) was added 4N HCl in 1,4-dioxane (3.06 ml) at 0°C, and the reaction mixture was stirred for 2 hours at room temperature. The precipitates were filtered, washed with ether and dissolved in water, neutralized with saturated aqueous  $NaHCO_3$ , desalted by using the resin of HP-20 eluting with isopropanol: $H_2O$  = (1:1), and 1N aqueous HCl was added, then freeze-dried to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3(R)-piperidylcarbonyl]-3(S)-

- 113 -

piperidylcarbonyl]-2-benzoyloxymethyl- $\beta$ -alanine  
 IR (KBr pellet) : 3398, 2937, 2862, 1635  $cm^{-1}$   
 NMR ( $D_2O$ ,  $\delta$ ) : 1.25-2.00 (12H, m), 2.24-2.50 (3H, m), 2.69-3.03 (4H, m), 3.08-3.32 (1H, m), 3.32-3.47 (4H, m), 3.56-3.88 (3H, m), 4.11-4.27 (1H, m), 4.50 (2H, s), 7.42 (5H, s)  
 MASS (m/z) : 460 ( $M^+$ +1)

**Example 139**

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-3(S)-methoxymethyl- $\beta$ -alanine  
 IR (KBr pellet) : 3074, 2935, 2862, 1624  $cm^{-1}$   
 NMR ( $D_2O$ ,  $\delta$ ) : 1.31-1.86 (9H, m), 1.93-2.05 (3H, m), 2.26-2.54 (5H, m), 2.76-3.05 (3H, m), 3.15-3.50 (2H, m), 3.37 (3H, s), 3.48 (2H, d,  $J=6.3$ Hz), 3.79-3.97 (1H, m), 4.15-4.44 (2H, m)  
 MASS (m/z) : 384 ( $M^+$ +1)

**Example 140**

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-2-benzoylaminomethyl- $\beta$ -alanine  
 IR (KBr pellet) : 3381, 3311, 3064, 2937, 2862, 1643  $cm^{-1}$   
 NMR ( $D_2O$ ,  $\delta$ ) : 1.27-1.99 (12H, m), 2.35-2.57 (3H, m), 2.72-3.08 (4H, m), 3.13-3.49 (5H, m), 3.56 (2H, d,  $J=6.7$ Hz), 3.80-4.31 (3H, m), 7.50-7.63 (3H, m), 7.75-7.79 (2H, m)  
 MASS (m/z) : 473 ( $M^+$ +1)

**Example 141**

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-2-acetylaminomethyl- $\beta$ -alanine  
 IR (KBr pellet) : 3444, 3086, 2939, 2862, 1647  $cm^{-1}$   
 NMR ( $D_2O$ ,  $\delta$ ) : 1.30-1.94 (11H, m), 2.06 (3H, s),

- 115 -

ethynyl- $\beta$ -alanine n-pentyl ester hydrochloride (184 mg, 32.2%).

IR (KBr pellet) : 3417, 3294, 3035, 2958, 2939, 2864, 2727, 1734, 1655  $\text{cm}^{-1}$

5 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 0.76-0.83 (3H, m), 1.18-1.32 (4H, m), 1.39-1.76 (7H, m), 1.88-2.00 (3H, m), 2.31-2.58 (2H, m), 2.67 (1H, d,  $J=2.4\text{Hz}$ ), 2.75-3.20 (4H, m), 3.29-3.42 (3H, m), 3.80-4.27 (2H, m), 4.07 (2H, d,  $J=6.5\text{Hz}$ ), 4.55-4.93 (2H, m), 6.38 (1H, d,  $J=15.2\text{Hz}$ ), 6.51-6.63 (1H, m)

10 MASS ( $m/z$ ) : 432 ( $M^+$ free+1)

The following compound was obtained according to a similar manner to that of Example 144.

#### Example 145

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-2(S)-acetylaminobenzoyl- $\beta$ -alanine n-pentyl ester hydrochloride

20 IR (KBr pellet) : 3439, 3390, 3359, 3064, 2956, 2941, 2864, 2731, 1738, 1653, 1622  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 0.85-0.93 (3H, m), 1.30-1.38 (3H, m), 1.43-1.88 (9H, m), 1.95-2.05 (6H, m), 2.34-2.54 (2H, m), 2.85-3.08 (2H, m), 3.14-3.46 (8H, m), 4.10-4.38 (2H, m), 4.54-5.01 (7H, m)

25 MASS ( $m/z$ ) : 467 ( $M^+$ free+1)

#### Example 146

30 A mixture of N-[(R)-1-[3-(1-benzoyloxypropanoyl)-4-piperidyl]propanoyl]-3-piperidylcarbonyl]-2(S)-acetylaminobenzoyl- $\beta$ -alanine (0.5 g) 1N HCl (0.94 ml) and 10% Pd-C (0.1 g) in tetrahydrofuran (5 ml) was hydrogenated at atmospheric pressure for 2 hours. After the catalyst was removed by filtration, the filtrate was concentrated in vacuo. The residue was resolved in water, and neutralized

35

- 116 -

with saturated aqueous  $\text{NaHCO}_3$ , desalted by using the resin of HP-20 eluting with isopropanol: $\text{H}_2\text{O}$  = (1:1), then freeze-dried to give N-[(R)-1-[3-(4-piperidyl)propanoyl]-3-piperidylcarbonyl]-2(S)-acetylaminobenzoyl- $\beta$ -alanine (0.34 g, 91.0%).

5 IR (KBr pellet) : 2943, 2862, 1608  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.31-1.88 (8H, m), 1.94-2.03 (4H, m), 2.03 (3H, s), 2.39-2.54 (3H, m), 2.80-3.05 (3H, m), 3.19-3.48 (5H, m), 3.63-3.74 (1H, m), 3.81-3.95 (1H, m), 4.18-4.34 (1H, m), 4.35-4.41 (1H, m)

10 Elemental Analysis Calcd. for  $\text{C}_{19}\text{H}_{32}\text{N}_4\text{O}_5 \cdot 1.6\text{H}_2\text{O}$  :

C 53.66, H 8.34, N 13.17

Found : C 53.63, H 8.56, N 13.03

15 The following compounds [Examples 147 to 148] were obtained according to a similar manner to that of Example 146.

#### Example 147

20 N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-2(S)-benzoylaminobenzoyl- $\beta$ -alanine

IR (KBr pellet) : 2943, 2862, 1643  $\text{cm}^{-1}$

25 NMR ( $\text{DMSO-d}$ ,  $\delta$ ) : 1.20-1.96 (13H, m), 2.22-2.45 (3H, m), 2.70-3.02 (3H, m), 3.08-3.27 (1H, m), 3.35-3.46 (2H, m), 3.58-3.80 (3H, m), 4.13-4.19 (1H, m), 4.57-4.70 (1H, m), 7.51-7.70 (3H, m), 7.78-7.86 (2H, m)

Elemental Analysis Calcd. for  $\text{C}_{24}\text{H}_{34}\text{N}_4\text{O}_5 \cdot 1.1\text{H}_2\text{O}$  :

C 60.26, H 7.63, N 11.71

30 Found : C 60.22, H 7.64, N 11.65

#### Example 148

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-

35 piperidylcarbonyl]-2(S)-(4-methoxybenzoylamino)- $\beta$ -alanine

- 117 -

- IR (KBr pellet) : 2943, 2860, 1632, 1608  $\text{cm}^{-1}$   
 NMR ( $\text{DMSO}_6$ ,  $\delta$ ) : 1.19-1.59 (7H, m), 1.65-2.00 (6H, m), 2.20-2.29 (1H, m), 2.37-2.45 (2H, m), 2.71-3.04 (3H, m), 3.12-3.25 (1H, m), 3.35-3.49 (2H, m), 3.60-3.82 (3H, m), 3.89 (3H, s), 4.08-4.20 (1H, m), 4.55-4.66 (1H, m), 7.09 (2H, dd, J=8.9 and 2.9Hz), 7.80 (2H, dd, J=8.8 and 1.9Hz)  
 Elemental Analysis Calcd. for  $\text{C}_{25}\text{H}_{36}\text{N}_4\text{O}_6 \cdot 1.4\text{H}_2\text{O}$  :  
 C 58.44, H 7.61, N 10.90  
 Found : C 58.43, H 7.73, N 10.85

Example 142

A solution of 3-[(R)-1-[3-(4-piperidyl)propanoyl]-3-piperidylcarbonyl]aminobenzoic acid hydrochloride (1 g) was neutralized by saturated aqueous  $\text{NaHCO}_3$ , desalted by using the resin of HP-20 eluting with  $\text{H}_2\text{O}$ :isopropanol = (1:1), then freeze-dried to give 3-[(R)-1-[3-(4-piperidyl)propanoyl]-3-piperidylcarbonyl]aminobenzoic acid (732 mg 80.1%).

- 20 IR (KBr pellet) : 2860, 1678, 1616  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.20-1.69 (6H, m), 1.77-2.09 (5H, m), 2.32-2.50 (2H, m), 2.56-2.94 (3H, m), 3.14-3.38 (4H, m), 3.53-3.93 (2H, m), 4.16-4.23 (1H, m), 7.47 (1H, t, J=7.8Hz), 7.62-7.72 (2H, m), 7.84-7.87 (1H, m)  
 MASS (m/z) : 388 ( $\text{M}^+ + 1$ )  
 $[\alpha]_D^{25} = -18.63^\circ$  (C=1.0, MeOH)  
 Elemental Analysis Calcd. for  $\text{C}_{21}\text{H}_{29}\text{N}_3\text{O}_4 \cdot 1.7\text{H}_2\text{O}$  :  
 C 60.33, H 7.81, N 10.05  
 Found : C 60.42, H 8.35, N 9.97

The following compounds [Examples 150 to 152] were obtained according to a similar manner to that of Example 142.

35

- 118 -

Example 150

- 3-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]aminobenzoic acid  
 IR (KBr pellet) : 2860, 1676, 1655, 1608  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.35-1.96 (8H, m), 2.26-2.76 (3H, m), 2.87-3.21 (3H, m), 3.28-3.53 (2H, m), 3.68-3.98, 4.38-4.44 (total 3H, m), 6.41 (1H, dd, J=15.4 and 4.8Hz), 6.60 (1H, td, J=15.4 and 6.1Hz), 7.46 (1H, t, J=7.9Hz), 7.62-7.71 (2H, m), 7.77-7.84 (1H, m)  
 MASS (m/z) : 386 ( $\text{M}^+ + 1$ )  
 $[\alpha]_D^{25} = -19.97^\circ$  (C=1.0, MeOH)  
 Elemental Analysis Calcd. for  $\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_4 \cdot 1.9\text{H}_2\text{O}$  :  
 C 60.10, H 7.40, N 10.01  
 Found : C 60.05, H 7.73, N 9.85

Example 151

- 4-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]aminobenzoic acid  
 IR (Nujol) : 1660, 1650, 1600  $\text{cm}^{-1}$   
 NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.36-1.74 (4H, m), 1.83-2.09 (4H, m), 2.19-2.34 (1H, m), 2.50-2.70 (1H, m), 2.77-3.49 (6H, m), 3.59-3.68 (1H, m), 3.81-4.00 (2H, m), 6.44-6.60 (2H, m), 7.51 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.6Hz)  
 MASS (m/z) : 386 ( $\text{M}^+ + 1$ )  
 $[\alpha]_D^{25} = -46.0^\circ$  (C=0.2, MeOH)  
 Elemental Analysis Calcd. for  $\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_4 \cdot 2.4\text{H}_2\text{O}$  :  
 C 58.84, H 7.48, N 9.80  
 Found : C 58.90, H 7.66, N 9.61

Example 152

- 4-[(R)-1-[3-(4-piperidyl)propanoyl]-3-piperidylcarbonyl]aminobenzoic acid  
 IR (KBr pellet) : 3477, 3051, 2943, 2862, 1680,

- 120 -

IR (Nujol) : 1610 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.20-2.10 (11H, m), 2.20-2.60 (3H, m), 2.65-3.55 (6H, m), 3.55-3.95 (3H, m), 4.00-4.25 (1H, m), 4.50-4.75 (2H, m), 7.84-7.97 (4H, m)

MASS (m/z) : 527 (M<sup>+</sup>+1)Example 155

N-[(R)-1-[3-(4-piperidyl)propanoyl]-3-

piperidylcarbonyl]-3(S)-trifluoroacetylaminomethyl)-β-alanine trifluoroacetate

IR (Nujol) : 1710 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.20-2.05 (12H, m), 2.25-2.85 (6H, m), 2.85-3.10 (3H, m), 3.10-3.55 (5H, m), 3.70-3.95 (1H, m), 4.05-4.30 (1H, m), 4.30-4.60 (1H, m)

MASS (m/z) : 465 (M<sup>+</sup>+1)Example 156

To a stirred solution of N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-

trifluoroacetyl-amino-β-alanine ethyl ester (334 mg, 0.58 mmol) in ethyl acetate (1.5 ml) was added a solution of

4N-hydrogen chloride in ethyl acetate (1.0 ml, 4 mmol). After the solution was stirred for 2 hours at ambient temperature, the solvent was evaporated in vacuo. The residue was dissolved in 0.1M phosphate buffer (pH=7.3, 200 ml). To the solution was added Porcine liver esterase

(0.5 ml), and the solution was stirred for 7 days at ambient temperature. Solvent was evaporated, and the residue was purified by HPLC to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-trifluoroacetyl-amino-β-alanine trifluoroacetate as a colorless oil (220 mg, 67.5%).

IR : 1720 cm<sup>-1</sup>

- 119 -

1624, 1603 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.27-1.73 (6H, m), 1.81-2.10 (5H, m), 2.45-2.54 (2H, m), 2.72-2.93 (3H, m), 3.29-3.54 (4H, m), 3.69-4.20 (3H, m), 7.54 (2H, d, J=8.6Hz), 7.89 (2H, d, J=8.6Hz)

MASS (m/z) : 388 (M<sup>+</sup>+1)[α]<sub>D</sub><sup>25</sup> = -28.8° (C=1.0, MeOH)Elemental Analysis Calcd. for C<sub>21</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>·2.1H<sub>2</sub>O :

C 59.31, H 7.87, N 9.88

Found : C 59.21, H 8.20, N 9.72

Example 153

To a solution of N-[(R)-1-[3-(4-piperidyl)-(E)-

acryloyl]-3-piperidylcarbonyl]-2(S)-trifluoroacetyl-amino-β-alanine trifluoroacetate in water (4 ml) was added Pd/C

(10% dry, 16 mg) and the mixture was stirred at room temperature under hydrogen at atmospheric pressure for 4 hours. Catalyst was filtered off and filtrate was

evaporated in vacuo to give N-[(R)-1-[3-(4-

piperidyl)propanoyl]-3-piperidylcarbonyl]-2(S)-

trifluoroacetyl-amino-β-alanine trifluoroacetate as a colorless oil (45 mg, 54.9%).

IR (Neat) : 1720 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.20-2.15 (11H, m), 2.35-2.65 (3H, m), 2.45-3.10 (3H, m), 3.05-3.30 (1H, m), 3.30-3.50 (2H, m), 3.60-4.00 (3H, m), 4.05-4.40 (1H, m), 4.50-4.70 (1H, m)

The following compounds [Examples 154 to 155] were obtained according to a similar manner to that of Example 153.

Example 154

N-[(R)-1-[3-(4-piperidyl)propanoyl]-2(S)-[4-trifluoromethyl)benzoylamino]-β-alanine

NMR ( $D_2O$ ,  $\delta$ ) : 1.35-1.90 (5H, m), 1.90-2.15 (3H, m), 2.35-2.70 (2H, m), 2.80-3.15 (3H, m), 3.15-3.40 (1H, m), 3.40-3.55 (2H, m), 3.60-4.05 (4H, m), 4.05-4.45 (1H, m), 6.49 (1H, d,  $J=15.6$ Hz), 6.55-6.75 (1H, m)

5

The following compounds [Examples 157 to 158] were obtained according to a similar manner to that of Example 156.

10

#### Example 157

N-[(R)-1-[3-(3-Azetidinyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine trifluoroacetate

IR (Nujol) : 1650  $cm^{-1}$

NMR ( $D_2O$ ,  $\delta$ ) : 1.35-1.65 (1H, m), 1.65-1.90 (2H, m), 1.90-2.15 (1H, m), 2.35-2.60 (1H, m), 2.73 (1H, d,  $J=2.5$ Hz), 2.75-2.95 (2H, m), 2.95-3.50 (2H, m), 3.70-4.00 (2H, m), 4.00-4.40 (5H, m), 4.85-5.15 (1H, m), 6.54 (1H, d,  $J=15.4$ Hz), 6.79 (1H, dd,  $J=15.4$  and 7.4Hz)

20

MASS (m/z) : 334 ( $M^+ + 1$ )

#### Example 158

N-[(R)-1-[4-(3-Azetidinyl)-(E)-2-butenyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine trifluoroacetate

IR (Neat) : 1720  $cm^{-1}$

NMR ( $D_2O$ ,  $\delta$ ) : 1.35-2.10 (5H, m), 2.30-2.55 (1H, m), 2.59 (2H, t,  $J=6.8$ Hz), 2.73 (1H, d,  $J=2.3$ Hz), 2.75-3.50 (5H, m), 3.80-4.35 (6H, m), 4.85-5.00 (1H, m), 6.42-6.65 (2H, m)

30

MASS (m/z) : 348 ( $M^+ + 1$ )

#### Example 159

To a solution of N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-

35

ethynyl- $\beta$ -alanine pivaloyloxymethyl ester (0.39 g) in ethyl acetate (4 ml) was added 4N HCl in ethyl acetate (1.61 ml) at 0°C, and the reaction mixture was stirred for 3 hours at room temperature. The precipitates were filtered and washed with diethyl ether, and dissolved with water. The solution was purified by HPLC eluting with 0.1% aqueous trifluoroacetic acid:CH<sub>3</sub>CN = (67:33) to give N-[(R)-1-[3-(4-piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine pivaloyloxymethyl ester trifluoroacetate (301.4 mg, 81.2%).

IR (KBr pellet) : 3373, 3049, 2981, 2943, 2870, 2536, 1757, 1674, 1659, 1601  $cm^{-1}$

15

NMR ( $D_2O$ ,  $\delta$ ) : 1.19 (9H, s), 1.46-1.86 (6H, m), 1.93-2.11 (3H, m), 2.39-2.66 (2H, m), 2.77 (1H, d,  $J=2.4$ Hz), 2.90-2.95 (2H, m), 3.00-3.30 (4H, m), 3.40-3.52 (3H, m), 3.90-4.13 (2H, m), 5.78 (2H, s), 6.45 (1H, d,  $J=15.7$ Hz), 6.64 (1H, dd,  $J=15.5$  and 6.2Hz)

20

MASS (m/z) : 476 ( $M^+ + 1$ )

The following compounds [Examples 160 to 161] were obtained according to a similar manner to that of Example 159.

25

#### Example 160

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]- $\beta$ -alanine pivaloyloxymethyl ester trifluoroacetate

IR (KBr pellet) : 3325, 2978, 2870, 2750, 1757, 1657, 1603  $cm^{-1}$

30

NMR ( $D_2O$ ,  $\delta$ ) : 1.19 (9H, s), 1.40-2.12 (10H, m), 2.37-2.59 (2H, m), 2.66 (2H, t,  $J=6.4$ Hz), 2.95-3.34 (3H, m), 3.43-3.52 (4H, m), 3.92-4.35 (2H, m), 5.76 (2H, s), 6.46 (1H, d,  $J=15.5$ Hz), 6.64

35

- 123 -

(1H, dd, J=15.5 and 6.2Hz)

MASS (m/z) : 452 (M<sup>+</sup>free+1)Example 161

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-

piperidylcarbonyl]-3(S)-trifluoroacetylaminomethyl-β-

alanine trifluoroacetate

IR (Nujol) : 1720, 1650 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 1.35-2.15 (9H, m), 2.30-2.80 (4H, m),

2.80-3.60 (9H, m), 3.75-4.05 (1H, m), 4.05-4.25

(1H, m), 4.35-4.60 (1H, m), 6.43 (1H, d,

J=14.9Hz), 6.55-6.70 (1H, m)

MASS (m/z) : 463 (M<sup>+</sup>+1)15 Example 162

1N aqueous LiOH (3.0 ml) was added to a solution of

N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)-(Z)-

acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine

ethyl ester (1.0 g) in tetrahydrofuran (5 ml)-EtOH (5 ml)

at 0°C. The reaction mixture was stirred for 2 hours at

room temperature, then water was added, and the whole was

washed with diethyl ether. The aqueous layer was made

acidic with 20% aqueous KHSO<sub>4</sub>, and extracted with ethylacetate. The organic layer was dried over MgSO<sub>4</sub>,

evaporated in vacuo. The residue was dissolved in ethyl

acetate (10 ml) and 4N HCl in ethyl acetate (5.1 ml) was

added. The reaction mixture was stirred for 2 hours and

diethyl ether was added. The precipitates were collected

with filtration and dissolved with water. The solution

was neutralized with saturated aqueous NaHCO<sub>3</sub> and purified

by HP-20 resin eluting with isopropanol/water= (0-30%) to

give N-[(R)-1-[3-(4-piperidyl)-(Z)-acryloyl]-3-

piperidylcarbonyl]-3(S)-ethynyl-β-alanine (0.5 g, 67.8%)

NMR (D<sub>2</sub>O, δ) : 1.10-1.58 (8H, m), 2.06-2.32 (5H,

m), 2.58-2.75 (2H, m), 2.80-2.89 (1H, m), 3.00-

- 124 -

3.11 (2H, m), 3.40-3.55 (1H, m), 3.73-3.86 (1H, m), 4.45-4.52 (2H, m), 5.39-5.52 (1H, m), 5.77 (1H, dd, J=2.4 and 11.6Hz)

MASS (m/z) : 362 (M<sup>+</sup>+1)

5

The following compounds [Examples 163 to 164] were obtained according to a similar manner to that of Example 162.

10 Example 163

N-[(R)-1-[1,2,3,4-Tetrahydroisoquinolin-6-yl]-

carbonyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine

IR (Nujol) : 1660 cm<sup>-1</sup>NMR (D<sub>2</sub>O, δ) : 1.40-2.35 (5H, m), 2.35-2.80 (1H, m),

2.45 (1H, dd, J=7.0 and 4.1Hz), 2.64 (1H, d,

J=7.6Hz), 3.05-3.50 (2H, m), 3.17 (2H, t-like),

3.50-3.85 (2H, m), 3.56 (2H, t, J=6.2Hz), 7.20-

7.50 (3H, m)

15

MASS (m/z) : 384 (M<sup>+</sup>+1)

20

Example 164

N-[(R)-1-[1,2,3,6-Tetrahydro-4-pyridyl]propanoyl]-3-

piperidylcarbonyl]-3(S)-ethynyl-β-alanine hydrochloride

NMR (D<sub>2</sub>O, δ) : 1.51-1.96 (5H, m), 2.26-2.50 (5H, m),

2.60-2.68 (6H, m), 2.86-3.07 (1H, m), 3.18-3.44

(3H, m), 3.65 (1H, br), 3.83-3.95 (1H, m), 4.09-

4.30 (1H, m), 5.49 (1H, br)

25

MASS (m/z) : 362 (M<sup>+</sup>+1)30 Example 165

1N aqueous LiOH (0.9 ml) was added to a solution of

N-[(R)-1-[3-(1-tert-butoxycarbonyl)-1,2,3,6-tetrahydro-4-

pyridyl]-3-piperidyl]-3-piperidylcarbonyl]-3(S)-ethynyl-

β-alanine ethyl ester (0.33 g) in tetrahydrofuran (1.5

ml)-EtOH (1.5 ml) at 0°C. The reaction mixture was

35

- 126 -

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-2(S)-[4-(trifluoromethyl)benzoylamino]- $\beta$ -alanine

IR (Nujol) : 1740, 1680  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.20-1.85 (5H, m), 1.85-2.15 (3H, m), 2.35-2.65 (2H, m), 2.85-3.35 (6H, m), 3.35-4.00 (3H, m), 4.00-4.40 (1H, m), 4.55-4.70 (2H, m), 6.35 (1H, dd, J=19.0 and 16.0Hz), 6.50-6.66 (1H, m), 7.85 (2H, d, J=9.0Hz), 7.93 (2H, d, J=9.0Hz)

MASS (m/z) : 525 ( $\text{M}^+ + 1$ )

Example 168

N-[(R)-1-[4-(3-Piperidyl)-(E)-2-butenoyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.10-2.10 (8H, m), 2.28 (1H, t, J=6.8Hz), 2.35-3.55 (10H, m), 2.67 (1H, d, J=2.3Hz), 2.65-4.40 (2H, m), 4.70-4.95 (2H, m), 6.40-6.55 (1H, m), 6.58-6.65 (1H, m)

MASS (m/z) : 476 ( $\text{M}^+ + 1$ )

Example 169

N-[(R)-1-[3-(1,2,3,6-Tetrahydro-4-pyridyl)propanoyl]-3-piperidylcarbonyl]-3(S)-[3-methyl-5-isoxazoly]- $\beta$ -alanine hydrochloride

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.28-1.66 (5H, m), 2.06 (3H, s), 2.06-2.09 (4H, m), 2.19-2.39 (3H, m), 2.62-2.84 (5H, m), 3.04-3.10 (3H, m), 3.37 (2H, br), 5.17-5.24 (1H, m), 5.99 (1H, br)

MASS (m/z) : 419 ( $\text{M}^+ + 1$ )

Example 170

LiOH (40 mg, 1.66 mmol) was added to a solution of N-[(R)-1-[4-(1-tert-butoxycarbonyl-3-azetidinyl)butanoyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine ethyl ester (663

- 125 -

stirred for 2 hours at room temperature, then water was added, and the whole was washed with diethyl ether. The aqueous layer was made acidic with 20% aqueous  $\text{KHSO}_4$ , and extracted with ethyl acetate. The organic layer was dried over  $\text{MgSO}_4$  and evaporated in vacuo. The residue was dissolved in ethyl acetate (5 ml) and 4N HCl in ethyl acetate (2.5 ml) was added. The reaction mixture was stirred for 2 hours and diethyl ether was added. The precipitates were collected with filtration and washed with diethyl ether to give N-[(R)-1-[3-(1,2,3,6-tetrahydro-4-pyridyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine hydrochloride (0.12 g, 44.6%).

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.20-1.38 (2H, m), 1.40-1.78 (4H, m), 2.20-2.35 (3H, m), 2.43 (1H, d, J=2Hz), 2.55-2.60 (3H, m), 2.75-3.14 (4H, m), 3.56-3.75 (2H, m), 3.90-4.02 (1H, m), 5.86 (1H, br), 6.23 (1H, d, J=15Hz), 6.88 (1H, dd, J=2 and 15Hz)

MASS (m/z) : 360 ( $\text{M}^+ \text{free} + 1$ )

The following compounds [Examples 166 to 169] were obtained according to a similar manner to that of Example 165.

Example 166

N-[(R)-1-[3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-[3-methyl-5-isoxazoly]- $\beta$ -alanine hydrochloride

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.55-1.79 (5H, m), 1.92-2.09 (4H, m), 2.26 (3H, s), 2.56-2.60 (2H, m), 2.93-3.29 (5H, m), 3.44-3.50 (2H, m), 3.93-4.27 (2H, m), 5.42-5.48 (1H, m), 6.25 (1H, s), 6.45 (1H, d, J=15.5Hz), 6.57-6.72 (1H, m)

MASS (m/z) : 419 ( $\text{M}^+$ )

Example 167



Example 172

Trifluoroacetic acid (3 ml) was added to N-[(R)-1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propanoyl]-3-piperidylcarbonyl]-3(S)-acetylaminomethyl-β-alanine tert-butyl ester. The solvent was evaporated in vacuo. The residue was neutralized with saturated aqueous NaHCO<sub>3</sub> and purified by HP-20 resin eluting with isopropanol/water (0-50% to give N-[(R)-1-[3-(4-piperidyl)propanoyl]-3-piperidylcarbonyl]-3(S)-acetylaminomethyl-β-alanine (120mg, 50.0%).

IR (Nujol) : 1640, 1600 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.20-1.70 (8H, m), 1.70-2.15 (7H, m), 1.98 (3H, s), 2.40-2.65 (3H, m), 2.65-3.10 (2H, m), 3.10-3.50 (6H, m), 3.70-4.05 (1H, m), 4.05-4.25 (2H, m)

MASS (m/z) : 411 (M<sup>+</sup>+1)

The following compound was obtained according to a similar manner to that of Example 172.

Example 173

N-[(R)-1-[3-(4-Piperidyl)propanoyl]-3-piperidylcarbonyl]-3(S)-benzoylaminomethyl-β-alanine.

IR (Nujol) : 1620 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.35-2.35 (13H, m), 2.35-2.65 (3H, m), 2.70-3.05 (2H, m), 2.10-3.65 (5H, m), 3.65-4.25 (2H, m), 4.25-4.40 (1H, m), 7.49-7.62 (3H, m), 7.75-7.79 (2H, m)

MASS (m/z) : 473 (M<sup>+</sup>+1)

The following compound was obtained according to a similar manner to that of Example 35.

Example 174

N-[(2-[3-(1-tert-Butoxycarbonyl-4-piperidyl)-(E)-

mg, 1.39 mmol) in tetrahydrofuran (6.0 ml)-EtOH (6.0 ml)-H<sub>2</sub>O (6.0 ml). The reaction mixture was stirred for 2 hours at room temperature. Solvent was evaporated in vacuo, then water was added, and the whole was washed with diethyl ether. The aqueous layer was made acidic with 5% aqueous H<sub>2</sub>SO<sub>4</sub>, and extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO<sub>4</sub> and evaporated in vacuo. Trifluoroacetic acid (2 ml) was added to the residue. The reaction mixture was stirred for 1 hour at room temperature. Solvent was evaporated in vacuo. The residue was purified by HPLC eluting with 0.1% aqueous trifluoroacetic acid:CH<sub>3</sub>CN = (14:86) to give N-[(R)-1-[4-(3-azetidiny)butanoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine trifluoroacetate (250mg, 38.8%).

IR (Neat) : 1720, 1640 cm<sup>-1</sup>

NMR (D<sub>2</sub>O, δ) : 1.30-2.15 (8H, m), 2.25-2.60 (3H, m), 2.73 (1H, d, J=2.3Hz), 2.90-3.45 (5H, m), 3.65-3.95 (3H, m), 4.00-4.30 (3H, m)

MASS (m/z) : 350 (M<sup>+</sup>+1)

Example 171

Trifluoroacetic acid (3 ml) was added to N-[(R)-1-[3-(1-tert-butoxycarbonyl-3-azetidiny)propanoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine (1.11 g, 2.55 mmol). The reaction mixture was stirred for 1 hour at room temperature. Solvent was evaporated in vacuo. The residue was purified by HPLC to give N-[(R)-1-[3-(3-azetidiny)propanoyl]-3-piperidylcarbonyl]-3(S)-ethynyl-β-alanine trifluoroacetate (270mg, 23.6%).

IR (Nujol) : 1650 cm<sup>-1</sup>


NMR (CDCl<sub>3</sub>, δ) : 1.30-2.15 (7H, m), 2.20-2.60 (3H, m), 2.73 (1H, d, J=2.3Hz), 2.80-3.50 (6H, m), 3.65-3.95 (3H, m), 3.95-4.35 (4H, m), 4.85-5.00 (1H, m)

MASS (m/z) : 336 (M<sup>+</sup>+1)

- 130 -

C L A I M S

1. A compound of the formula :



wherein

$R^1$  is piperidyl, piperidyl having amino protective group, tetrahydropyridyl, tetrahydropyridyl having amino protective group, azetidiny, azetidiny having amino protective group, having amino protective group, tetrahydroisoquinolyl or tetrahydroisoquinolyl having amino protective group, having amino protective group,  $R^2$  is carboxy or protected carboxy,  $A^1$  is lower alkylene, lower alkanyl-ylidene, lower alkenylene, cyclo(lower)alkylene or arylene,  $A^2$  is lower alkylene which may have one or more suitable substituent(s) or arylene,

$\text{N} \begin{array}{c} \text{O} \end{array}$  is piperidinediyl or

tetrahydroisoquinolinediyl, and

m is an integer of 0 or 1,

with proviso that

when  $R^1$  is piperidyl,

$A^1$  is lower alkylene, and

$A^2$  is lower alkylene which may have one or more

suitable substituent(s) except 5 or 6-membered heteromonocyclic group containing 1 to 2

oxygen atom(s) and 1 to 3 nitrogen atom(s),

which may have one or more lower alkyl;

ar(lower)alkoxy(lower)alkyl;

hydroxy(lower)alkyl;

- 129 -

acryloyl]-1,2,3,4-tetrahydroisoquinolin-4-yl]carbonyl-

3(S)-ethynyl- $\beta$ -alanine ethyl ester

MASS (m/z) : 538 ( $M^+ + 1$ )

5 The following compound was obtained according to a similar manner to that of Example 170.

#### Example 175

10 N-[(2-{3-(4-Piperidyl)-(E)-acryloyl]-1,2,3,4-tetrahydroisoquinolin-4-yl]carbonyl]-3(S)-ethynyl- $\beta$ -alanine trifluoroacetate

IR (Neat) : 1740  $\text{cm}^{-1}$

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.50-1.80 (2H, m), 2.00-2.20 (2H, m), 2.45-2.90 (4H, m), 3.00-3.25 (2H, t-like), 3.35-3.55 (2H, m), 3.65-3.85 (1H, m), 3.85-4.00 (1H, m), 4.30-4.65 (1H, m), 4.65-5.30 (3H, m), 6.40-6.55 (1H, m), 6.65-6.80 (1H, m), 7.20-7.45 (4H, m)

MASS (m/z) : 410 ( $M^+ + 1$ )

20 The following compound was obtained according to a similar manner to that of Examples 35, 75 and 110.

#### Example 176

25 N-[(R)-1-{3-(4-Piperidyl)-(E)-acryloyl]-3-piperidylcarbonyl]-3(S)-(2H-1,2,3-triazol-4-yl)- $\beta$ -alanine trifluoroacetate

NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ) : 1.56-2.07 (9H, m), 2.50-2.64 (2H, m), 3.02-3.50 (7H, s), 3.85-4.27 (2H, m), 5.53-5.57 (1H, m), 6.45 (1H, d, J=15.5Hz), 6.56-6.63 (1H, m), 7.86 (1H, d, J=5.0Hz)

MASS (m/z) : 405 ( $M^+ + 1$ )

lower alkoxy(lower)alkyl; cyclo(lower)alkyl; aroylamino(lower)alkyl; lower alkanoylamino(lower)alkyl which may have halogen; lower alkanoylamino having halogen; and aroylamino having halo(lower)alkyl; then R<sup>2</sup> is pentyloxycarbonyl, isopentyloxycarbonyl, isohexyloxycarbonyl, phenethyloxycarbonyl, aryloxycarbonyl or indanyloxycarbonyl, or a salt thereof.


2. A compound of claim 1, wherein

A<sup>2</sup> is lower alkylene which may have one or more suitable substituent(s) selected from the group consisting of lower alkyl; lower alkynyl; aryl; ar(lower)alkyl which may have one or more lower alkoxy; lower alkanoylamino which may have one or more halogen; aroylamino which may have one or more suitable substituent(s) selected from the group consisting of lower alkoxy and halo(lower)alkyl; 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) which may have lower alkyl; 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s); lower alkoxy(lower)alkyl; cyclo(lower)alkyl; hydroxy(lower)alkyl; ar(lower)alkoxy(lower)alkyl; lower alkanoylamino(lower)alkyl which may have one or more halogen and aroylamino(lower)alkyl, or arylene.

3. A compound of claim 2, wherein

A<sup>1</sup> is lower alkenylene,  
A<sup>2</sup> is lower alkylene which may have 1 to 3 suitable substituent(s) selected from the group consisting of lower alkyl, lower alkynyl, aryl, ar(lower)alkyl which may have 1 to 3 lower alkoxy, lower

alkanoylamino which may have 1 to 3 halogen, aroylamino which may have 1 to 3 halo(lower)alkyl, heterocyclic group which may have 1 to 3 lower alkyl, lower alkoxy(lower)alkyl, cyclo(lower)alkyl, hydroxy(lower)alkyl, ar(lower)alkoxy(lower)alkyl and lower alkanoylamino(lower)alkyl which may have 1 to 3 halogen, or arylene,

 is piperidinediyl or tetrahydroisoquinolinediyl,

and

m is an integer of 1.


4. A compound of claim 3, wherein

R<sup>1</sup> is piperidyl, piperidyl having amino protective group, tetrahydropyridyl, tetrahydropyridyl having amino protective group, azetidyl, azetidyl having amino protective group, tetrahydroisoquinolyl or tetrahydroisoquinolyl having amino protective group,

A<sup>2</sup> is lower alkylene,

lower alkylene which has one suitable substituent selected from the group consisting of lower alkyl, lower alkynyl, aryl, ar(lower)alkyl which may have 1 or 2 lower alkoxy, lower alkanoylamino which may have 3 halogens, aroylamino which may have one tri-halo(lower)alkyl, 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) which may have one lower alkyl, 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), lower alkoxy(lower)alkyl, cyclo(lower)alkyl, hydroxy(lower)alkyl, ar(lower)alkoxy(lower)alkyl and lower alkanoylamino(lower)alkyl which may have 3 halogens, or phenylene,

from the group consisting of 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) having lower alkyl, phenyl(lower)alkoxy(lower)alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, cyclo(lower)alkyl, benzoylamino(lower)alkyl, lower alkanoylamino(lower)alkyl, tri-halo(lower)alkanoylamino, benzoylamino having tri-halo(lower)alkyl and tri-halo(lower)-alkanoylamino(lower)alkyl or phenylene,

 is piperidinediyl, and

m is an integer of 1.

8. A compound of claim 7, wherein

R<sup>1</sup> is piperidyl,

R<sup>2</sup> is carboxy,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of isoxazolyl having lower alkyl, tri-halo(lower)alkylbenzoylamino, benzoylamino(lower)alkyl, and tri-halo(lower)alkanoylamino(lower)alkyl.


9. A compound of claim 2, wherein

R<sup>1</sup> is tetrahydropyridyl or tetrahydropyridyl having amino protective group,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of lower alkynyl and 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) having lower alkyl,

 is piperidinediyl, and

 is piperidinediyl or tetrahydroisoquinolinediyl.

5. A compound of claim 4, wherein

R<sup>1</sup> is piperidyl or tetrahydropyridyl,

A<sup>2</sup> is lower alkylene or lower alkylene which has one

suitable substituent selected from the group consisting of lower alkyl, lower alkynyl, phenyl, phenyl(lower)alkyl which may have 1 or 2 lower alkoxy, lower alkanoylamino, benzoylamino which may have one tri-halo(lower)alkyl, isoxazolyl which has one lower alkyl, triazolyl and phenyl(lower)alkoxy(lower)alkyl,

 is piperidinediyl.


6. A compound of claim 2, wherein

R<sup>1</sup> is piperidyl,

R<sup>2</sup> is pentyloxycarbonyl, isopentyloxycarbonyl, ishexyloxycarbonyl, phenethyloxycarbonyl, phenyloxycarbonyl or indanyloxycarbonyl,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected from the group consisting of lower alkynyl and lower alkanoylamino,

 is piperidinediyl, and

m is an integer of 1.

7. A compound of claim 2, wherein


R<sup>1</sup> is piperidyl or piperidyl having amino protective group,

A<sup>1</sup> is lower alkylene,

A<sup>2</sup> is lower alkylene which has one substituent selected

or a salt thereof,


(ii) reacting a compound of the formula :



wherein  $R^1$ ,  $A^1$ ,  $-N-$  and  $m$  are each as defined in


claim 1,

or its reactive derivative at the carboxy group  
or a salt thereof, with a compound of the formula :



wherein  $R^2$  and  $A^2$  are each as defined in claim 1,  
or its reactive derivative at the amino group  
or a salt thereof, or

(iii) subjecting a compound of the formula :



wherein  $R^2$ ,  $A^1$ ,  $A^2$ ,  $-N-$  and  $m$  are each as defined

in claim 1, and

$R_a^1$  is piperidyl having amino protective group,  
tetrahydropyridyl having amino protective  
group, azetidynyl having amino protective  
group or tetrahydroisquinolyl having

$m$  is an integer of 1.

10. A compound of claim 9, wherein

$R^1$  is tetrahydropyridyl,

$R^2$  is carboxy,


$A^1$  is lower alkylene and

$A^2$  is lower alkylene which has one substituent selected  
from the group consisting of lower alkynyl and  
isoxazolyl having lower alkyl.

11. A process for preparing a compound of claim 1,

or a salt thereof, which comprises


(i) reacting a compound of the formula :



wherein  $R^1$ ,  $A^1$ ,  $-N-$  and  $m$  are each as defined in

claim 1,

or its reactive derivative at the carboxy group  
or a salt thereof, with a compound of the formula :




wherein  $R^2$  and  $A^2$  are each as defined in claim 1, and

$HN-$  is piperidyl or tetrahydropyridyl,

or its reactive derivative at the amino group

- 137 -

amino protective group,  
or a salt thereof, to elimination reaction of the amino  
protective group, to give a compound of the formula :




wherein  $R^2$ ,  $A^1$ ,  $A^2$ ,  $-N$  and  $m$  are each as defined in

claim 1, and

$R_6^1$  is piperidyl, tetrahydropyridyl, azetidinyll or tetrahydroisoquinolyl,

or a salt thereof, or

(iv) subjecting a compound of the formula :




wherein  $R^1$ ,  $A^1$ ,  $A^2$ ,  $-N-$  and  $m$  are each as defined in

claim 1, and

$R_a^2$  is protected carboxy,  
or a salt thereof, to elimination reaction of carboxy  
protective group, to give a compound of the formula :



- 138 -

wherein R<sup>1</sup>, A<sup>1</sup>, A<sup>2</sup>,  and m are each as defined above, or a salt thereof, or

(v) subjecting a compound of the formula :




wherein  $R_a^1$  is as defined above, and

$A^1, A^2, -N$  and  $m$  are each as defined in

claim 1,

or its reactive derivative at the carboxy group  
or a salt thereof, to protecting reaction of the  
carboxy, to give a compound of the formula :



wherein  $R_a^1$  and  $R_a^2$  are each as defined above, and  $A^1, A^2, -N-$  and  $m$  are each as defined in

claim 1,

or a salt thereof.

13. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.

14. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.

15. A method for the prevention and/or the treatment of diseases caused by thrombus formation; restenosis or reocclusion; the thrombus formation in case of vascular surgery, valve replacement, extracorporeal circulation or transplantation; disseminated intravascular coagulation; thrombotic thrombocytopenic; essential thrombocytosis; inflammation; immune diseases; or metastasis; or for the adjuvant therapy with thrombolytic drug or anticoagulant; which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

Udall has no design on the position, and he is not even a member of the Senate.

**B. FIELDS SEARCHED**

\_\_\_\_\_ documents are included in the fields searched

Citations that have contradicted during the international search (name of data base and where practical, search terms used)

### **C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Case name	Citation of document with indication where appropriate of the relevant passages	Relevant to claim No.

P,X WO,A,95 25991 (ORTHO PHARMACEUTICAL CORP.,  
USA) 21 September 1995  
see the whole document

P,X  
WO,A,95 11228 (SUMITOMO PHARMACEUTICALS  
CO., LTD., JAPAN) 27 April 1995  
see page 62

P,X  
W.O.A.95 08536 (FUJISAWA PHARMACEUTICAL  
CO., LTD., JAPAN) 30 March 1995  
see the whole document

11

<input checked="" type="checkbox"/>	Further documents are listed in the continuation of box C.
-------------------------------------	--

Patient family members are listed in annex.

**Special categories of cited documents :**

\*A. document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

1. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document

\*O: document referring to an oral disclosure, use, exhibition or creation of other special reason (as specimen)  
other means

\*p. document published prior to the international filing date but

Date of the actual completion of the international search	Date of mailing of the international search report

18 June 1996

28. 06. 96

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 631 epo nl,  
Fax (+ 31-70) 340-2016

**Authorized officer**

## INTERNATIONAL SEARCH REPORT

International Application No. PC JP 96/00643	
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category	Citation of document, with indication, where appropriate, of the relevant passages
P, X	J. MED. CHEM. (1995), 38(10): 1582-92 CODEN: JMCHEM; ISSN: 0022-2623, 12 May 1995, XP002006052 HOEKSTRA, WILLIAM J. ET AL: "Design and Evaluation of Nonpeptide Fibrinogen, gamma. Chain-Based GPIIb/IIIa Antagonists" see the whole document
A	--- BIOORG. MED. CHEM. LETT. (1994), 4(11), 1361-4 CODEN: BMCLEB; ISSN: 0960-894X, 1994, XP002006053 HOEKSTRA, WILLIAM J. ET AL: "Adamantane and nipecotic acid derivatives as novel beta.-turn mimics" see the whole document
X	--- EP, A, 0 445 796 (HOFFMANN-LA ROCHE, F., A.-G., SHITZ.) 11 September 1991 see claim 1 see example 15
A	--- WO, A, 91 07976 (RORER INTERNATIONAL, INC., USA) 13 June 1991 see the whole document

Form PCT ISA/210 (continuation of second sheet) (July 1992)

International Application No. PCT/JP 96/00643	
INTERNATIONAL SEARCH REPORT	
Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1.	<input type="checkbox"/> Claims Nos. because they relate to subject matter not required to be searched by this Authority, namely: Although claim 15 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	<input type="checkbox"/> Claims Nos. because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.	<input type="checkbox"/> Claims Nos. because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
1.	<input type="checkbox"/> As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	<input type="checkbox"/> As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	<input type="checkbox"/> As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	<input type="checkbox"/> No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest	<input type="checkbox"/> The additional search fees were accompanied by the applicant's protest. <input type="checkbox"/> No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)



# INTERNATIONAL SEARCH REPORT

(Information on patent family members)

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9525091	21-09-95	AU-B- 2119195 CA-A- 2163027 FI-A- 955498 NO-A- 954609	03-10-95 21-09-95 15-01-96 05-01-96
WO-A-9511228	27-04-95	AU-B- 7862794	08-05-95
WO-A-9508536	30-03-95	AU-B- 7665794 CN-A- 1116847 EP-A- 0869912 ZA-A- 9407350 JP-A- 8053415	10-04-95 14-02-96 06-09-95 10-05-95 27-02-96
EP-A-0445796	11-09-91	CA-A- 2037153 IL-A- 97401 JP-A- 4217652 US-A- 5438024 US-A- 5273982	10-09-91 15-03-95 07-08-92 04-07-95 28-12-93
WO-A-9107976	13-06-91	US-A- 5053392 AT-T- 135367 AU-B- 636426 AU-B- 6890091 DE-D- 69025952 EP-A- 0502926 JP-T- 5504762	01-10-91 15-03-96 29-04-93 26-06-91 18-04-96 16-09-92 22-07-93

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**